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ABSTRACT 
This thesis is c oncerned with the me tabolism of v e r y low density 
lipoproteins (VLDL) and low density lipoproteins (LDL) in ma n . I t is 
presented in the form of seven chapters, the first of which reviews 
and discusses concepts relevant to this work. The remaining chapters 
report investigations of the metabolism of these macromolecules in 
normal and hyperlipoprote inaemic subjects. The signifi c ancP of t hese 
findings to the development of hyperlipoproteinaemia (and the patho-
genesis of atherosclerosis) is discussed. 
The B apolipoprotein moiety of the above-mentioned lipoprotein 
species was chosen for study as it alone remains common to these lipo-
proteins during their entire circulatory life. A method for obtaining 
the B apolipoprotein free of other VLDL and LDL apolipoproteins was 
devised. This procedure was based on the relative insolubility of the 
B apolipoprotein in SmM NH4Hco3 , pH 8.0. The isolation procedure was 
used to obtain B apolipoprotein specific activity data which facilitated 
many of the analyses and interpretations included in this work. 
Using an in vitPo system employing normal human plasma contain-
ing varying concentrations of post-heparin lipolytic activity, it 
was demonstrated that the sequential transformation of VLDL to LDL was 
dependent upon lipolytic activity; no ~onversion of VLDL or inter-
mediate lipoproteins to LDL was observed in its absence. Furthermore , 
in the presence of lipolytic activity of hepatic origin only, no 
transformation of the B apolipoprotein into LDL was seen thus suggesting 
a minor role of hepatic lipases in LDL formation. 
A series of in vivo investigations on the metabolism of various 
radioiodinated VLDL and LDL preparations in normal and hyperlipoprotein-
aemic subjects is also reported. B apolipoprotein specific activity-
time curves were analysed for precursor-product relationships between 
various lipoprotein fractions. From these curves it was deduced that, 
in man, LDL is ultimately derived from the catabolism of VLDL via an 
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intermediate lipoprotein species. This intermediate species may be 
defined (in terms of Svedberg flotation units) as lying in the range 
sf 12-60. Likewise, from appropriate kinetic analyses of the rate s of 
disappearance and labelling (in vivo) of the B apolipoprotein in various 
lipoprotein fractions, it was deduced (from turnover data) that, in 
normotriglyceridaemics, all VLDL is catabolised to LDL. However, in 
hypertriglyceridaemics, a relatively large proportion of VLDL B apolipo-
protein may be removed from the circulation prior to conversion to LDL 
(probably as the intermediate lipoprotein). The relationship between 
VLDL B apolipoprotein synthesis and VLDL B plasma pool size described 
a 'saturable system' suggesting that the rate of VLDL production is a 
major determinant of VLDL pool size but that in severe hypertrigly-
ceridaemia, VLDL removal mechanisms may also be impaired. 
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CHAPTER 1 
INTRODUCTION 
The association between plasma lipids and atherosclerosis 
has focussed attention on the metabolism of the plasma lipoprotcins 
which transport lipids, not only through plasma, but probably also into 
the arterial wall. This thesis is concerned with studies into the 
metabolism of two lipoprotein species, the very low density and low 
density lipoproteins. Both of these lipoproteins, as well as the 
intermediate lipoproteins formed during the transformation of very 
low density into low density lipoproteins, have been implicated in the 
genesis of the atherosclerotic lesion. The studies to be described 
have examined the metabolism of these lipoproteins in man, under in 
2 
vivo and in vitro conditions, in an attempt to elucidate some of the 
mechanisms involved in the catabolism of the very low density lipo-
proteins both in normal and hyperlipoproteinaemic subjects. The 
metabolism of the various lipid moieties has been studied by others in 
great detail and will be discussed later. The present experiments 
have been concerned with the major common protein of both very low 
density and low density lipoprotein since the secretion of the lipo-
protein macromolecule is dependent on the synthesis of this protein, 
the B apolipoprotein. The catabolism of very low density lipoprotein 
is also regulated by other proteins - the C apolipoproteins, which 
have also been studied in this work. Much less is known of the 
physiological and clinical significance of the proteins than of the 
lipids of lipoproteins, though in recent years, this area has come 
under intense study. This has led to a clearer understanding of the 
functioning of the entire lipoprotein and of the interactions of the 
lipid with the proteins. 
The interaction between lipids and proteins is fundamental 
to many biological processes such as the functioning of cell membranes, 
enzyme reactions, formation of plasma lipoproteins and blood 
coagulation. Plasma lipoproteins, because of their solubility in 
aqueous media, are referred to as soluble lipoproteins. This property 
is not shared by the structural (or membrane) lipoproteins. 
The maJor lipid classes found in plasma are phospholipids, 
triglyceride, various hydrocarbons including free fatty acids, 
cholesterol and fat soluble vitamins (Fredrickson and Lees, 1972). 
Plasma lipids are largely insoluble in watet. They do not occur in a 
free state in the aqueous plasma environment but in combination with 
proteins as lipoproteins. 
3 
Although lipid-protein complexes were isolated early in the 
last century, they were at that time considered no more than artifacts. 
Lipoproteins were first envisaged as metabolic entities following the 
pioneer work of Macheboeuf (1929) who isolated various water soluble 
protein-lipid complexes from horse serum using ammonium sulphate -
sulphuric acid precipitation. 
The ratio of lipid to protein in plasma lipoproteins is highly 
variable. As the lipid to protein ratio determines the density of the 
lipoprotein, lipoproteins may be separated by ultracentrifugation into 
various density ranges. This has led to one system of lipoprotein 
nomenclature which is based on terms of hydrated lipoprotein density. 
1.1 PLASMA LIPOPROTEIN CLASSES 
Lipoproteins in human plasma may be divided into five major 
classes. 
1. free fatty acid - albumin complexes 
2. high density lipoproteins (HDL) 
3. low density lipoproteins (LDL) 
4. very low density lipoproteins (VLDL) 
5. chylomicrons 
4 
1.1.1 Free fatty acid - albumin complexes 
Although these complexes are not usually referred to as lipo-
proteins, they constitute an important group of lipid-protein complexes. 
Free (or unesterified) fatty acids (FFA) are transported in plasma bound 
to albumin (Fredrickson and Gordon, 1958). FFA, liberated by lipolysis 
of adipose tissue triglyceride, serve as an essential energy source 
(particularly in the post-absorptive state) for skeletal and cardiac 
muscle as well as liver. These complexes do not float in the ultra-
centrifuge and may be found in the ultracentrifugal residue 
(d. 1.21 g/ml fraction) . 
1.1.2 High density lipoproteins 
Plasma HDL may be floated by ultracentrifugation in the salt 
density range 1.063 -1.21 g/ml {Havel et al., 1955). These lipoproteins 
are also referred to as a-lipoproteins since their mobility on paper 
or starch gel electrophoresis is similar to the a-globulins (Levy and 
Fredrickson, 1965). Analytical ultracentrifugation studies have 
demonstrated that lipoprotcins in the 1.063 -1.21 g/ml density range 
are heterogeneous and may be classified into two populations, HDL2 
(1.063 -1.12 g/ml) and HDL 3 (1 . 12 -1.21 g/ml) (Shore and Shore, 1957). 
HDL is characterised by a high protein to lipid ratio (approx-
imately 1). It has a chemical composition (H~L2 + HDL 3) of approximately 
15% cholesteryl ester, 3% free cholesterol, 6% triglyceride, 21% 
phospholipid with 55% protein (Skipski, 1972). The phospholipid 
moiety consists of almost 75% lecithin. 
The molecular weights of HDL2 and HDL 3 are 3. 6 x 10
5 dal tons 
and 1. 7 x 105 daltons respectively (Scanu and Granada, 1966). HDL2 
5 
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molecules range in size from 60 - 140 A and HDL 3 from 40 - 100 A 
{Forte et al., 1968} . 
. 1.3 Low density lipoproteins 
Plasma LDL may be floated in the ultracentrifuge in t h e density 
range 1 .006-1.063 g/ml . As with HDL, they are desc ribed as B-lipo-
proteins because of their 8-g l obulin mobility on paper or starch 
electrophoresis. This density range { 1. 006 - 1. 063 g/ml ) also cont ain~, 
small amounts of HDL referred to as HDL1 . 
LDL is the major carrier of cholesterol in the circulation. 
It consists of approximately 25% protein, 38% cholesteryl ester, 10% 
free cholesterol, 5% triglyceride and 22% phospholipid {Lindgren et al., 
1959}. 6 Estimates of the molecular weight vary from 2. 2 to 2. 7 x 10 
daltons {Lindgren et al., 1951; Scanu and Wisdom, 1972). LDL is a 
0 
spherical particle with an average diameter of 220 A (Forte et al., 
1968) . 
The major LDL fraction of hµman plasma lies in the d. 1.019 -
1.050 g/ml range. Although lipoprotein particles in the ranged. 
1. 006 - 1. 019 g/ml are usually included in the LDL range, recent 
metabolic studies {Bilheimer et al., 1972; Eisenberg et al., 1973), 
as well as those in this thesis, indicate that lipoproteins in this 
class {termed LDL1 ) are distinct in their metabolic behaviour from the 
major LDL class and so should be considered as a separate lipoprotein 
species. These lipoproteins appear to belong to a remnant lipoprotein 
class, the characteristics of which are discussed in section 1.5.2. 
1.1.4 Very low density lipoproteins 
Plasma VLDL float in the ultracentrifuge at salt density 
1.006 g/ml. VLDL particles thus have a hydrated density of less than 
1.006 g/ml which is the density of plasma (Havel et al., 1955). These 
lipoproteins are referred to as pre B-lipoproteins because they migrate 
slightly further on paper or starch electrophoresis than the B-lipo-
protein class. 
6 
VLDL is a heterogeneous class of lipoprotein particles. It is 
often further divided into various subfractions based on the flotation 
rate (in the ultracentrifuge) of various sized particles. The flotation 
rate (sf) of a lipoprotein is expressed in Svedberg flotation units 
-13 (i.e. negative sedimentation units as 10 cm/sec/dyne/g) in a medium 
of salt density 1.063 g/ml. Using this form of reference, VLDL particles 
are in the sf 20 - 400 range (while LDL1 and LDL2 are in the sf 12 - 20 
and O - 12 ranges respectively) . 
The chemical composition of VLDL is variable because of the 
considerable variation in particle size. Larger VLDL particles contain 
more triglyceride and phospholipid at the expense of protein and 
cholesteryl ester. Average values for VLDL composition (sf 20 - 400) 
are 55% triglyceride, 20% phospholipid, 11% free cholesterol, 4% 
cholesteryl ester with 10% protein (Skipski, 1972). 
1.1.5 Chylomicrons 
In contrast to the other plasma lipoproteins, which are always 
seen in normal human plasma, chylomicrons are found only after a fatty 
meal. They are not present in plasma from normal fasting subjects. 
7 
Chylomicrons, which are very large triglyceride - rich particles consist 
of approximately 1% protein, 86% triglyceride, 1% free cholesterol, 
6% esterified cholesterol and 6% phospholipid (Skipski, 1972). Chylo-
microns do not migrate from the origin on par,cr or starch electro-
0 
phoresis. They range in size from 750 -6,000 A (Bierman et al., 1966). 
The basis of distinguishing between VLDL and chylomicrons 
(both float in the ultracentrifuge at d. 1.006 g/ml) is that almost all 
of the triglyceride carried in chylomicrons is considered to be of 
exogenous origin only, i.e. triglyceride absorbed from the intestine, 
whereas VLDL carries triglyceride of endogenous origin predominantly 
derived from the liver. Chylomicrons are usually defined as particles 
with flotation rates of sf >400, though, there is some overlap of 
particles in the VLDL and chylomicron range. 
1.1.6 Lp-a 
In addition to the major lipoprotein classes described, a 
further lipoprotein class, Lp-a, may also be isolated in the range 
d. 1.050 -1.12 g/ml in the majority of people. This lipoprotein, which 
exhibits pre-6 mobility on agarose electrophoresis, has a molecular weight 
of approximately 5 x106 daltons. The functional significance of this 
lipoprotein, which is similar in lipid but not apolipoprotein composition 
to LDL is unknown. Its plasma concentration is thought to be determined 
by polygenic inheritance (Albers et al., 1974). 
1.2 APOLIPOPROTEINS 
1.2.1 Nomenclature 
It is convention to refer to the protein moieties of lipo-
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proteins a? 'apolipoproteins' or 'apoproteins'. Apolipoproteins may 
be obtained by the removal of the lipid moieties from the lipoproteins, 
thus leaving the protein moiety only. This process, usually employing 
organic solvents, is termed delipidation. 
Two systems of apolipoprotein nomenclature are in current 
use. The system proposed by Alaupovic and colleagues stems from the 
premise that apolipoproteins are the sole determinants of lipoprotein 
families which exist as definable physical entities. Thus Alaupovic 
defines an apolipoprotein as 'a protein which binds through pre-
dominantly non-covalent interactions, neutral lipids and phospholipids 
to form a soluble polydiverse lipoprotein family' (Alaupovic, 1971). 
Thus, the A apolipoproteins form the LP-A family which are found 
primarily, but not exclusively in HDL. Similarly, the B apolipoprotein 
forms the LP-B family constituting almost solely LDL but also present 
in significant amounts in VLDL. The LP-C family predominates in VLDL 
8 
and HDL. Further lipoprotein families have been more recently postulated, 
namely LP-D and LP-E as will be described. 
The other system in use for apolipoprotein nomenclature is 
to classify apolipoproteins according to their carboxy terminal amino 
acid residue e.g. apolipoprotein-serine (apo-ser) (Fredrickson et al., 
1972). Though there are difficulties with both systems, the ABC system 
is most commonly employed because of the occurrence of different apo-
lipoproteins with the same carboxy terminal amino acid (Kastner and 
Alaupovic, 1971) and because errors have been made in the initial 
determination of the apolipoprotein carboxy terminal amino acids 
(Herbert et al., 1971). 
Apol.ipoprote ins may be separated by a vari e ty of technique s 
that separate proteins according to their respective sizes and/or 
electrostatic charges. These include gel chromatography on Sephadex 
G-150 and G-200, affinity chromatography on concanavalin-A sepharose, 
ion - exchange chromatography .on DEAE cellulose, polyacrylamide gel 
electrophoresis and solubility in weak salt solutions (Brown, Levy 
and Fredrickson, 1970a, 1970b; Shore and Shore, 1973; Herbert et al., 
1973; Kane, 1973; Lee and Alaupovic, 1974). 
1.2.2 The B apolipoproteins 
9 
After delipidation of VLDL, the resulting apo-VLDL may be 
fully solubilised only in buffers containing detergents, e.g. sodium 
dodecyl sulphate. Solubilized apo-VLDL may be resolved into two 
fractions by chromatography on Sephadex G~lSO (Brown, Levy and 
Fredrickson, 1970a). The protein that elutes in the void volume of the 
column is identical to the major apolipoprotein of LDL i.e. the B 
apolipoprotein (Gotto et al., 1972). This protein is therefore common 
to VLDL and LDL and is also a maJor apolipoprotein of chylomicrons 
(Kestner and Holasek, 1972). The B apolipoprotein imposes extreme 
difficult ie s in characterisation because of its aqueous insolubility 
when delipidated with organ ic solvents. It has been reported to 
consist of two subunits each having a molecular weight of 250,000 
(Smith et al., 1972). Further sub-unit structure has been suggested 
from studies with maleyated B apolipoprotein (Kane et al., 1970), and 
with B apolipoprotein of LDL delipidated using sodium deoxycholate and 
then applied to SOS gels. Molecular weights of 9,500 and 13,000 have 
been suggested for the fundamental subunits (Chen and Aladjan, 1974). 
i: I 
1.2.3 The .c apolipoproteins 
The other major protein of VLDL i s the C apolipoproteins. 
These apolipoproteins, which are also found in HDL, may be further 
fractionated into at least four distinct proteins (C-1, C-11, C-111-1 
and C-111-2) by chromatography on DEAE cellulose (Herbert et al., 
1973). 
column. 
Apo C-1 i s the first peptide to elute from the ion-exchange 
It is a single polypeptide chain of 57 amino acids of known 
sequence (Shulman et al. , 1975; Jackson et al., 1974) with serine as 
its carboxy terminal amino acid. Hence, it is also referred to as 
apo-ser1ne. It was initially named apo-valine due to the incorrect 
identification of the carboxy terminal amino acid (Brown et al., 
10 
1970b). The molecular weight of apo C-1 is approximately 7,000. This 
peptide has been reported to be an activator of a lipoprotein lipase 
purified from post-heparin plasma (Ganesan et al., 1971; Ganesan and 
Bass, 1975), as well as an activator of the plasma enzyme lecithin: 
cholesteryl acyl transferase (LCAT) (Garner et al., 1972). Apo-C-1 has 
slight stimulatory activity on lipoprote in lipase activities from a 
number of sources (except milk lipase) but js inhibitory at higher 
concentrations of the peptide (Havel el al ., 1973aj. 
The second protein to be eluted from the ion-exchange column 
1s apo C-11, which is a single polypeptide chain of approximately 95 
amino acids and a molecular weight of 11,000 (Brown et al., 1970b). 
It is a potent activator of lipoprotein lipase from all sources 
(Havel et al., 1973a). The amino acid sequence is, at present,unknown. 
Glutarnic acid is the carboxy terminal amino acid and hence it 
is also referred to as apo-glutamic acid (apo-glu) (Brown et al.,1970b). 
The two final major proteins to be eluted.from the column are 
the apo C-111 peptides. They are polymorphic forms of the same 
peptide of 79 amino acids of known sequence. To the amino acid in 
the 74th position of the sequence (threonine) is attached a single 
carbohydrate chain containing one molecule of galactosamine and 
galactose plus one or two molecules of sialic acid (Brewer et al., 
1974). A third polymorphic form of apo C-111 isolated by iso-electric 
focussing contains no sialic acid residues (Albers and Scanu, 1971). 
These three peptides, having a molecular weight of 9,500, are 
distinguished according to their sialic acid residue content as apo 
C-111-0, apo C-111-1 and apo C-111-11. A fourth polymorphic form of 
apo C-111, apo C-111-111 has recently been described, though its 
sialic acid content has not been confirmed (Kane et al., 1975). It 
is unstable upon delipidation, losing some of its sialic acid content. 
The effect of apo C-111 on lipoprotein lipase is similar to that 
observed for apo C-1 (Havel et al., 1973a). 
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All the apo C proteins are capable of forming stable complexes 
with phospholipid (Forte et al., 1974)· which may then bind neutral 
lipids. 
The C apolipoprote ins have also been referred to as 'D 
peptides' in the literature (Brown et al., 1969), however, this 
nomenclature system is no longer employed and should not be confused 
with the D apolipoprotein (section 1.2.6). 
1.2.4 Apolipoprotein E 
A further apolipoprotein, enriched in arginine, is found 
preferentially in cholesteryl ester rich VLDL (Shore and Shore, 1974; 
Shelburne and Quarfordt, 1974). The af>olipoprotein is also found 
in HDL from cholesterol fed swine (Mahley et al., 1975) and from HDL 
of LCAT deficient humans (Utermann et al., 1974). This protein is 
termed arginine-rich protein or apolipoprotein E (Utermann et al., 
1974, 1975). It has a molecular weight of between 3.3 and 3.9 x 104 
daltons and has alanine as its carboxy terminal amino acid residue. 
It elutes off G-150 Sephadex in association with the B apolipoprotein 
(first fraction). 
1.2.5 The A apolipoproteins 
The A apolipoproteins, found predominantly in HDL consist 
of at least two proteins, apoA-1 and apoA-11 (Shore and Shore, 1969; 
Scanu et al., 1969). Both proteins have carboxy-terminal glutamine 
(Kastner and Alaupovic, 1971) and so are also termed apo-gln-1 and 
apo-gln-11. 
ApoA-1, the major protein of HDL, 1s a single polypeptide 
chain of 245 amino acids of known sequence (Baker et al., 1975). It 
has a molecular weight of 28,000. It 1s an activator of lecithin: 
cholesteryl acyl transferase. 
ApoA-11 consists of two identical polypeptides of 77 amino 
acids of known sequence linked together at the 6th position by a 
disulphide bond (Brewer et al., 1972). It has a molecular weight of 
16,000. 
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Both apoA-1 and apoA-11 readily bind lipids, A-11 having a 
greater affinity than A-1. However, when both apolipoproteins are 
present, A-11 increases the binding capacity of A-1 (Ritter et al., 1974). 
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1.2.6 D apolipoprotein 
A- further apolipoprotein, found predominantly in HDL, has 
been referred to as the 'thin line polypeptide' because of the size of 
the precipitin line on double diffusion analysis of HDL and anti-HDL 
(Alauvovic et al., 1972; Mcconathy and Alaupovic, 1976). This protein 
is inununologically different to the A, B or C proteins (Kastner, 1974a). 
It has been designated apolipoprotein D (Mcconathy and Alaupovic, 1973, 
1976) and said to be a completely separate moiety of plasma lipoproteins 
with a distribution extending from VLDL to HDL. Kastner has claimed 
that the 'thin line peptide' is always associated with apoA proteins 
and so has termed it apoA-111. It has a molecular weight of approx-
imately 20,000 with a carboxy terminal amino acid of serine (Kastner, 
1974a). 
1.3 LIPOPROTEINS AND APOLIPOPROTEINS IN OTHER SPECIES 
The plasma lipoproteins described for man occur in many 
animal species, though the circulating levels of these lipoproteins 
may vary markedly probably suggesting species differences in lipop-
rotein metabolism and function. Por example, dogs, rats and guinea 
pigs have a much lower plasma LDL conccntr;-1.tion to tbi:lt observed 1.n 
man. Guinea pigs have an almost complete absence of circulating HDL 
while dogs have higher HDL levels to that observed in man (Nichols, 
1967; Mahley and Weisgraber, 1974; Schonfeld et al., 1974; Sardet 
et aZ., 1972) . 
Many of the maJor apolipoproteins isolated from animal 
species are analogous to those of the human. The B apolipoprotein 
has been found in many species though no species variation has been 
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described. A-1 and A-11 apolipoproteins have been described in the 
rat, l\-1 having a molecular weiqht of 26,000 daltons while A-11 
(molecular weight 8,000 claltons) is in the monomeric fonn rather than 
the dimer observe:d in humans (JTcrl.Jcrt rt al. , 1974) . l\-1 and l\-11 
have also been isolated from several non-human primates (Blaton ct al., 
1974; Edelstein et al., 1974; Scanu et al., 1974). 
Low molecular weight apolipoproteins analogous to the human 
C apolipoproteins have also been identified in VLDL and HDL of 
several animal species. In the rat, four C apolipoproteins have been 
described, C-1, C-11 , C-111-0 and C-111-111. C-11 is an activator of 
lipoprotein lipase (Henderson et al ., 1974). Apolipoprotein E has also 
been found in several species. The amino acid composition of apo E 
from cholesterol fed rabbits is similar to that of man (Shore and 
Shore, 1974; Shore et al ., 1974). 
Many aspects of human lipoprotein mctuboljsm, particularly 
those related to lipoprotcin biosynthesis, have been deduced from 
studies in the rat. Some studies cannot be readily carried out in 
man and it should be borne in mind that similar mechanisms may not 
necessarily operate in both species. 
1. 4 BIOSYNTHESIS OF LIPOPRO'l1 EINS AND TIJEIR METl\BOLIC FUNCTION 
1.4.1 Chylomicrons and VLDL of intestinal origin 
Chylomicrons are the principal form in which absorbed (or 
dietary) lipid is transported from the intestine, first, into the 
lymph channels and then finally via the thoracic duct into the blood-
stream. Synthesis of chylomicrons takes place in the small intestine 
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during active fat absorption. 
In the intestinal lumen, dietary triglycerides (emulsified) 
are hydrolysed by pancreatic lipases at the 1 and 3 positions of the 
triglyceride molecule, forming free fatty acids and monoglycerides. 
These products, in combination with bile salts, form miccllar structures 
which are then absorbed into the mucosal cell (Johnston, 1968). The 
absorption process of trigJyceride (and probably cholesterol) appears 
to be influenced by the nature of the fatty acid in position 2 of the 
triglyceride molecule (Klauda and Quackenbush, 1971). 
The formation of micellar complexes of bile salts, fatty 
acids and monoglycerides is a prerequisite for the absorption of 
dietary cholesterol (Simmonds et al., 1967; Sylven and Borgstrom, 
1968). Dietary cholesteryl esters are hydrolysed by pancreatic 
cholesteryl esterase prior to absorption (Shiratori and Goodman, 1965). 
The intestine is capable of cholesterol (Dietschy and Gamel, 1971), 
phospholipid (Sinclair, 1929) and triglyceride synthesis (Johnston, 
1968). Cholesteryl esters of intestinal origin exhibit a marked 
specificity for oleic acid and are largely independent of the dietary 
fatty acid (Karmen et al., 1963; Blomstrand et al., 1964). 
The synthesis of the B apolipoprotein by the intestine has 
been demonstrated in the rat (Windmueller and Levy, 1968; Kessler et al., 
1970; Windmueller et al., 1973) and recently in man (Rachmilewitz et al., 
1976). The synthesis and assembly of the lipid moieties of chylomicrons 
occur in the smooth and rough endoplasmic reticulum of the intestinal 
cell. Final assembly of the lipoprotein takes place in the Golgi 
apparatus from which it is released into the lymphatics. 
I, 
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VLDL is also synthesised by the intestine even in the fasting 
state (Jones and Ockner, 1971; Tytgat et al., 1971). It is not known 
whether chylomicrons and VLDL (of intestinal origin) belong to a 
single lipoprotein class or whether they represent two functionally 
distinct lipoprotein species. The B apolipoprotein content of 
chylomicron and lymph VLDL demonstrate differing relationships with 
lipoprotein size suggesting that VLDL and chylomicrons are discrete 
lipoprotein species and VLDL is not transformed into chylomicrons 
merely by the addition of lipid (Glickman and Kirsch, 1974). 
Lymph contains lipoproteins of a and B mobility on paper 
electrophoresis (Courtice and Morris, 1955). However, examination of 
the density distribution of the A, Band C apolipoproteins in lymph 
reveals striking differences to that observed in plasma (Reichl et al., 
1973). Plasma LDL and probably HDL appear to be able to pass from the 
plasma compartment into lymph although probably undergoing some 
modification (Reichl et al., 1973; Reichl et al., 1975). The ability 
of plasma VLDL to pass into lymph is not known. The C apolipoproteins 
of plasma VLDL may be found in lymph (Reichl et al., 1975) but their 
entry is probably via HDL rather than VLDL, as in these studies, early 
and rapid loss of VLDL C apolipoproteins to HDL was observed in the 
plasma. 
1.4.2 Very low density lipoproteins 
VLDL is the major carrier of triglyceride of endogenous 
origin in the circulation. The liver appears to be the most important 
site of VLDL synthesis (Havel et al., 1962; Stein and Shapiro, 1959; 
Sundler et al., 1973). However, as previously mentioned, the relative 
1, 
1, 
I 
I, 
I 
I! 
; 
Ii 
Ii 
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I 
' 
: contribution of VLDL of intestinal origin to the plasma VLDL pool in 
man is not known. 
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In the post-absorptive state, plasma FFA are the sole pre-
cursors of VLDL triglycerides released into the circulation by the 
liver (Havel, 1961). The hepatic uptake of plasma FFA is directly 
proportional to the plasma FFA concentration (McElroy et al., 1960; 
Fine et al., 1960). The release of triglyceride by perfused rat livers 
is related to the FFA concentration of the perfusing medium (Nestel 
and Steinberg, 1963). In man, the in vivo secretion of triglyceride by 
the liver appears to be highly correlated to the hepatic uptake of plasma 
FFA (Havel et al., 1970a; Boberg et al., 1972). 
Liver and adipose tissue are capable of lipogenesis from 
carbohydrate (Jansen et al., 1966; Zakim et al., 1969; Ballard et al., 
1969). In man, the synthesis of fatty acids is potentially greater in 
the liver than adipose tissue (Shrago et al., 1971) although adipose 
tissue is capable of fatty acid synthesis de nova (Goldrick and Galton, 
1974). Barter et al. (1972) have demonstrated significant incorporation 
of glucose carbon atoms into VLDL triglyceride - fatty acids only in 
subjects consuming large amounts of carbohydrates. The liver is also 
capable of phospholipid (Glauman and Dallner, 1968) and cholesterol 
synthesis (Chesterton, 1968). 
The origin of the cholesteryl ester moiety of human VLDL is 
not clear. In the rat, perfusion of the liver leads to the secretion 
of newly synthesised cholesteryl ester in VLDL (Roheim et al., 1963) ·. 
Gidez et al. (1967) demonstrated, in rats fed diets of differing fatty 
acid composition, a similarity in plasma VLDL and hepatic cholesteryl 
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esters. In man, the cholesteryl ester composition of the various plasma 
lipoproteins are similar and mostly contain linoleic acid though they 
can be influenced by the fatty acid composition of the diet (Nestel and 
Couzens, 1966; Goodman and Shiratori, 1964). Furthermore, the chol-
esteryl esters of liver and plasma lipoproteins are different in man 
(Nestel and Monger, 1967). Cholesteryl esters have been shown to 
transfer in vitro from HDL to VLDL in exchange for triglyceride 
(Rehnborg and Nichols, 1964; Nichols and Smith, 1965). Since the plasma 
cholesteryl esterifying enzyme, LCAT (lecithin: cholesteryl acyl 
transferase) is more active, in vitro, in the presence of HDL than 
with VLDL (Akanuma and Glomset, 1968) it is thought that cholesteryl 
esters are initially formed in HDL and then transferred to VLDL. On 
the other hand precursor-product relationships between VLDL and HDL 
cholesteryl ester following the injection of 3H-mevalonic acid into man 
have not confirmed that VLDL cholesteryl esters were derived from HDL 
(Barter, 1974). More recently Barter and Lally (1976) have described 
the existence of two pools of IIDL cholesteryl esters one of which may 
be the source of VLDL cholesteryl esters (the role of LCAT in the 
formation of cholesteryl esters of VLDL will be discussed further in 
section 1.6.2). 
Synthesis of the B apolipoprotein is necessary for the release 
of VLDL from the liver and from intestine (Isselbacher et al;, 1964 ; 
Bar-On et al., 1973). The liver in the rat is capable of synthesising 
all VLDL apolipoproteins (Windmueller et al., 1973). It is not clear, 
however, whether VLDL gains its complement of C apolipoproteins prior to 
release from the liver or, following release from circulatory HDL. The 
intestine of the rat does not appear to synthesise C apolipoproteins 
(Windmueller et al., 1973). Studies on the rates of labelling of VLDL 
and HDL C apolipoproteins from labelled amino acids during perfusion 
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of rat liver are not consistent; the results appear to be dependent upon 
the nature of the perfusing medium (Windmueller et al., 1973; Noel and 
Rubinstein, 1974). However, the relative rates of labelling of VLDL and 
HDL C apolipoproteins from amino acids may not necessarily indicate the 
origin of VLDL C apolipoproteins as (1) the hepatic pools from which 
the C apolipoproteins may be derived are, as yet, not defined (Kook 
and Rubinstein, 1973) and (2) the rapid and ready exchange of Capo-
lipoproteins observed between VLDL and HDL may possibly be more 
pronounced with nascent lipoproteins. Examination of VLDL in the Golgi 
apparatus of rat liver suggests that nascent VLDL obtain some of their 
C apolipoprotein following release into the circulation (Nestruck and 
Rubinstein, 1975). The arginine-rich protein of VLDL may also be derived 
from HDL (Marsh, 1976) though it has been observed in VLDL prior to 
release from the Golgi apparatus (Nestruck and Rubinstein, 1975). 
1.4.3 High density lipoprotein 
In the rat, HDL is synthesised by the liver (Windmueller 
and Levy, 1967) and to some extent by the small intestine (Windmueller 
and Spaeth, 1972). Hepatic HDL synthesis is independent of VLDL 
synthesis as demonstrated by studies using orotic acid to inhibit 
hepatic VLDL production. The liver appears to · synthesise all of the 
apolipoproteins of HDL (Roheim et al., 1966; Windmueller et al., 1973; 
Marsh, 1976) though HDL lipoproteins synthesised by the intestine are 
devoid of C apolipoproteins (Windmueller et al., 1973). 
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1.4.4 Low density lipoproteins 
Studies examining the synthesis of LDL by perfused rat livers, 
while not confirming the absence of hepatic LDL synthesis, indicate that 
it is minor in comparison to VLDL and HDL synthesis (Windmueller et al., 
1973). In the above study, it was suggested that the incorporation of 
radioactivity into the d. 1.006 ~l.063 g/ml range was the result of HDL 
contamination, though this was not ascertained. Marsh (1974) has 
suggested the possibility of VLDL being converted to LDL by the hepatic 
triglyceride lipase, during the secretion of VLDL. This appears 
unlikely however, as the presence of heparin in liver perfusates does 
not appear to alter the labelling patterns of the lipoprotein proteins 
(Windrnueller et al., 1973). Thus, in the rat, the origin of LDL is 
not clear although recent in vivo studies of Faergeman et al. (1975) 
suggest that all LDL is derived from VLDL in the circulation. In 
squirrel monkeys, a small fraction of LDL may be derived from direct 
secretion but most (at least 80%) of circulating LDL is derived from 
VLDL catabolism (Illingworth, 1975). LDL, in man, is thought to be 
the product of VLDL catabolism (Bilheimer et al., 1972; Sigurdsson 
et al., 1975) and not independently synthesised by the liver (as will 
be discussed in section 1.5.2). 
1.5 LIPOPROTEIN CATABOLISM 
1.5.1 Chylomicron catabolism 
Upon entering the circulation, chylomicron triglyceride and 
cholesteryl esters are removed very rapidly. The steps involved in 
chylomicron catabolism, as proposed by Redgrave (1970) involve the 
removal of .triglyceride by extra-hepatic tissues followed by removal 
of the 'remnant'. The remnant lipoproteins are rich in cholesterol, 
but poor in triglyceride. This proposal was first put forward by 
Nestel et al. (1963) who demonstrated chylomicron triglyceride, but 
not cholesteryl ester, clearance from the circulation of a hepatectom-
ised dog. 
Thus, the first step in chylomicron catabolism involves the 
hydrolysis of triglycerides by lipases of extra-hepatic origin. 
Purified lipoprotein lipase is more active against plasma chylomicrons 
than against chylomicrons isolated from the thoracic duct (Dolphin and 
Rubinstein, 1974). Havel et al. (1973b) have shown that when chylo-
microns enter the circulation, there is net transfer of apolipoprotein 
C-11, the activator of adipose tissue lipoprotein lipase, from HDL to 
chylomicrons. This stage of lipase mediated chylomicron catabolism is 
probably similar to that for VLDL utilizing similar mechanisms for the 
removal of surface components as will be discussed in subsequent 
sections. Both chylomicrons and VLDL serve as substrates for lipo-
protein lipase though chylomicrons are hydrolysed at a greater rate 
(Fielding and Higgins, 1974). 
In animals the remnant particles of chylomicron catabolism 
are thought to be removed by the liver. Chylomicron cholesteryl ester 
is removed by the liver (Goodman, 1962; Nestel et al., 1963; 
Quarfordt and Goodman, 1967; Stein et al., 1969; Redgrave, 1970). The 
cholesterol taken up by the liver is converted to bile acids or is 
secreted from the liver as unesterified cholesterol either into the 
21 
22 
bile or intQ the plasma lipoproteins (Nilsson and Zilversmit, 
1972). The fate of the chylomicron protein components are not entirely 
known. The chylomicron C apolipoproteins, which were probably originally 
derived from HDL, are thought to return to HDL during catabolism. 
1.5.2 Catabolism of VLDL 
The removal of triglyceride from the circulation is mediated 
by the enzyme lipoprotein lipase (Korn, 1955). This enzyme (glyceryl 
ester hydrolase - E.C. 3.1.1.3) acts at the endothelial surface of the 
capillaries, hydrolysing triglycerides to FFA and glycerol. Some of 
the resulting FFA are removed from the circulation, mainly into adipose 
tissue and muscle (Eaton et aZ., 1969; Bergman et aZ., 1971). Lipo-
protein lipase (which is discussed more fully in section 1.6.1) may be 
released into the circulation following the intravenous administration 
of heparin, resulting in an elevation of plasma FFA with concomitant 
decrease in plasma triglyceride concentration (Levy et aZ., 1966). 
The catabolism of VLDL triglyceride is said to proceed via a 
step-wise conversion of large (and triglyceride-rich) particles to 
smaller particles of higher density and lower triglyceride content 
(Barter and Nestel, 1972). In these studies, precursor-product relation-
ships were demonstrated between triglyceride fatty acids of VLDL 
subfractions sf 100-400 and sf 20-100. Following the injection of 
heparin into man, there is a rapid reduction in plasma VLDL concentration 
with concomitant increase in the low density lipoproteins (sf 5-30) and 
HDL (Nichols et aZ., 1968; Levy et al., 1966). Shore and Shore (1962) 
observed that post-heparin lipolytic activity resulted in the in vitro 
conversion of VLDL sf 20-400 to smaller lipoprotein particles sf 11-20. 
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These remnant lipoproteins, when compared to VLDL, contained more B apo-
lipoprotein and cholesteryl ester but less triglyceride and C apolipo-
proteins (Eisenberg et al., 1973). 
Precursor-product relationships between VLDL and LDL tri-
glyceride fatty acids suggest that the small amount of triglyceride in 
LDL is derived from VLDL (Havel, 1961; Farquhar et al., 1965; Quarfordt 
et al., 1970). Administration of nicotinic acid to man, which reduces 
plasma FFA levels, results in an initial fall in VLDL lipids followed 
by a later delayed fall in the lipids of LDL, suggesting that the lipids 
of LDL may be derived from VLDL. The lipids of HDL do not change 
(Carlson et al., 1968). 
Precursor-product relationships between VLDL and LDL protein 
(total lipoprotein protein) in man using VLDL labelled in its protein 
. . h 131I 125 65 1 h. . ( . 1. t l 1958 moiety wit , I or Se- se enomet ionine Git in e a., ; 
Bilheimer et al., 1972; Eisenberg et al., 1973; Eaton et al., 1976) 
have, as for the triglyceride moiety, suggested that the protein moiety 
of LDL is derived from VLDL. The interpretation of these relationships 
however is limited. VLDL and LDL have, in common, the B apolipoprotein 
(Gotto et al., 1972) as part of their protein moiety. However the 
apolipoproteins of VLDL are markedly heterogeneous. Although, in some 
of the other studies, the B apolipoprotein of VLDL and LDL was isolated 
by polyacrylamide gel electrophoresis and gel chromatography, specific 
activity data of the B apolipoprotein, which is required for a kinetic 
demonstration of a precursor-product relationship (Zilversmit, 1960) 
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between VLOL and LDL was not measured. Isolation of the B apolipoprotein 
of human VLDL and LDL by immunological techniques during the catabolism 
of isotopically-labelled human VLDL injected into monkeys demonstrated 
clearly that the B apolipoprotcin of VLDL was transferred into the LDL 
range (Gulbrandsen et al., 1971). 
In two recent studies of the catabolism of isotopically 
labelled VLDL in man, the specific activities of the B apolipoprotein 
of VLDL and LDL have been measured. Sigurdsson et al., (1975) isolated 
the B apolipoprotein of VLDL and LDL (d. 1. 006 - 1. 063 g/ml) following 
the injection of VLDL - 125I. The B apolipoprotein was isolated by 
chromatography on Sephadex G-150. The precursor-product relationships 
(from seven studies) between VLDL and LDL suggested that most, if not 
all, of the B apolipoprotein of LDL was derived from VLDL. A further 
section of these studies involving eight investigations (on normo-
triglyceridaemic subjects) demonstrated that, in these subjects at 
least, all VLDL was converted to LDL. In contrast, the results of a 
study on a single type 4 hyperlipoproteinaemic subject indicated a 
further pathway for LDL synthesis (Phair et al., 1975). In this study 
th b
. · · d · h 14c 1 · d h f d' e su Ject was inJecte wit - eucine an t e appearance o ra 10-
activity in the B apolipoprotein of VLDL and three subfractions of LDL 
(d. 1.006 - 1.02 g/ml; d. 1.02 - 1.04 g/ml; d. 1.04 - 1.06 g/ml) was 
observed. A computer-devised model of lipoprotein metabolism was 
formulated to fit the specific activity data obtained and the results 
suggested that in this individual, VLDL was catabolised by more than 
one route. Not all VLDL B apolipoprotein was transferred to LDL. 
Similar studies in the rat are also conflicting with respect to 
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the origin of the plasma LDL. While the nature of the precursor-product 
relationships of VLDL and LDL B apolipoprotein obtained by Faergeman 
et al. (1975) suggest that LDL is derived solely from VLDL, those of 
Fidge (personal conunun.) indicate a second origin of LDL other than from 
VLDL. In marked contrast to observations in man, almost 90% of VLDL 
is removed in the rat predominantly by the liver, without being converted 
to LDL (Fidge and Paulis, 1975; Faergeman et al., 1975). 
In vitro incubations of labelled VLDL in plasma have demonstrat-
ed the ready capacity of the VLDL C apolipoproteins to exchange between 
the various lipoproteins and particularly with HDL (Bilheimer et al., 
1972). Similar exchange of phospholipids between VLDL and HDL has been 
demonstrated (Illingworth and Portman, 1972). These exchange processes 
are dependent upon the relative lipoprotein concentrations present in 
the system (Bilheimer et al., 1972; Eisenberg et al., 1972). In contrast, 
the B apolipoprotein does not exchange between the various lipoprotein 
fractions and its passage from one lipoprotein species to another is an 
active conversion process requiring catabolic activity. The transfer 
of B apolipoprotein, in contrast, to the exchange of C apolipoproteins 
is solely unidirectional (Bilheimer et al., 1972; Eisenberg et al., 
1972). The catabolism of VLDL involves a process of active triglyceride 
removal from the lipoprotein. During this enzyme-mediated process, the B 
apolipoprotein is transferred into the LDL cla~s while the loss of VLDL 
C apolipoproteins to the HDL fraction may still be the result of an 
exchange process (concentration dependent), the equilibrium of which is 
determined by the relative concentrations of the accepting lipoproteins 
(mainly VLDL and HDL) (Schonfeld et al., 1972). From estimates of the 
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B apolipoprotein content of individual particles, Eisenberg et al. (1973) 
have concluded that the catabolism of one VLDL molecule results in the 
formation of only one LDL molecule. 
In the studies of Bilheimer et al. (1972) it was observed 
that lipoproteins in the sf 12-20 range (LDL1 ) were labelled far more 
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rapidly than LDL2 (sf 0-12) following the injection of VLDL- I into 
humans. Shore and Shore (1962) had previously described the in vitro 
conversion of VLDL (sf 20-400) into sf 12-20 particles during incubation 
in post-heparin plasma. From these observations, the role of LD\ as an 
intermediate in the conversion of VLDL to LDL2 was postulated (Bilheimer 
et al., 1972). Precursor-product relationships between free cholesterol, 
triglyceride,phospholipid and some cholesteryl ester of VLDL, LDL
1 
and 
LDL2 have been suggested from studies in monkeys (Illingworth et al., 
1974). Analytical ultracentrifugation studies have suggested that the 
intermediate lipoprotein has an sf value of 12-60 rather than 12-20 
(Eisenberg et al., 1973). These authors also suggested that the 
conversion of the intermediate lipoprotein to LDL
2 
was mediated by a 
process not clearly influenced by heparin induced lipolytic activity. 
The catabolism of VLDL to LDL2 may therefore be a two-step process 
involving the initial formation of intermediate lipoproteins followed 
by the formation of LDL. 
Few studies have characterised the physical and chemical 
properties of the remnant or intermediate lipoprotein. Shore and Shore 
(1962) examined the remnant produced, in vitro, by the action of human 
plasma post-heparin lipolytic activity on VLDL. 65% of the VLDL protein 
was recovered in the d. 1.006 -1.022 g/ml range. Lipoproteins in this 
range contained 15% protein, 7% free cholesterol, 22-26% cholesteryl 
l . 
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ester, 17% phospholipid and 35-39% triglyceride. 
Remnants produced in vitro, by the action of rat plasma post-
heparin lipolytic activity mostly are contained in the d< 1.006 g/ml 
range {sf 20-100). Diameters of chylomicron remnants range from 
0 0 
400-600 A {Mj¢s et al., 1975) and 150-300 A for VLDL remnants (Eisenberg 
and Rachmilewitz, 1975). When compared to their precursors, these 
remnants are rich in cholesteryl ester and B protein and depleted of 
phospholipids, triglyceride and C apolipoproteins. 
In the formation of remnants from VLDL (in the rat) not only 
are C apolipoproteins, triglyceride and phospholipids lost from the 
lipoprotein but also 40% of esterified cholesterol and 60% of free 
cholesterol {Eisenberg and Rachmilewitz, 1975). A mechanism by which 
free cholesterol may be removed, involving LCAT and HDL, has been 
proposed by Glomset {1968) and will be discussed in section 1.6.2. A 
process by which esterified cholesterol may be removed other than 
through uptake by the liver has not been described. 
1.5.3 Low density lipoprotein 
The catabolism of LDL is less clearly defined than that of 
VLDL, particularly in man. LDL is not converted to lipoproteins of 
higher density and so its catabolism presumably involves its removal 
from the circulation. 
Until recently it has been accepted that plasma cholesterol, 
carried predominantly in LDL in man, is removed primarily by the liver, 
though a small but significant percentage is excreted through the skin 
{Bhattacharyya et al., 1972; Nikkari et al., 1974). Cholesterol is 
I 
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also excreted directly by the gut (Dietschy and Wilson, 1970). 
Cholesterol, upon being taken up by the liver, is partly converted to 
bile acids (Bloch At al., 1943) which then enter the gastrointestinal 
tract where they are largely reabsorbed and returned to the liver via 
the portal vein, thus completing an 'enterohepatic cycle' of bile 
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salts (Reinke and Wilson, 1967; Wheeler, 1972). The rate of catabolism 
is dependent upon several enzymes including 7a-hydroxylase which 
catabolises the first reaction in the pathway of bile acid formation. 
This enzyme is regulated by the reabsorbed bile acids returning to the 
liver from the gastrointestinal tract (Shefer et al., 1970). Hepatic 
cholesterol is also directly secreted into the bile and is partly 
reabsorbed in the gut. 
The liver has been implicated as the major site of LDL 
catabolism in the rat (Hay et al., 1971). These authors demonstrated, 
in normal rats and in male rats treated with oestrogen (which reduces 
131 the level of circulating LDL), uptake and degradation of I-LDL 
(d. 1.006-1.040 g/ml) in the liver. Enhanced uptake and degradation 
was observed in the oestrogen treated animals. However, as previously 
described, VLDL remnants arc also rapidly taken up and degraded by rat 
liver (Faergeman et al., 1974; Faergeman et al., 1975; Fidge and 
Paulis, 1975; Stein et al., 1974) whereas in normotriglyceridaemic 
humans at least, VLDL remnants are probably co~verted to LDL
2 
before 
being removed from the circulation (Sigurdsson et al., 1975). The LDL 
particle in the rat is far more triglyceride-rich than in the human 
(Fidge and Calder, 1972) and so its removal may possibly involve 
different mechanisms. 
Recent studies have indicated that peripheral tissues may play 
an important role in the catabolism of LDL. Sniderman et al. (1974) 
I 
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have compared the catabolism of LDL in normal and hepatectomised pigs 
and found a more rapid disappearance of LDL in the hepatectomised animals. 
The bi-exponential disappearance of LDL observed in the intact animal 
became mono-exponential in the hepatectomised animal. These studies 
demonstrated that some extra-hepatic tissues had the capacity to remove 
LDL irreversibly from the plasma compartment and so have indicated that 
the liver was not the sole site of LDL catabolism. The reason for the 
increased disappearance of LDL from the hepatectomised animals is not 
known, though it was suggested that the liver may serve some function 
which prolongs the life-time of LDL in the plasma-hepatic compartment. 
Many recent investigations, mainly employing cultures of 
human smooth muscle cells (Bierman and Albers, 1975; Albers and 
Bierman, 1976), swine arterial smooth muscle cells (Weinstein et al., 
1976), human fetal aorta cells (Goldstein and Brown, 1975), human 
skin fibroblasts (Goldstein and Brown, 1974; Stein et al., 1975; 
Assman et al., 1975) and human lymphocytes (Vijayogopal and Nestel, 
personal comm.) have demonstrated that cells of many peripheral tissues 
probably have the capacity to catabolise LDL. 
As a result of studies employing cultured skin fibroblasts, 
Goldstein and Brown have proposed a scheme for LDL catabolism, based 
on the initial binding of LDL to the fibroblast, in which the rate of 
cholesterol synthesis and LDL catabolism are linked (Goldstein and 
Brown, 1975). The binding of LDL to these cultured cells leads to 
(1) a transfer of the lipoprotein into the cell (2) hydrolysis of 
cholesteryl ester to free cholesterol within the cell with the subsequent 
inhibition of the enzyme HMG Co A reductase (a regulatory enzyme in 
cholesterol synthesis) by free cholesterol and (3) degradation of 
the LDL protein. Since it appeared that the binding LDL might be 
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defective or absent in fibroblasts prepared from subjects with homo-
zygous familial hypercholesterolaemia, these investigators have proposed 
that, in this disorder, defective binding of LDL resulted in (1) a 
reduced rate of LDL catabolism and (2) a lack of feed-back inhibition 
of HMG Co A reductase. Both these factors would contribute to elevated 
plasma cholesterol and LDL concentrations 
Goldstein and Brown do not comment on the subsequent fate 
of the cholesterol from catabolised LDL (other than that it is re-
esterified in the fibroblast) although others have suggested that the 
cholesterol moiety might be transported back to the liver by another 
protein, possibly in HDL or in the lipoprotein free fraction of plasma 
(Bailey, 1973; Stein et al., 1975). A possible role for HDL in 
cholesterol transport is suggested by the marked deposition of 
cholesteryl esters in peripheral tissues of patients with Tangier 
disease (an abnormality characterised by a marked reduction in the 
concentration of plasma HDL). 
The quantitative importance .of peripheral tissues in LDL 
degradation is uncertain. Recent studies have shown that membranes 
of liver cells bind LDL protein with the same affinity as do fibro-
blasts and other extra-hepatic cells (Bachorik et al., 1976). 
Calculations have shown that the capacity of extra-hepatic tissues to 
degrade LDL, based on ~n vitro studies, greatly exceeds the mass of 
LDL catabolised in vivo. The discrepancy probably arises from the 
artificial conditions of the in vitro studies in which cells, deprived 
temporarily of lipoprotein cholesterol, synthesise surface receptors 
for LDL resulting in an abnormally high rate of LDL binding and cata-
bolism when· the cells are again exposed to LDL. Nevertheless, there is 
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qualitative agreement between the in vitro and in vivo findings in 
homozygous familial hypercholesterolaemia. LDL catabolism is consider-
ably reduced when measured under either condition (Bilheimer et al., 
.l 97 '..J ) . 
1.5.4 High density lipoprotein 
Rachmilewitz et al. (1972) examined the uptake of radio-
activity in various tissues of the rat at time intervals following the 
· · · f 125r ( ' 1 d f h 1nJect1on o HDL- previous y screene so as to remove most o t e 
labelled C apolipoproteins). Highest percentages of TCA precipitable 
radioactivity were located in the liver and small intestine. The degree 
of irnmunochemical recognition of labelled HDL taken up by intact or 
perfused rat liver, using an antibody against HDL, decreased progressively 
with time. These observations ascertained that HDL degradation was 
occurring in the liver (Rachrnilewitz et al., 1972). The removal rates 
of the different apolipoproteins of HDL have been found to be identical 
and similar to the removal rate of the slow component of VLDL suggest-
ing a common pool of C apolipoprotein catabolism that involves HDL 
(Roheim et al., 1972). 
1.6 ENZYMES INVOLVED IN LIPOPROTEIN METABOLISM 
1.6.1 Lipases 
Hahn (1943) first described 'clearing' of chylomicron-rich 
plasma of dogs following intravenous administration of heparin. The 
in vitro addition of heparin to the plasma caused no reduction in 
,turbidity. Similar findings were reported in humans (Anderson and 
Fawcett, 1950). These observations led to the concept that intra-
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venously i~jected heparin releases a 'clearing factor' from some tissue 
site (or sites) in the body and that the 'clearing factor' induces the 
degradation of chylomicrons in plasma. 
Korn (1955) studied the lipase contained in acetone powder 
extracts of heart muscle and adipose tissue. In the presence of 
albumin (to accept released FFA) the enzyme in the tissue extracts 
I 
actively hydrolysed chylomicron triglycerides to FFA and glycerol. 
Little or no hydrolysis occurred when an artifictal emulsion was used 
as substrate, unless the emulsion was pre-incubated with plasma lipo-
proteins or whole plasma. The reaction rate could be increased by the 
addition of small amounts of heparin to the assay system. Korn suggest-
ed that the tissue triglyceride lipase was the same enzyme present in 
post-heparin plasma. This enzyme was referred to as lipoprotein lipase 
and was inhibited by pre-incubation with protamine sulphate or IM NaCl. 
Following intravenous injection of heparin into normal fasting 
humans, lipoprotein lipase rapidly appears in the plasma. The amount of 
lipase released is dependent upon the dose of heparin administered 
(Boberg, 1972). Robinson and Harris (1959) concluded that lipoprotein 
lipase was located on capillary endothelial surfaces and that heparin 
was able to displace it into the circulation. A variety of sulphated 
and non-sulphated polysaccharides produce a similar response when inject-
ed intravenously (Robinson el al., 1959). Histochemical studies with 
perfused adipose tissue and mammary gland also suggest that one site of 
action of the enzyme is at the luminal surface of the capillary endo-
thelium (Blanchette-Mackie and Scow, 1971; Schoefl and French, 1968). 
Lipoprotein lipase released into the circulation is rapidly removed by 
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the liver .(Naito and Felts, 1970). The enzyme has been demonstrated in 
many tissues including heart muscle, skeletal muscle, kidney, spleen, 
aorta and adipose tissue. The enzyme appears to be absent from the liver 
(Mayes and Felts,1968). 
Adipocytes, which are capable of very active lipoprotein 
lipase synthesis, release the enzyme on exposure to heparin, even in 
the presence of inhibitors of protein synthesis (Stewart and Schatz, 
1971, 1974; Stewart et al., 1969; Wing et al., 1967). The inference, 
from these studies, is that cells may store the enzyme, perhaps in an 
inactive form. The secretion of the enzyme from the adipocyte into the 
surrounding tissue has been proposed as an important regulatory mechanism 
of adipose tissue lipoprotein lipase activity (Garfinkel et al., 1976). 
This secretory process is influenced by insulin. Adipose tissue lipo-
protein lipase may also be influenced by administration of glucose 
(Schatz and Garfinkel, 1965) and by the nutritional state (Schatz and 
Garfinkel, 1972; Borensztajn and Robinson, 1970). Interestingly, those 
hormones that inhibit lipoprotein lipases (i.e. catecholamines, 
cortisol,ACTH, TSH and glucagon (Nestel and Austin, 1969) stimulate the 
other major adipose tissue lipases (hormone-sensitive lipases) that 
hydrolyse stored triglyceride. Conversely, insulin, which potentiates 
lipoprotein lipase activity, inhibits hormone sensitive lipase. This 
allows for fine adjustments of fuel flux under different nutritional 
circumstances. In contrast to the hormone sensitive lipase, lipoprotein 
lipase activity does not appear to be dependent upon cyclic-AMP (Khoo 
et al., 1976). In this way, a fine balance of triglyceride uptake, 
storage and utilisation is achieved during varying nutritional states. 
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The small molecular weight apolipoprotein, C-11 (LaRosa 
et al., 1970; Havel et al., 1970b) is a potent activator of lipoprotein 
lipase from many sources. This peptide, because of its surface film 
properties, possibly facilitates access of the enzyme to its substrate 
(Miller and Smith, 1973). C-11 is transferred from HDL to chylo-
microns during alimentary lipemia (Havel et al., 1973b). C-1 and C-111 
apolipoproteins have slight stimulatory effects, in vitro, on purified 
lipoprotein lipase from human plasma when present in low concentrations. 
However, at high concentrations, they markedly inhibit lipolytic 
activity and may abolish the stimulatory effects of C-11 (Havel et al., 
1973a). 
At least three different triglyceride lipases may be found in 
post-heparin plasma. The enzymes differ in their pH optima, inhibit-
ion by protamine sulphate or lM NaCl and activation by the C apolipo-
proteins. One enzyme, identical to lipoprotein lipase is of extra-
hepatic origin and is activated by apolipoprotein C-11 but inhibited 
by NaCl or protamine sulphate (LaRosa et al., 1972; Fielding, 1972; 
Krauss et al., 1973). A second lipase, also similar in properties to 
lipoprotein lipase but not found in adipose tissue, is activated by 
apolipoprotein C-1 and inhibited by lM NaCl and protamine sulphate 
(Ganesan and Bass, 1975; Ganesan et al., 1971). Its origin is at 
present unknown. A third enzyme found in post-heparin plasma differs 
from the first two lipases in that it is insensitive to inhibition by 
protamine sulphate or IM NaCl (LaRosa et al., 1972; Krauss et al., 
1973). This enzyme is secreted by the liver (Greten et al., 1974) and 
has recently been reported to be inhibited by the C apolipoproteins 
(Kinnunen and Ehnholm, 1976). It is termed hepatic triglyceride lipase 
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and will hydrolise a triglyceride emulsion in the absence of serum or 
C apolipoprotein cofactors (Krauss et al., 1973), while for lipoprotein 
lipase activity the presence of phospholipids and serum cofactors is 
obligatory. 
Post-heparin plasma also contains diglyceride and mono-
glyceride activities (Greten et al., 1969; Biale and Shafrir, 1969; 
Nilsson-Ehle and Belfrage, 1972) and phospholipases (Vogel et al., 
1971). Zieve and Zieve (1972) have concluded that most of the phos-
pholipase activity of rat plasma originates in the liver. Recent 
reports have indicated that hepatic triglyceride lipase and possibly 
lipoprotein lipase also have phospholipase A1 activity (Ehnholm et al., 
1975; Scow and Egelrud, 1976). 
1.6.2 Lecithin: cholesteryl acyl transferase 
Sperry (1935) demonstrated an enzyme in normal human serum 
capable of esterifying cholesterol in vitPo. Glomset (1962, 1968) 
proposed that the formation of cholesteryl esters in plasma is catalysed 
by an enzyme which transfers a fatty acyl group from the posit i on 2 of 
lecithin to the 3 hydroxy group of cholesterol. This plasma enzyme, 
which is synthesised by the liver (Osuga and Portman, 1971; Simon and 
Boyer, 1971), is referred to as lecithin: cholesteryl acyl trans-
ferase (LCAT) (E.C.2.3.1.43). While no significant fatty acid transfer 
is observed from phospholipids other than lecithin (Nichols and Gong, 
1971), other sterols than cholesterol may be esterified e.g., B-
sitosterol, cholestanol, stigmasterol and desmosterol (Salen and 
Grundy, 1973; Nordby and Norum, 1974). LCAT is stimulated by A-1, 
C-1 and possibly A-111 apolipoproteins (Fielding et al., 1972; Garner 
et al., 1972; Kostner, 1974b). The enzyme has been shown to complex 
with HDL (Glomset, 1972; Lossow, Shah and Charkoff, 1966). 
The importance of LCAT in lipoprotein metabolism has been 
demonstrated from the lipoprotein patterns observed in patients with 
familial LCAT deficiency (Glomset and Norum, 1973). All known plasma 
apolipoproteins may be found in the lipoproteins of these patients 
though often in abnormal concentrations. All the plasma lipoproteins 
in LCAT deficiency contain low amounts of cholesteryl ester with 
elevated levels of free cholesterol and phospholipid. Abnormally 
large particles, disc shaped, with diameters between 900 and 1200 A, 
may be found in the LDL fraction. An abnormal lipoprotein associated 
with cholestasis, Lp-X, is also found in these subjects. This lipo-
protein is characterised by the presence of albumin (65%) and Capo-
lipoprotein (35%) forming its protein moiety (Alaupovic et al., 1969). 
VLDL in LCAT deficient patients have S rather than pre S migration 
on paper electrophoresis. The HDL concentration may be reduced by 
approximately 66%. These abnormalities can be reversed in vitro by 
the addition of LCAT. 
The in vivo interaction between LCAT and plasma lipoproteins 
is not clear. LCAT may have several functions. First, in man, it may 
provide a large proportion of the cholesteryl esters of plasma lipo-
proteins. The in vitro rates of cholesteryl ester formation (Glomset, 
1968) are similar to those obtained by in vivo measurement of choles-
teryl ester turnover (Nestel and Monger, 1967). Secondly, the LCAT 
reaction may prevent the accumulation of free cholesterol and phospho-
lipids on the surface of lipoproteins, particularly VLDL and chylo-
microns, during their catabolism. Finally, LCAT may assist in the 
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transport of free cholesterol from peripheral tissues to the liver 
(Glomset, 1968; Glomset and Norum, 1973). 
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Akanuma and Glomse t (1968) have demonstrated, using partially 
purified enzyme preparations, that HDL is a preferred substrate for 
LCAT than VLDL. This finding suggested that VLDL cholesteryl esters, 
1n man, are derived from HDL, as implied by the studies of Rehnborg 
and Nichols {1964) and Nichols and Smith {1965) in which HDL 
cholesteryl esters transferred to VLDL in exchange for triglyceride. 
The nature of this exchange is unknown as cholesteryl ester, because of 
its non-polar nature, would be expected to occupy spaces in the core 
of the lipoprotein and so not be available for exchange. Glomset et al. 
{1966) have shown that some HDL species react preferentially with LCAT. 
These "substrate" molecules have higher free to esterified cholesterol 
and higher lecithin to lysolecithin ratios than other, possibly "older", 
HDL. These "substrate" molecules are probably species in the HDL
3 
class {Fielding and Fielding, 1971). 
Recent evidence indicates that free cholesterol in VLDL may 
also serve as an effective s ubstrate for LCAT in the presence of an 
undefined plasma component (d. > 1.225 g/ml) {David et al., 1976). The 
substantial stimulation of LCAT activity by the addition of VLDL and 
chylomicrons has also been described (Marcel and Vezina, 1973). VLDL 
is rich in lecithin (Skipski, 1972). The postu1ated origin of 
cholesteryl esters in HDL has been disputed by Barter (1974) who observed 
from kinetic studies that VLDL cholesteryl ester may be derived directly 
from free cholesterol. It has been proposed that, during the catabolism 
of VLDL, when the triglyceride moiety is being removed by the action of 
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lipolytic enzymes, the exc ess s urface lipids (free cholesterol and 
phospholipid) may be removed by the action of LCAT (Schumaker and Adams, 
1970). If LCAT utilises VLDL free cholesterol as a substrate, the LCAT 
reaction would promote a migration of cholesterol to the core of the 
lipoprotein as it is converted from the free to the esterified form. 
Lysolecithin, the phospholipid product of the reaction may be accepted 
by circulating albumin. If LCAT utilises HDL free cholesterol as a 
substrate, the removal of surface free cholesterol and phospholipids 
from HDL (by the action of LCAT similar to that described for VLDL) 
might result in a transfer of free cholesterol and phosph~lipid from 
VLDL to HDL as these lipid moieties transfer between VLDL and HDL. 
This would result in a net removal of free cholesterol and phospho-
lipid from VLDL. This would be in agreement with the observed net loss 
of cholesterol (free and esterified) from the VLDL during the formation 
of remnants (Eisenberg and Rachmilewitz, 1975). In a similar manner to 
that described for removal of free cholesterol from VLDL, HDL may accept 
free cholesterol from peripheral tissues and transport them back to 
the liver in the esterified form for further metabolism in the liver 
(Glomset, 1968). 
1.7 THE HYPERLIPOPROTEINAEMIAS 
An abnormally increased concentration of one or more of the 
plasma lipoprotein families constitutes hyperlfpoproteinaemia {HLP). 
A system for the correct classification of HLP is hampered by the fact 
that many of the individual steps of lipoprotein metabolism and their 
controlling factors are incompletely understood. 
Primary forms of HLP are generally defined as those which 
result from a genetic defect and are not the result of a separate 
endocrine or metabolic disorder. Those HLPs that are the result of 
other disorders are termed secondary. For example, they may be found 
in patients with uncontrolled diabetes, hypothyroidism and the 
nephrotic syndrome. 
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In classifying hyperlipoproteinaemias, the aim is to be able 
to define, from inheritable characteristics, a particular abnormal 
genotype. On the basis of lipoprotein separation obtained by electro-
phoresis of plasma on paper, Fredrickson et al. (1967) have described 
five abnormal and inheritable phenotypes, classified types 1-5. 
Although this system is almost universally used for HLP classification, 
it has become apparent that the original five described phenotypes do 
not sort out into five distinct genotypes. The classification system 
has been revised and at present HLPs are categorised into six classes 
though many more may exist. 
The limitations of this classification system include (a) the 
variability in an individuals phenotype which may depend on changes in 
nutrition and hormonal status e.g. weight loss in an obese individual 
may cause the HLP phenotype to change from type 4 to type 2A or 2B; 
oral contraceptives may cause a change in phenotype from normal to type 
4 or 2B; (b) the heterogeneity of phenotypes observed within a family e.g. 
phenotypes 2A, 2B and 4 frequently aggregate within a family afflicted 
with hyperlipoproteinaemia. 
1.7.1 Type 1 (familial hyperchylomicronaemia) 
Type 1 HLP is characterised by a marked presence of plasma 
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chylomicrons following an overnight fast. In this abnormality, chylo-
microns are metabolised very slowly and may persist in the circulation 
for more than 48 hours after a meal (Quarfordt et al., 1970). VLDL, 
however, appears to be catabolised at a normal rate (Fredrickson and 
Levy, 1972). Havel and Gordon (1960) found that following heparin 
injection, the rate of chylomicron clearance from plasma of type 1 
HLPs was 25% of that observed in normals. These patients have a 
reduced post-heparin lipolytic activity (Fredrickson et al., 1963). 
Hydrolysis of diglycerides, monoglycerides and phospholipids is 
normal (Greten, 1972). LaRosa et al. (1972) have shown that in type 
1 HLP, while the activity of the hepatic triglyceride lipase is 
normal, lipoprotein lipase activity is markedly reduced. These obser-
vations are compatible with low lipoprotein lipase activities measured 
in adipose tissue biopsies from members of a family with type 1 HLP 
(Harlan et al., 1967). 
1.7.2 Type 2A (familial hypercholesterolaemia) 
Familial type 2 HLP is characterised by an increased plasma 
LDL concentration. Since LDL are cholesterol-rich lipoproteins, it 
follows that plasma cholesterol levels are also elevated. As this 
abnormality is often observed in conjunction with an elevation in the 
plasma VLDL concentration, the type 2 HLP classification is further 
subdivided into two types (2A and 2B). Type 2A HLP is characterised 
by an elevation in LDL alone. 
The expression of primary type 2 HLP may be related to the 
inheritance of the 'familial hypercholesterolaemic' gene (Khachadurian, 
1964). This autosomal mutant allele has a more pronounced expression 
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in the homozygous form. The disorder is detectable at birth by analysis 
of cord blood LDL leve ls (Kwiterovich c t al., 1970). 
Abnormal mechanisms resulting in the accumulation of LDL in 
familial hypercholesterolaemia (FH) may be related to an abnormally 
high rate of LDL synthesis (over-production) or a reduced rate of LDL 
clearance. Brown et al. (1974), in examining HMG Co A reductase 
activity and cholesterol synthesis of cultured skin fibroblasts found 
that the cells. cultured from homozygous FH patients had abnormally 
high HMG Co A reductase activity when compared to cells cultured from 
normals. Furthermore, this enzyme was not inhibited in cells cultured 
from type 2A HLP by increasing concentrations of LDL in the culture 
medium. From these and further observations (reviewed by Goldstein 
and Brown, 1975) on LDL binding and cholesteryl esterase activities, 
Brown and Goldstein (1974) have proposed that the primary abnormality 
in FH involves defective or absent cell surface receptors for LDL. 
The non-function of this receptor, in type 2A HLP, leads to (1) a 
decreased rate of catabolism of LDL and (2) lack of product inhibition 
of IIMG Co A reductase activity therchy resulting in an overproduction 
of cholesterol. 
When these observations on skin fibroblasts are extrapolated 
to intact man, type 2A HLP would result from both mechanisms described, 
i.e. overproduction and decreased removal. Th~re is little evidence 
for an overproduction of cholesterol in hypercholesterolaemia in 
general (Nestel, 1973a). However, in type 2A HLP, homozygous for FH, 
there is some evidence for an overproduction of LDL. Simons et al. 
(1975) reported an increased production of LDL in four type 2A homozy-
gates as well as a decreased fractional catabolic rate. These 
observations are in agreement with later reports of Bilheimer et al. 
(197S) and Thompson and Myant (1976) with single studies on type 2A 
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homozygotes. In the latter study the reduced fractional catabolic rate 
of LDL was shown to be independent of the plasma LDL concentration. 
These observations were made on patients before and after plasma 
exchange (which reduced the size of the LDL pool). 
A decreased clearance of plasma cholesterol has been documented 
in hypercholesterolaemia (Nestel, 1973a). In agreement with these 
findings are those of the previously described studies (Simons et al., 
1975; Thompson and Myant, 1976) where a reduced fractional catabolic 
rate for LDL was described in patients homozygous for FH. Likewise, 
in heterozygotes, the fractional catabolic rate of LDL is reduced 
though an overproduction of LDL has not been observed (Langer et al., 
1972). These observations tend to discriminate between homozygotes and 
heterozygotes for FH. The abnormality in homozygous FH is probably an 
overproduction of LDL with a concomitant decreased clearance in 
accordance with the predictions of the Brown and Goldstein model. 
However, in patients heterozygous for FH, only a reduced clearance of 
LDL may be demonstrated from in vivo turnover studies. Brown and 
Goldstein have reported that the abnormality of LDL catabolism in 
fibroblasts from patients heterozygous for FH is a partially reduced 
. 
binding of LDL leaving values of LDL degradation and cholesterol 
synthesis that are intermediate between those for normals and homo-
zygotes (Brown and Goldstein, 1974). In heterozygotes, LDL and 
cholesterol turnover may be normal though at the expense of increased 
pools. 
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Turnover studies are carried out in the steady state and 
reflect long-term equilibrium conditions. It may therefore not be 
possible to detect the initiating abnormality and consequently the 
failure of the &n vivo studies to correlate with the findings in 
tissue culture do not necessarily rule out the validity of the latter 
studies in demonstrating · the initiating defect. On the other hand, it 
is possible that the in vitro conditions uncover only potential 
. 
abnormalities that do not contribute significantly &n V&VO. 
The abnormality of type 2A HLP does not appear to depend on 
the structure or chemical composition of the LDL molecule. However 
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LDL isolated from type 2A HLP is not identical, in chemical composition 
to that of normal individuals (Slack and Mills, 1970; Brown et al., 
1973; Bagnall, 1972). However, as suggested by Simons and colleagues, 
this abnormal lipid composition is a consequence, rather than cause, 
of type 2A HLP. These authors have compared, simultaneously, the 
catabolism of autologous LDL and LDL from normal subjects in type 
2A homozygotes and found . the rate of catabolism to be similar for both 
types of LDL (Simons et al., 1975). 
1.7.3 Type 2B or combined hyperlipoproteinaemia 
The phenotype corresponding to 2B HLP in the revised 
Fredrickson classification has been termed combined hyper-
lipoproteinaemia by others. It is characterised by an increased plasma 
concentration of both VLDL and LDL. The expression of this phenotype 
need not necessarily be related to the type 2A genotype previously 
described. Rose et al. (1974) and Goldstein et al. (1973) have 
described patients with the type 2B phenotype who have no familial 
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grouping of type 2A HLP and so have concluded that this condition 
-(combined HLP) is distinct from type 2B HLP. Type 2B HLP might 
best be restricted to the phenotype which describes an environmentally 
induced elevation of VLDL seen in association with type 2A HLP. 
Combined HLP appears to be an inheritable phenotype and so must be 
considered a distinct HLP class. 
Combined HLP, which is characterised by moderate elevations 
of plasma VLDL and LDL only, may be seen in association with obesity, 
impaired glucose tolerance and hyperuricaemia as in secondary type 
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4 HLP. A clear distinction between type 4 and combined HLP is possible 
on the basis of LDL concentration. The biochemical abnprmality 
associated with this disorder has not been elucidated. 
1.7.4 Type 3 hyperlipoproteinaemia 
Type 3 HLP is characterised by the presence of an unusual 
class of cholesteryl ester rich lipoproteins in the d. 1006 g/ml range 
(Fredrickson and Levy, 1972). These lipoproteins have B rather than 
pre B migration on paper or agarose electrophoresis and may be found 
throughout the whole VLDL spectrum (Quarfordt e t al., 1971). As a 
result of an elevated concentration of these 'abnormal' lipoproteins, 
the plasma triglyceride and cholesterol concentrations are both elevated 
( Lees et a l . , 19 7 3 ) . 
It is uncertain whether this disease involves an accumulation 
of abnormal lipoproteins or an abnormal concentration of a remnant of 
VLDL or chylomicron catabolism (Quarfordt et al., 1970). VLDL of type 
3 HLP appears similar in core and surface layer composition to normal 
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VLDL (Sata et al., 1972) as arc the apolipoproteins of chylomicrons 
in this disease (Havel e t al., 1973). Newly secreted chylomicrons have 
a normal cholesterol to triglyceride ratio which increases abnormally 
only during the clearing of the alime ntary lipaemia. These findings 
suggest that the abnormal particle with its high cholesterol:triglyceride 
ratio develops as a result of defective lipoprotein catabolism. 
VLDL from type 3 HLP contain a disproportionally high amount 
of apolipoprotein E which is usually associated with cholesteryl ester 
rich VLDL populations (Shore and Shore, 1973; Havel and Kane, 1973; 
Shore et al., 1974). Utermann et al. (1975) have recently demonstrated 
a deficiency of a specific component of this apolipoprotein in type 
. 
3 HLP and claim that this may be the underlying defect of the 
abnormality. However, the studies of Bilheimer et al. (1971) suggest 
that the abnormal accumulation of remnants in type 3 HLP is not due 
to a defective lipoprotein. In comparing VLDL catabolism in type 3 
HLP and type 4 HLP subjects, these authors demonstrated that the 
catabolism of VLDL isolated from type 3 HLP subjects, when injected into 
type 4 HLP subjects, was normal whereas the catabolism of VLDL isola ted 
from type 4 HLP subjects, was delaye d when injected into type 3 HLP 
patients. Hazzard and Bierman (1971), using 14c-vitamin A as a lipid 
tag for VLDL and chylomicrons, observed that the remnants of catabolism 
of chylomicrons and VLDL accumulated in type 3 HLP, while in type 4, 
their catabolism was not delayed and they were converted to LDL
2
. 
1.7.5 Type 4 
Type 4 HLP is characterised by an elevation of the plasma 
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VLDL concentration during fasting. Since these particles are tri-
glyceride-rich, the plasma triglyceride concentration is likewise 
elevated. As VLDL also contains approximately 15% cholesterol 
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(Section 1.1.4), some elevation in the plasma cholesterol concentration 
may also be seen. The predicted plasma cholesterol increase due to 
VLDL elevation alone, is approximately 1/5 of the plasma triglyceride 
increase (Friedwald et al., 1972). In order to differentiate between 
type 4 and combined HLP, these authors propose that LDL cholesterol 
may be approximated from the formula. 
LDLchol = plasmachol - HDLchol - plasmatrig/5 
(assuming an absence of type 3 HLP). In type 4 HLP, 
LDLchol may be lower than normal. 
Type 4 HLP is often observed in association with obesity 
(Barter and Nestel, 1973), excessive caloric intake (Schonfeld, 1970), 
diabetes (Bagdade et al., 1968) nephrotic syndrome (Losowsky and Kenward, 
1968, Ibels et al., 1976) and alcohol intake (Kudzma and Schonfeld, 
1971) . 
Possible biochemical defects associated with type 4 HLP 
may involve an overproduction or a decreased clearance of circulating 
VLDL. VLDL overproduction might result from (1) an increased rate of 
apolipoprotein synthesis; (2) an increased production of triglyceride 
as a result of increased plasma FFA flux (as discussed in section 
1.4.2); (3) increased synthesis of triglyceride from carbohydrate 
(lipogenesis); (4) a decreased rate of FFA utilization through 
alternative pathways in the liver. Decreased clearance of VLDL may 
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result from reduced tissue lipolytic activity (particularly lipo-
protein lipase). No abnormalities in the structure of VLDL from type 
4 HLP have been reported, though, in carbohydrate-induced hyper-
triglyceridaemia, VLDL particles are larger and contain relatively 
more triglyceride than normal VLDL particles (Ruderman et al., 1971). 
A number of studies have investigated the causes of hyper-
triglyceridaemia. These studies have elucidated complex inter-
relationships between lipid, lipoprotein and carbohydrate metabolism. 
Reaven et al. (1965, 1967) and Nestel (1966) concluded that over-
production of VLDL was an important factor in development of hyper-
triglyceridaemia. The former group has proposed that increased 
peripheral resistance to the action of insulin provokes an enhanced 
production of insulin with a resultant increase in the synthesis and 
release of triglycerides by the liver (Stern et al., 1972). On the 
other hand, other investigators have not demonstrated an abnormal 
increase in production of triglycerides in type 4 HLP on carbohydrate-
rich diets and have suggested that endogenous hypertriglyceridaemia 
may result from a reduced clearance of triglyceride from the plasma 
(Quarfordt et al., 1970; Neste l el al., 1970; Ryan and Schwartz, 
1965; Harris and Felts, 1973). Post-heparin lipolytic activity is 
usually normal in type 4 HLP (Fredrickson et al., 1963; Schreibman 
et al., 1969) though it is reduced in type 4 HLP secondary to diabetes 
(Bagdade et al., 1968) and hypothyroidism (Kirkeby, 1968). 
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It is generally agreed now that both overproduction and a 
relative inefficiency in clearance contribute to the development of this 
condition. Turnover studies describe only the equilibrium state and 
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do not necessarily identify the initiating cause. Thus overproduction 
may lead to the development of hypertriglycerideaemia which only 
becomes established if removal rates do not increase correspondingly 
(Nestel, 1973b). Recent studies on the metabolism of the B apolipo-
protein (Sigurdsson et al., 1976) also suggest that the underlying 
defect in endogenous hypertriglyceridaemia is heterogenous. In 
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these studies, overproduction as well as a reduced fractional clearance 
of VLDL B apolipoprotein was observed. Saturation of removal mechanisms 
for VLDL and chylomicron triglyceride in type 4 and 5 HLP has been 
demonstrated by Brunzell et al. (1973). 
1.7.6 Type 5 
Type 5 HLP is characterised by an accumulation of both 
chylomicrons and VLDL in plasma during fasting. Thus the fasting 
plasma triglyceride is markedly elevated. It occurs most commonly 
as a secondary form (diabetes, alcoholism) than as a familial form. 
The biochemical defect of type 5 HLP is not understood. 
Post-heparin lipolytic activity may be reduced as in diabetes but is 
generally normal (Fredrickson and Levy, 1972). The factors responsible 
for type 5 HLP may be similar to those discussed for endogenous hyper-
triglyceridaemia and may in fact represent the overloading of removal 
mechanisms by dietary particles when clearance has been saturated by 
endogenous VLDL. 
1.8 LIPOPROTEINS AND ATHEROSCLEROSIS 
In the past fifty years, human diseases characterised by 
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atherosclerotic changes in arteries have become prevalent. The most 
common and lethal manifestation of atherosclerosis is coronary heart 
disease. This disease is the most common serious disease in Australia, 
as in most Western culture s, and accounts for approximately 30% of 
all deaths. 
Coronary heart disease (ischaemic heart disease) has been 
defined as ''cardiac disability, acute or chronic, arising from re-
duction or arrest of blood supply to the myocardium in association 
with disease processes in the coronary arterial system" (Report, 
W.H.O., 1957). The primary event leading to myocardial infarction 
is occlusion of a major coronary artery or one of its subdivisions, 
usually by a thrombus in an atheromatous vessel. In most cases 
coronary heart disease occurs only when the walls of the coronary 
arteries have been altered by atherosclerosis. 
Atherosclerosis has been defined as a "variable combination 
of changes in the intima of arteries (as distinct from arterioles) 
consisting of the focal accumulation of lipids, complex carbohydrates, 
blood and blood products, fibrous tissue and calcium deposits with 
associated medial changes" (Report, W.H.O., 1958). Atherosclerosis 
affects the aorta and larger distributing arteries and may manifest 
itself in, other than coronary heart disease, cerebrovascular accidents 
and intermittent claudication. 
Three types of arterial lesions are associated with athero-
sclerosis - fatty streaks, fibrous plaques and complicated lesions. 
The latter two are raised lesions that result in a constriction within 
the lumen of the artery. Fibrous plaques are localised lesions of the 
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arterial wall that consist primarily of an ,"lccumulation of smooth 
muscle cells and fibroblasts. Complicated lesions appear to be an 
advanced stage of atherosclerosis involving calcification and 
ulceration of the whole vessel wall. The relevance of fatty streaks, 
which have often been observed in arteries of children, to the 
development of raised lesions is not known. The most widely accepted 
hypothesis for the primary stimulation of plaque formation is damage 
to the endothelial cell lining resulting in changes of permeability 
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to macromolecules, such as lipoproteins. This leads to the proliferation 
of smooth muscle cells which accumulate lipid and become transformed 
into foam cells, the characteristic cells of the early lesion. Recent 
reports have described avid uptake and degradation of VLDL and LDL 
by cultured human aortic smooth muscle cells (Albers and Bierman, 
1976). Furthermore, hypoxia in these cultures leads to a decreased 
degradation of LDL thereby promoting lipid accumulation within the cell. 
It has long been recognised that atherosclerosis is character-
ised by an accumulation of lipids, mainly cholesteryl esters, in the 
intima of the arterial wall. Smith and Slater (1973) have concluded 
that the major part of cholesteryl ester in the advanced athero-
sclerotic lesion originates directly from ~lasma LDL and that only a 
small proportion accumulates as a result of arterial cholesterol 
esterification. Substantial amounts of electrophoretically and 
immunologically intact LDL (7 times that of albumin), but not VLDL, 
has been found in the intima of human aorta. However, the low proportion 
of triglyceride found in both normal intima and lesions also suggests 
that VLDL does not enter the intima, possibly because of its larger size 
(Smith, 1974). A comparatively greater accumulation of LDL has been 
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reported in the intima of patients with elevated plasma cholesterol 
levels than in those with normal cholesterol levels (Smith and Slater, 
1972). The addition of LDL has b ee n shown to cause proliferation of 
aortic smooth muscle cells in culture (Dzoga e t al., 1971). 
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Cholesterol feeding in swin0 results in an elevation of plasma 
cholesterol levels and an accelerated development of atherosclerosis. 
In the plasma of these animals may be found cholesteryl ester rich 
lipoproteins (B-VLDL) resembling those found in type 3 HLP in man. 
These lipoproteins, as in type 3 HLP, contain significant amounts of 
apolipoprotein E. Also, an a-migrating species, termed HDL, contain-
. C 
1ng apolipoproteins A-1 and E and rich in cholesteryl ester, may be 
found in HDL and LDL density ranges. Similar observations have been 
made in cholesterol fed dogs, rabbits and rats (Mahley et al., 1974; 
Mahley et al., 1975). These authors suggest a possible association 
between this spectrum of abnormal cholesteryl ester rich lipoproteins 
(8-VLDL and HDL) and atherogenesis. 
C 
Epidemiological studies have ·illustrated an association between 
various risk factors (environmental and genetic) and coronary heart 
disease (Keys, 1970; Cotton et al., 1972; Welborn et al., 1969; 
Blackct, 1973). These risk factors include age, family history, 
cigarette smoking, hypertension and hyperlipoproteinaemia. Types 2A, 
2B, combined, 3, and 4 HLP have a high incidence of coronary heart 
disease (Fredrickson, 1971). 
1.9 AIMS OF THE PROJECT 
The purpose of the studies reported in this thesis was to 
~I 
1. 
' 
I 
•• j 
investigate and describe various metabolic inter-relationships between 
the plasma lipoproteins in man. These studies were particularly 
concerned with an elucidation of the mechanisms involved in the 
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catabolism of VLDL to LDL in normal and hyperlipoproteinaemic subjects. 
As . the apolipoproteins of these lipoproteins are the determinants of 
this relationship, methods used for the separation and quantitation 
of the individual apolipoproteins are discussed (Chapter 3). A 
system was designed for use in metabolic studies for obtaining the B 
apolipoprotein free of the remaining apolipoproteins in order to obtain 
specific activity data for the B apolipoprotein of VLDL and LDL. 
Chapter 4 describes a series of in vitro investigations 
in which the conversion of VLDL to remnants and subsequently to LDL
2 
was studied in relation to post-heparin lipolytic activity. The role 
of hepatic and extra-hepatic lipases in the process was examined. 
Chapter 5 describes studies on the in vivo catabolism of 
VLDL. These studies, carried out in normal and hyperlipoproteinaemic 
patients, involve kinetic analysis of the B apolipoprotein specific 
activity-time curves of VLDL, LDL1 and LDL2 , following injection of 
125 
VLDL- I. From these curves it has been possible to measure the 
turnover of the B apolipoprotein in various lipoproteins and define 
differences in VLDL catabolism in normal and hypertriglyceridaemic 
subjects. 
In chapter 6 are described a further series of studies on 
the catabolism of various VLDL and remnant subfractions in an attempt 
to define, on the basis of precursor-product relationships and turnover 
data, the probable major intermediate between VLDL and LDL
2
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Chapter 7 summarises and generally discusses the implications 
of the 7,n vil,r>o and in vivo studi0~.; in tc~rms of documented normal and 
abnormal lipoprotein metabolism. 
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CHAPTER 2 
GENERAL METHODS. 
Techniques and procedures used to implement the studies in 
this thesis are described in this chapter. In subsequent chapters , 
these methods are cross-referenced to the appropriate section numbers 
of this chapter. 
2.1 CHEMICAL ESTIMATIONS 
54 
(a) Protein: The protein content of lipoprotein and apolipo-
protein samples was determined using the method of Lowry et al. (1951). 
Folin-Ciocalteau reagent was obtained from British Drug Houses, England. 
Bovine albumin (Fraction V, Sigma, U.S.A.) was used as protein standard 
and was particularly suitable in these experimencs since it has similar 
chromogenicity to the B apolipoprotein. Turbidity due to the presence 
of lipid was cleared by extracting the final assay mixture with diethyl 
ether or chloroform and centrifuging at 600xg. for 1 min. 
High salt concentration was found to interfere with this 
colourimetric procedure. Lipoproteins could not be assayed in solutions 
of d. > 1.019 g/ml and had to be dialysed back to d. 1.006 g/ml prior to 
assay. Other compounds which interfere with the Lowry method, such as 
SDS (sodium decyl or dodecyl sulphate) or high tris (tris(hydro-
xylmethyl) aminomethane, Sigma, U.S.A.) concentration, were added to 
standards and blanks at similar concentrations as present in the 
unknown solutions. 
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(b) Lipids: Triglycerides and cholesterol were simultaneously 
estimated by a semi-automated procedure in a Technicon Auto-analyser 
AA-11 (as described in Technicon publication number AAll-24, 1971). 
This procedure assayed cholesterol colourimetrically following the 
Lieberman-Burchard reaction and triglycerides by fluorimetry using a 
modification of the method of Kessler and Lederer as described by 
Leon et al. (1970). 
The auto-analyser was calibrated using known standards of 
cholesterol and triglyceride (triolein) and SMA reference serum. 
Although plasma lipids are now more routinely expressed in molar units, 
values in this thesis are expressed in mg/lOOml plasma similar to the 
units to describe apolipoprotein concentrations. 
(c) Free fatty acids: Plasma free fatty acids were extracted 
from plasma by the procedure of Dole and Meinertz (1960) and assayed 
using the colourimetric assay of Duncombe (1964). The Doles extraction 
procedure was preferred to the direct two-phase chloroform extraction 
described by Duncombe (1964) as many of the samples to be assayed 
contained significant amounts of post-heparin lipolytic activity. In 
contrast to the two-phase chloroform extraction, the addition of the 
plasma aliquot to Doles extraction medium immediately arrests any further 
lipolytic activity. 
2.2 LIPOPROTEIN ISOLATION AND PURIFICATION PROCEDURES 
Plasma lipoproteins were isolated and purified by ultra-
centrifugation using the conditions described by Havel et al. (1955) 
and Gustafson et al. (1965) as shown in Table 2.1. For these procedures, 
35, 40, 40.3 and 50 rotors well spun in L 2-50 and L 3-50 Beckman 
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preparative ultracentrifuges. 
A number of various lipoprotein fractions were investigated 
during these studies. These fractions were isolated by the usual 
sequential flotation techniques. An ux~mr>lc will be described where the 
required fractions were sf 60-400, sf 12-60, sf 0-12 and HDL (as in 
section 6.2). In the metabolic studies, 10ml plasma samples obtained 
at each time point were centrifuged. Larger volumes were used for 
preparation of lipoproteins for iodination or apolipoprotein 
characterisation. 
The plasma (10 ml) was pipetted into Spinco 40 tubes (cellulose 
nitrate) and overlaid with buffered saline (0.15M NaCl, 0.001M EDTA 
adjusted to pH 7.4 with tris) which has a salt density of 1.006 g/ml. 
Lipoproteins of sf >400, if present, were removed by centrifugation 
at 20,000 xg. for 30 min. and slicing the top 3.5 ml of the tube. The 
infranate (bottom 10 ml of the tube after slicing) was transferred to 
a separate tube, overlaid with a further 3.5 ml of buffered saline and 
spun for 2 hours at 100,000 xg. to isolate lipoproteins of sf 60-400. 
After removing this top fraction, the infranate (which then contained 
particles of sf <60) was adjusted to d. 1.019 g/ml and spun at 
108,000 xg. for 18 hours to float sf 12-60 lipoproteins. The subsequent 
isolation of sf 0-12 lipoprotein and HDL followed this sequential 
procedure using the conditions described in Table 2.1. 
Each lipoprotein fraction was recentrifuged at its respective 
density, in a 40.3 rotor, using the same conditions for its isolation. 
The efficacy of this two spin procedure in isolating lipo-
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TABLE 2.1 
CONDITIONS USED TO FLOAT AND PURIFY LIPOPROTEINS OF 
VARIOUS SIZES FROM HUMAN PLASMA BY ULTRACENTRIFUGATION. 
These conditions include salt density, centrifugal force and time. 
Most fractions may be denoted by Svedberg flotation units (10- 13 cm/sec/ 
dyne/g) at d. 1.063 g/ml with the exception of HDL which floats at a 
salt density of 1.21 g/ml. These conditions are as defined by Havel et 
al. (1955) and Gustafson et aZ. (1965). 
1 
2 
Lipoprotein Particles Density 1 Centrif. Force2 Time 
g/ml g. hours 
> 400 1.006 20,000 0.5 
> 100 1.006 80,000 1.0 
> 60 1.006 100,000 2.0 
> 50 1.006 108,000 2.0 
> 20 1.006 108,000 16.0 
> 12 1.019 108,000 18.0 
> 0 1.063 108,000 20.0 
HDL 1.21 108,000 24.0 
The infranate densities were adjusted by addition of solutions of 
higher density according to the formula of Havel et al. (1955). 
Standard density solutions were prepared by the addition of KBr to 
buffered saline. The densities were checked by picnometry. 
Average centrifugal force. 
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proteins free of other plasma proteins was tested by immunodiffusion 
(Ouchterlony, 1958) against albumin, the protein of highest concentration 
in plasma. In almost all cases, the two spin regime was found to be 
sufficient to isolate lipoproteins free of albumin. In a few extremely 
concentrated preparations of VLDL, further washings were required to 
remove traces of albumin. 
2.3 LIPOPROTEIN IODINATION 
. . . d' d . h 1251 1311 . Lipoprotein fractions were io inate wit or using 
the iodine-monochloride technique of McFarlane (1958) as modified 
for lipoprotein iodination by Fidge and Paulis (1974). 1251 and 1311, 
carrier free, for iodination (lMS.30) were obtained from The Radio-
chemical Centre, Amersham, England. Lipoproteins were iodinated at pH 
10 using 0.4M glycine -NaOH, pH 10 as the buffer medium throughout the 
entire process. The amount of iodine monochloride added to the iod-
ination mixture was calculated to give an iodine:protein ratio of less 
than 1. Lipoprotein bound iodine was separated from free iodine initially 
by filtration on sephadex G-50 (column -0.6 x25 cm) followed by dialysis 
against numerous changes o f buffered saline over a minimum period of 
4 hours. 
Intramolecular distribution of radioisotope was determined 
in all iodinated preparations. Lipid was extracted by the Folch 
procedure (Folch e t al., 1957). Protein in the aqueous phase of the 
Folch extraction was precipitated (following removal of the methanol by 
evaporation using a stream of nitrogen) by the addition of an equal 
volume of 10% (w/v) TCA (trichloroacetic acid) followed by centrifugation 
(2,000 xg. for 5 min.). The TCA precipitate was dissolved in O.lM 
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NaOH and an aliquot counted for radioactivity. An aliquot of the TCA 
soluble phase (containing free iodine) and of the lipid (redissolved 
in ethanol) was likewise counted and so the percentage of radioisotope 
bound to lipid or protein or remaining free could be calculated. In 
preparations used in these studies the percentage radioisotope bound 
to protein varied from 89-96% with 3~8% being lipid bound and 1~3% 
remaining free. 
2.4 STERILISATION OF LIPOPROTEINS FOR RE-INJECTION 
Radioiodinated autologous lipoproteins for re-injection 
(chapters 5 and 6) were passed sequentially through 0.45 and 0.22mµ 
millipore filters (Millipore Corp., Mass., U.S.A.) before iodination 
and then finaliy, under sterile conditions, prior to injection. An 
aliquot of the sterile preparation was routinely selected for radio-
activity determination and culture in thioglycolate medium to test 
for any bacterial contamination. 
2.5 LIPOPROTEIN DELIPIDATION 
Lipoproteins were dialysed against SmM NH
4
Hco
3
, pH 8.0, prior 
to delipidation. Large preparations of apolipoproteins for subsequent 
column procedures (as described in Chapter 3 where 15-150 mg apolipo-
protein was prepared) were delipidated using the chloroform: methanol: 
diethyl ether procedure as described by Herbert et al. (1973). 
Smaller amounts of lipoprotein, such as used for separation 
of the B apolipoprotein by the NH4Hco3 procedure (described in 3.2.5) 
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were delipidated using a 'scaled-down' procedure of that described by 
Herbert et al. (1973) in order to obtain quantitative recoveries of 
protein. Aliquots containing 0.3 - 1.0 mg protein were lyophylised in 
their respective delipidation tubes (glass centrifuge tubes of 4 ml 
capacity). The dried lipoprotein was resolubilised in 100 pls 
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0.05M NH 4Hco3 , pH 8.0. Delipidation was performed using 1/12 the volume 
of organic solvents described by Herbert et al. (1973). Recovery of 
protein was improved by placing the samples at -10°C for 1 hour at 
each step of the delipidation process. Apolipoproteins were dried, 
after the final diethyl step, under a gentle stream of nitrogen. Protein 
recoveries using this procedure ranged from 87-107%. 
2.6 PREPARATION OF UREA 
Urea (Univar Chemicals, Australia) was used for column and 
polyacrylamide gel electrophoresis (PAGE) procedures. Prior to use a 
40% (w/v) solution of urea was passed over a column (5 x 50 cm) of 
Rexyn I-300 (Fisher Scientific, U.S.A.) to reduce the cyanate content 
in order to prevent protein carbamylation. The effectiveness of this 
procedure was monitored by determining the conductivity of the solution 
after passage through the column. This was routinely found to be less 
than 3 µmhos. The 40% urea solution was reduced to 36% (6M) and 
buffered with tris for column procedures or lyophylised prior to use 
in PAGE techniques. It was maintained at 2°C until use to minimise further 
cyanate formation. 
2.7 POLYACRYLAMIDE GEL ELECTROPHORESIS PROCEDURES 
Two types of PAGE separations were used throughout these 
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studies. Polyacrylamide gels containing 6M urea were used for most 
apolipoprotein separations because of the excellent resolution of apo-
lipoproteins by this technique. SOS-gels were used for molecular weight 
determinations and in particular the presence of apolipoprotein E in 
VLDL apolipoprotein preparations. 
Urea-gels were prepared and operated using the method of 
Kane (1973). Following electrophoresis, gels were stained in 1% 
(w/v) Amidoschwartz lOB (Schmidt and Co., Stuttgart, West Germany) in 
7% (v/v) acetic acid for 1 hour after whic.h they were destained in 7% 
(v/v)acetic acid by diffusion. 
SOS-gel electrophoresis was performed using the system 
originally described by Laemmli (1970) but more recently outlined by 
Weber (1975). Following electrophoresis, the gels were stained in 
0.25% (w/v) coomassie blue R (Sigma, U.S.A.) in 50% (v/v) methanol 
containing 7% (v/v) acetic acid and destained by diffusion in 15% 
(v/v) methanol in 7% (v/v) acetic acid. 
2.8 AMINO ACID ANALYSES 
(a) Total: Proteins (0.5 mg) were dialysed against distilled 
water and lyophylised. The dried protein was hydrolysed with 6M HCl 
for 22 hours at 105°C. Amino acid analysis of the hydrolysate was 
performed on a Technicon 120B model amino acid analyser using the method 
of Spackman et al. (1958). Cysteine, if determined, was estimated as 
cysteic acid on a separate hydrolysate following performic acid 
oxidation. 
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(b) Carboxy-terminals: Carboxy-terminal amino acids were 
hydrolysed by incubation with carboxy-peptidare A (Worthington Bio-
chemical Corp., New Jersey, U.S.A.) using the procedure outlined by 
Ambler (1972). The relative release rates of amino acids over a 2 hour 
incubation period were determined by quantitative estimation of amino 
acids on the amino acid analyser. The carboxy-terminal amino acids 
were also determined by hydrazinolysis (Akabori et al., 1952; 
Schroed€r, 1972). Anhydrous hydrazine was obtained from the Pierce 
Chemical Co., New Jersey, U.S.A. Protein samples (1 mg) were incubated 
in vacuo, at 80°C for 24 hours in 0.2 ml hydrazine. 
2.9 LIPOPROTEIN LIPASE ASSAY 
A radiolabelled triolein emulsion (Glyceryl tri [9,10(n)-
3H] oleate obtained from The Radiochemical Centre, Amersham, England) 
was prepared by sonication with egg yolk lecithin (Fielding, 1970). 
The enzyme activity was assayed using the procedure of Schatz et al. 
(1970). The concentration of albumin (bovine, fatty acid poor obtained 
from Gallard-Schlesinger Chemical Corp . . , N.Y., U.S.A.) in the assay 
medium was 60 mg/ml. 
Milk lipase was prepared by spinning fresh cow's milk at 
20,000 g for 30 min. and then lyophylising the infranate. 1 gm of 
lyophylised material was dissolved in 10 ml of O.OSM NH
4
c1, pH adjusted 
to 8.4 with NH 40H. 0.1 ml of this preparation was used in each incubation. 
2.10 CLINICAL PROCEDURES 
Most of the studies of this thesis required the co-operation 
of consenting human volunteers to whom the nature of the studies was 
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fully explained. All procedures were carried out according to the 
conditions of the Helsinki declaration of human experimentation 
(appendix 1). 
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CHAPTER 3 
ISOLATION AND QUANTITATION OF THE 
BAND C APOLIPOPROTEINS 
3.1 INTRODUCTION 
63 
The plasma lipoproteins are complex structures. Each lipo-
protein class contains all of the main lipid groups and at least one 
of the apolipoprotein species although the proportions of these 
individual components may vary from one lipoprotein class to another. 
The nomenclature system used for apolipoproteins in this thesis is 
that proposed by Alaupovic et al. {section 1.2.1) and is based on the 
premise that certain apolipoproteins, upon binding lipids, form 
individual lipoprotein families. At present, five lipoprotein families 
have been described though many more may exist. The presence of sub-
classes within these lipoprotein families (i.e. LP-A-1, LP-A-11) has 
also been suggested. 
The A apolipoproteins are found primarily, but not exclusively, 
in HDL. TheC apolipoproteins are also found in HDL though their 
concentration is relatively minor in comparison to that of the A apo-
lipoproteins (Kastner et al., 1974). The major apolipoprotein of LDL is 
the B apolipoprotein, although small quantities of A, C and D apolipo-
proteins may also be present (Lee and Alaupovic, 1974; Kastner et al., 
1974). All apolipoprotein classes have been found in VLDL, although 
some are present in trace and probably insignificant amounts. VLDL 
apolipoprotein composition is a reflection of the lipoprotein particle 
size with the larger particles being relatively richer in C apolipo-
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proteins (particularly C-11) but containing relatively less of the 
Band E apolipoproteins (Kane et al., 1975). 
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The synthesis of the B apolipoprotein is essential for the 
release of VLDL into the circulation (Isselbacher et al., 1964; Bar-On 
et al., 1973). The catabolism of VLDL, leading to the formation of LDL, 
involves losses of all of the VLDL components except the B apolipo-
protein (Eisenberg et al., 1973; Eisenberg and Rachmilewitz, 1975). 
Thus, the B apolipoprotein is the only component to remain within these 
macromolecules (VLDL and LDL) during their entire circulatory life. 
It is therefore appropriate, when studying VLDL and LDL inter-relation-
ships, to investigate the metabolism of this apolipoprotein. The 
studies of chapters 4, 5 and 6, which are concerned with the trans-
formation of VLDL to LDL and the respective production and removal 
rates of these lipoproteins, involve studies on the catabolism of 
various radioiodinated lipoprotein preparations. B apolipoprotein 
specific activity data was obtained in these studies and thus made 
possible kinetic analyses of the metabolism of this apolipoprotein 
in each lipoprotein fraction and its conversion from 9ne lipoprotein 
species to another; The first part of this chapter (section 3.2) deals 
with methods in current use for the preparative isolation of the B apo-
lipoprotein. The suitability of these procedures for routine deter-
minations of B apolipoprotein specific activities will be discussed. 
Many investigators have quantitated the B apolipoprotein using radio-
immunoassay procedures (Schonfeld et al., 1974; Bautovich et aZ., 
1975) however these techniques are unsuitable for the purposes of 
the metabolic studies here as they have not been designed for the 
preparative isolation of the B apolipoprotein and consequently, 
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the direct determination of specific activities. 
Apolipoproteins perform essential functions, not only as 
structural elements of lipoproteins but also as modulators (at least 
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in vitro) of the activities of enzymes essential in lipoprotein 
metabolism (section 1.6.1). If in vitro findings are applicable in vivo, 
apolipoproteins may determine the rates of metabolism of lipoproteins. 
In this regard, the possible role of the · c apolipoproteins in regulating 
the activities of various lipases and phospholipases is of particular 
interest. It is possible that a deficiency in one or more of these 
apolipoproteins may result in a defect in a lipoprotein catabolic 
step and so lead to an accumulation of a lipoprotein fraction in the 
circulation. Thus, it is important to be able to determine the 
concentration of these individual apolipoproteins in various lipoprotein 
fractions and to establish their respective turnover characteristics, 
both in normal and hyperlipoproteinaemic subjects. The second part of 
this chapter describes a densitometric method for the quantitation of 
the C apolipoproteins which depends on the use of individual Capo-
lipoprotein standards. Therefore, the preparative isolation and 
identification of these apolipoproteins will also be described. 
In this chapter, sections describing methodology actually 
employed for the preparative isolation of apolipoproteins, either for 
further characterisation or for use in the metabolic studies, is 
presented under section headings marked 'experimental'. 
3.2 ISOLATION AND QUANTITATION OF THE B APOLIPOPROTEIN 
3.2.1 Gel filtration techniques 
Separation of the apolipoproteins of apo-VLDL by gel filtrat-
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ion was first described by Brown et al. (1969). Apo-VLDL, solubilised 
in the presence of O.lM sodium decyl (or dodecyl) sulphate (SDS) was 
resolved into two protein fractions by filtration on Sephadex G-100 
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in the presence of O.OOlMSDS. Improved separations have recently b een 
achieved with sephadex G-200 superfine (Herbert et al., 1973) and 
sepharose 1-B columns (Shelburne and Quarfordt, 1974). 
3.2.2 Experimental: separation of apo-VLDL on sephadex G~200 
The flow rate with which sephadex columns may be run is 
limited by the development of compression in the gel bed and the 
consequent diminution in flow rate. Sachs and Painter (1972) have 
devised a column system whereby glass beads inside the column provide 
an internal support to the sephadex gel, thereby allowing the use of 
much higher flow rates without impairment of column elution. This 
system has been used by Herbert et al. (1973) for the rapid separation 
of apo-VLDL on sephadex G-200 superfine in the presence of 6M urea. 
Using the procedure of Herbert et al. (1973) a sephadex 
G-200 superfine glass bead column (150 x 5 cm with 6 mm glass beads) 
was prepared. The column buffer was 0.2M tris-HCl, 6M urea, pH 8.2. 
All urea, prior to preparation of the buffers had been deionised as 
described in section 2.6. Glass surfaces had been previously treated 
with Siliclad (Clay Adams) to minimise non-specific adsorption of 
protein. Chromatography was carried out at 2°C to minimise protein 
carbamylation by urea . 
Figure 3.1 illustrates a typical G-200 superfine elution 
profile obtained after gel filtration of apo-VLDL. Two major peaks 
were obtained. As the firstpeak (Fl) contains the B apolipoprotein as 
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well as other VLDL apolipoproteins, this peak was divided arbitrarily 
into three fractions (A, Band C as described in figure 3.1) in an 
attempt to obtain a fraction containing B apolipoprotein only. Follow-
ing cxh~ustivc dialyses of th0. fractions against SmM NH 4Hco 3
, pH 8.0 
and then lyophylisation, the protein of each fraction (except F2 which 
was soluble in 0.05M NH 4Hco 3 , pH 8.0) was resolubilised in 0.05M tris-
HCl, O.OSM SOS, pH 8.2 and monitored by electrophoresis on poly-
acrylamide gels (figure 3.2). The protein band remaining at the inter-
face of the main and stacking gel was consistent with the electro-
phoretic behaviour of the B apolipoprotein when using this PAGE system 
(described by Kane, 1973) ~ This .protein was present in all fractions 
except F2 which contained the C apolipoproteins only. All fractions of 
Fl contained, as well as the B apolipoprotein, other protein components, 
one of which was presumably apolipoprotein E. These proteins however 
were mainly confined to the second half of Fl (Band C fractions). 
Although other proteins than the B apolipoprotein were present in the 
A fraction of Fl (gel Fl/A), the amount present would be relatively 
minor in terms of the total amount of protein loaded onto the gel 
(- 1-5%) • 
An aliquot of Fl/A was exhaustively dialysed (for approximate-
ly 10 days with many changes) against distilled H2o and lyophylised. A 
solution was then prepared (in O.lM NaOH) containing a known mass, 
determined gravimetrically, of the dried apolipoprotein. The chromo-
genicity of this preparation (using the Lowry techniqµe - section 2.1) 
was similar to that of the albumin standard giving almost identical 
standard curves. This observation has also been reported by Kane 
et al. (1975). 
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Figure 3.1 The elution profile obtained when apo-VLDL 
(62 mg) was chromatographed on sephadex G-200 super-
fine (glass bead column: 150 x 5 cm - see section 
3.2.2) in the presence of 0.2M tris-HCl, 6M urea, pH08.2. The column was run at a flow rate of 30 ml hour at 2 c. 
Two major fractions (Fl and F2) were obtained. Fl was 
further subdivided into three fractions (A, Band C) 
as discussed in section 3.2.2. 
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Figure 3.2. Polyacrylamide gel electrophoresis (using the system of 
Kane, 1973) of proteins from each fraction collected when apo-VLDL 
was separated by filtration on a sephadex G-200 superfine as 
described in section 3.2.2 and figure · 3.1. 80 µg protein (in 6M 
urea) was loaded onto each gel. Gels were stained (with amide 
black) and destained as described in section 2.7. 
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Using the glass bead column described for the separation of 
apolipoproteins of VLDL, excellent resolution of the Band C apolipo-
proteins was obtained. However, a clear separation of the Band E 
apolipoproteins was not achieved. These observations are similar to 
those of Herbert et al. (1973) who originally described the column 
procedure. 
3.2.3 Use of gel filtration techniques in B apolipoprotein specific 
activity determinations 
Although protein recoveries from gel filtration chromate-
. graphy are usually high, small quantities of apolipoprotein are often 
difficult to separate because of problems in detecting low concentrat-
ions of separated proteins in the · relatively large elution volumes. 
Sigurdsson et al. (1975), in order to determine the specific 
activities -of the B apolipoprotein of VLDL, chromatographed samples 
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of apo-VLDL on sephadex G-150 in the presence of 0.001M SDS. To obtain 
B apolipoprotein for further analysis, these authors collected a 
fraction in the maximal portion of the first peak. Amino acid 
analysis of this fraction was reported to be similar to that of the 
corresponding fraction when apo-LDL was chromatographed in an identical 
manner thus suggesting that the apo-VLDL fraction that was isolated 
contained B apolipoprotein only. In these studies however, the authors 
were not able to determine the specific activities of the B apolipo-
protein of LDL1 as the low plasma concentration of this lipoprotein was 
insufficient for routine apolipoprotein separation using gel 
filtration techniques. 
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3.2.4 Preparative isolation of the B apolipoprotein using 1,1,3,3-
tetramethylurea (TMU) 
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Kane (1973) has described a technique, employing the organic 
solvent 1,1,3,3-tetrame thylurea (Sigma, U.S.A.) for the selective 
precipitation of the B apolipoprotein from whole lipoproteins. The use 
and function of TMU as an organic solvent has been reviewed by 
Luttringhaus and Dirksen (1964). The TMU technique has recently been 
applied, with minor modifications, to describe the mean apolipoprotein 
composition of human VLDL (Kane et al., 1975). With this procedure, the 
amino acid composition of the TMU insoluble protein of VLDL is similar 
to that of LDL suggesting that apolipoprotein Eis not co-precipitated 
with the B apolipoprotein. The TMU technique, which is simple in that 
lipoprotein delipidation is not necessary to obtain apolipoprotein 
separation, requires lipoprotein solutions of approximately 600 µg/ml 
in buffers of ionic strength ~0.05 and in the pH range 6-9. Technical 
problems may be encountered, however, in this procedure as the separation 
of the TMU soluble phase is difficult without some disturbance of the B 
apolipoprotein-lipid pellicle. 
The TMU technique has been employed in a recent report of 
Faergernan et al. (1975) where rat VLDL B apolipoprotein specific 
activities were determined by calculating differences between protein 
concentrations and radioactivity present in whole VLDL and TMU soluble 
VLDL protein fractions. Direct estimations of the specific activities 
of TMU insoluble protein carried out during the course of the project will 
be described in section 3.2.5. 
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3.2.5 Experimental: separation of VLDL and LDL apolipoproteins using 
A procedure for isolating the B apolipoprotein of VLDL and LDL 
has been developed for the me tabolic studies described in this the sis. 
This method depends on the relative insolubility of the B apolipoprote in 
in low ionic strength buffers (5rnM NH4Hco3 , pH 8.0). The differential 
solubility of apolipoproteins in aqueous buffers has been exploited by 
other investigators in determining lipoprotein apolipoprotein compositions 
(Lee and Alaupovic, 1974). 
NH4Hco3 separation procedure: 
Following dialysis against 5mM NH4Hco3 , pH 8. 0, 0. 5 - 1. 0 mg 
of lipoprotein-protein (either VLDL or LDL) is delipidated as previously 
described (section 2.5). The apolipoprotein is then incubated, at room 
temperature, for at least 12 hours in 0.5 ml of SmM NH
4
Hco
3
, pH 8.0. 
The insoluble apolipoprotein is precipitated from the NH
4
Hco
3 
soluble 
apolipoproteins by centrifugation (60,000 x g .min). After removal of 
the soluble phase, the insoluble pellet is resuspended in a further 
0.5 ml NH4Hco3 and then r eprecipitated by centrifugation. The pellet is 
dried, after removal of the wash, and is then available for further 
analysis. 
To test the validity of this separation procedure, the amino 
acid compositions of the NH4Hco3 insoluble apolipoprotein of samples 
of VLDL, LDL1 , and LDL2 were determined (Table 3.1). A comparison of 
these values suggested that an identical protein had been isolated from 
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each lipoprotein fraction by the insolubility procedure. The composition 
of this fraction was similar to published reports of the amino acid 
composition of the B apolipoprotein of LDL (Gotto et al., 1972) and 
TMU insoluble protein from VLDL and LDL (Kane e t al., 1975) as shown 
in Table 3.1. 
The homogeneity of the NH 4Hco 3 insoluble fraction was also 
tested by solubilising it in 0.SM tris-Ilcl, 0.2M SOS, pH 8.2 and then 
applying a sample to 10% polyacrylamide-SDS gels (Section 2.7). The 
insoluble fraction was found to be relatively free of proteins that 
could enter the main gel (Figure 3.3) confirming that this fraction 
contained predominantly the B apolipoprotein. 
This method of obtaining the B apolipoprotein apparently free 
of other apolipoproteins was used to isolate the B apolipoprotein of 
VLDL and LDL fractions for specific activity determinations in most 
of the studies described in the later chapters of this thesis. After 
dissolving the NH4Hco3 insoluble fraction in O.lM NaOH, the protein 
(section 2.1) and radioactivity were measured and so the specific 
activity of the B apolipoprotein was calculated. 
To ascertain the practical efficacy of the NH4Hco3 
technique 
a comparison of specific activity-time curves of VLDL B apolipoprotein 
from study 8 (Chapter 5) determined using the procedure outlined above 
or the TMU procedure is shown in Figure 3.4. The specific activities 
using the TMU procedure were estimated using the same procedure described 
by Kane et al. (1975) for apolipoprotein separation but with subsequent 
lipid removal from the lipid-protein pellicle (plus precipitate) by the 
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Figure 3.3. Polyacrylarnide gel electrophoresis (10% acrylamide SOS gels 
using the system of Weber, 1975) of proteins of whole and 5rnM 
NH 4 HC0 3 soluble and insoluble fractions of apo-VLOL (see section 
3.2.5). Approximately 100 µg protein was incubated for 12 hours in 
D.1% (w/v) SOS (as described by Weber) and then loaded onto gels for 
electrophoresis. Following electrophoresis, gels were stained (with 
coornassie blue) and destained as described in section 2.7. 
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usual delipidation procedures, thereby leaving the TMU insoluble protein 
for specific activity determination as was described for NH4Hco 3 
insoluble protein. 
As can be seen in Figure 3.4 the specific activity time curves 
are virtually identical using either procedure. Importantly, the bi-
. 
exponential nature of this curve is observed using both methods. 
3.2.6 Conclusions 
A number of procedures have been described for the isolation 
and/or quantitation of the B apolipoprotein of plasma lipoproteins. As 
the aims of the studies in the subsequent chapters were to investigate 
the metabolic apolipoprotein interrelationships mainly between low and 
very low density lipoproteins (which have in common the B apolipo-
protein) a technique was required for the determination of the specific 
activity of this apolipoprotein. Although gel chromatographic techniques 
could have been employed, they required larger masses of lipoprotein-
protein that, in practice, were not always available (particularly from 
LDL1 ). Secondly, good resolution between the Band E apolipoproteins 
by these methods has not been definitively confirmed. 
Both TMU and HN 4Hco3 procedures depend on the relative 
insolubility of the B apolipoprotein and both require delipidation 
(either before or after apolipoprotein separation) to accurately determine 
the specific activity by direct measurement (which is preferable to the 
difference method used by Faergeman et al., 1975). For the purposes 
of the present studies, the NH 4Hco3 procedure was employed as the method 
was less critically dependent on sample concentration and was found to 
be technically easier in the separation of soluble and insoluble apolipo-
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Figure 3.4 A comparison of the specific activities of VLDL 
B apolipoprotein determined either by the NH4Hco3 or TMU procedures on VLDL samples from study # 8 (descrined in 
chapter 5). The bi-exponential nature of the curve is 
observed with both techniques. Both apolipoproteip 
separation procedures are described in section 3.2.5. 
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protein phqses. 
3.3 ISOLATION AND QUANTI!ATION OF THE INDIVIDUAL C APOLIPOPRaI'EINS 
The C apolipoprotcins always occur, as does the B apolipo-
protein, in conjunction with other apolipoproteins except in the ab-
normal lipoprotein associated with LCAT deficiency and cholestasis, . 
Lp-X, where the C apolipoproteins are found in association with albumin 
(Alaupovic et al., 1969). Isolation of the C apolipoprotein group of 
apo-VLDL has been previously described (section 3.2.2). Subsequent 
procedures for isolation and quantitation of the individual C apolipo-
proteins will be described in this section. Kane et al. (1975) and 
Schonfeld et al. (1976) have recently described six C apolipoproteins 
although only four of these peptides has been functionally investigated . 
The two most recently described apolipoproteins are polymorphic forms 
of C-111, being termed C-111-0 and C-111-3 (3 sialic acid residues has 
not been confirmed in the latter peptide). These two latter peptides 
are present in low, but not necessarily insignificant amounts in VLDL. 
C-111-3 tends to lose some of its sialic acid residues upon being 
delipidated and so is not always seen in this form (Kane et al., 1975). 
The C apolipoproteins may be separated, on the basis of charge, 
by ion-exchange chromatograr1hy or polyacrylamide gel electrophoresis 
(Shore and Shore, 1969; Brown et al., 1969, 1970a, 1970b; Albers and 
Scanu, 1971; Kane, 1973; Herbert et al., 1973). All of these methods 
involve the use of urea as a dissociating agent. 
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3.3.1 Experimental: isolation of the individual C apolipoproteins 
using DEAE cellulose 
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The small molecular weight C apolipoproteins were isolate d 
from apo -VLDL by gel filtration chromatography as desc ribed in s ectio n 
3.2.2. Preparative separation of the individual C apolipoproteins was 
achieved by ion exchange chromatography on DEAE cellulose columns 
(1.5 x 90 cm) using the procedure described by Herbert et al. (1973). 
Prior to packing these columns, the DEAE cellulose resin was 
washed, in sequence, in the following solutions: 0.5M HCl; O.OlM tris-
HCl, pH 8.0; 0.25M tris-HCl, pH 8.0; O.OlM tris-HCl, 6M urea, pH 8.0. 
The resin column was poured in the latter buffer. These columns were 
loaded with 30-80 mg of C apolipoprotein (in O.OlM tris-HCl, 6M urea, 
pH 8.0), after which progressive elution with a gradient of tris-HCl 
( 0. OlM - 0. 2 SM) was commenced. The gradient (linear) was established 
using 1 litre reservoirs of O.OlM and 0.25M tris-HCl, both containing 
6M urea and at pH 8.0. This tris gradient was found to achieve a better 
resolution of the apolipoproteins than the NaCl gradient of Brown et al . 
(1969). 
The elution profile of a C apolipoprotein separation from 
DEAE cellulose is shown in Figure 3.5. Recoveries of protein with t hi s 
system varied from 47-73%. The individual proteins peaks were collec ted 
and exhaustively dialyse d against SmM NH4Hco3 , pH 8.0 and then lypo-
phylise d. The dried prote in residue was resolubilised in various solutes 
as described by Herbert et al. (1973). Although the C apolipoprotein 
complex (i.e. F2 of the apo-VLDL separation by gel filtration) was 
soluble in O.OSM NH4Hco3 , pH 8.0, some of the isolated apolipoproteins 
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Figure 3.5 Elution profile obtained when 86 ug of C apolipo-
protein were applied to DEAE cellulose (column: 
1.5 x 90 cm) and eluted with a tris gradient of O.Ol -0.25M 
at pH 8.2. The separation was performed in the presence 
of 6M urea at 2°c. The flow rate of the column was 12 ml/ 
hour. The identity of the protein collected in each peak 
was confirmed as described in section 3.3.2. 
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Figure 3.6. Polyacrylarnide gel electrophoresis (using the system of 
Kane, 1973) of protein from each fraction of the separation of C 
apolipoproteins on DEAE cellulose as described in section 3.3.1 and 
figure 3.5. 40 µg of each isolated C apolipoprotein were loaded in 
the presence of 6M urea. The unlabelled gel was that of the 
unlabelled peak in figure 3.5 and probably represents a carbamylated 
form of C-1 as suggested by amino acid analysis. Gels were stained 
(with amide black) and destained as described in section 2.7. 
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were not. ~-1 was soluble in O.lM acetic acid, C-11 in O.lM NH40H, 
and C-111 in 0.05M NH 4Hco3 , pH 8.0. Following solubilisation, the 
proteins were electrophoresed on urea-polyacrylamide gels (Figure 3.6) 
and shown to b e single prote in bands. The identity of the apolipo-
proteins was confirmed by a variety of techniques. 
3.3.2 Experimental: identification of the isolated C apolipoproteins 
• 
The total amino acid composition of each isolated protein, as 
shown 1n Table 3.2, was determined by the procedure described in section 
2.8. These values when compared to those of Herbert et al. (1973) 
confirm that similar proteins were isolated. Although not included in 
Table 3.2, the protein of unidentified peak in Figure 3.5 and gel of 
Figure 3.6 was similar in amino acid composition to C-1 except for a 
reduced lysine content suggesting that this protein was a carbamylated 
form of C-1 apolipoprotein. This band was not routinely found on other 
separations. Although not shown in Figure 3.5, a peak similar to C-X 
described by ·He rbert et al. (1973) was observed in some separations but 
insufficient protein was available for. further analysis. 
The carboxy terminal amino acid of the major C apolipoproteins 
was det0rmined after carboxy-pcptidase A digestion and hydrazinolysis 
(as described in section 2.8). As expected, the terminal amino acids 
released with incubations of C-1, C-11, C-111-1 and C-111-2 were 
s e rine, glutamic acid, alamine and alamine respectively. 
The ability of these peptides to potentiate the activity of 
milk lipoprotein lipase preparations on an artificial triglyceride 
emulsion (section 2.9) was ascertained as shown in Table 3.3. 30µg of 
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s e c t i o n  3 . 3 . 1 .  
T h e  a m i n o  a c i d  c o m p o s i t i o n s  s h o w n  [ a ]  a r e  c o m p a r e d  t o  t h o s e  o f  H e r b e r t  e t  
a l .  
(  1 9 7 3 )  
[ b ]  .  
V a l u e s
1  
a r e  e x p r e s s e d  a s  µ m o l e s / 1 0 0 0  µ m o l e s  a m i n o  a c i d  r e c o v e r e d .  
C - 1  
C - 1 1  
C - 1 1 1 - 1  
C - 1 1 1 - 2  
[ a ]  
[ b ]  [ a ]  
[ b ]  [ a ]  
[ b ]  
[ a ]  [ b ]  
l y s i n e  
1 4 3  1 5 6  
7 9  
7 7  
6 1  7 5  
7 8  
6 7  
h i s t i d i n e  6  0  
0  0  
1 6  
1 2  
1 6  1 1  
a r g i n i n e  2 3  
5 4  
1 8  
1 6  3 0  2 5  
2 5  2 5  
a s p a r t a t e  
7 6  9 6  
7 6  7 0  9 4  9 5  
9 8  9 6  
t h r e o n i n e  
4 1  
4 8  
9 3  1 0 8  
6 4  6 4  
6 3  6 9  
s e r i n e  
1 3 0  
.  1 1 8  
1 1 1  
1 1 5  
1 3 6  1 4 0  
1 3 0  1 4 1  
g l u t a m a t e  
1 3 8  1 6 5  1 6 9  1 7 8  
1 3 7  1 3 6  1 3 1  1 3 6  
p r a l i n e  
1 6  1 3  5 3  5 3  2 9  2 8  
3 9  2 9  
g l y c i n e  4 5  
2 2  
4 9  3 0  
5 1  
4 2  
5 6  4 1  
a l a n i n e  9 8  5 6  8 6  
8 3  1 2 6  1 3 3  1 2 6  1 2 9  
v a l i n e  
3 2  
3 7  5 7  5 0  
8 6  7 8  7 7  
7 5  
m e t h i o n i n e  
6  
1 6  2 3  2 2  
1 9  
2 4  2 0  
2 4  
i s o l e u c i n e  3 8  5 0  1 0  
9  2  
0  
0  
0  
l e u c i n e  1 1 8  1 1 1  9 3  1 0 2  
6 6  
7 0  6 9  
7 1  
t y r o s i n e  0  
1  
5 1  6 1  2 7  2 7  2 2  
2 7  
p h e n y l  a l a n i n e  4 1  5 4  
3 2  
2 6  5 6  5 5  
5 3  5 4  
1  
T h e  v a l u e s  o b t a i n e d  i n  t h i s  s t u d y  a r e  t h e  m e a n  o f  t w o  o b s e r v a t i o n s .  
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11 TABLE 3.3 
C APOLIPOPROTEIN ACTIVATION 
OF LIPOPROTEIN LIPASE 
A comparison of the activation of milk lipoprotein 
lipase (prepared as described in section 2.9) by 
each of the major C apolipoproteins. Lipase act-
ivity was assayed, as described in section 2.8, in 
the absence of C apolipoproteins (control) or 
following the addition of 30 µg of isolated Capo-
lipoprotein. Values for activation (mean± 1 
standard deviation of four observations) are expressed 
in relation to the control activity. 
C 
l 
apolipoprotein 
ACTIVATION 1 addition 
C-1 0.46 
C-11 17.94 
C-111-1 1.27 
C-111-11 1.94 
Activation= activity in presence of 
C apolipoprotein/control. 
± 0.21 
± 2.16 
+ 0.09 
± 0.42 
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isolated apolipoprotein was added to each incubation (volume of 1 ml). 
C-11 apolipoprotcin only was found to markedly stimulate the enzyme. 
I 
3.3.3 Experimental: quantitation of the individual C apolipoproteins 
_ex densitometry 
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Even though the individual C apolipoproteins may be isolated 
by ion exchange chromatography, this method is not suitable for the 
quantitation of small amounts of these proteins because of the low (and 
therefore non-quantitative) recoveries using these procedures. 
Polyacrylamide gel electrophoresis has been widely used to 
study microgram quantities of proteins. With this procedure the quantity 
of protein in the stained gel band may be ascertained by estimating 
the amount of stain taken up by the protein in the respective band 
(Fishbein, 1972). This method requires that the relationship between 
dye and protein concentration obeys Beers Law. The concentration of dye 
in the band may be estimated directly by extraction of the dye from the 
gel (Johns, 1967) or by densitometry. As amido black stains protein 
metachromatically, it is of particular importance to establish the 
relationship between dye uptake and protein concentration when this stain 
is employed ( Gorovsky el al. , 1970) . 
Having preparatively isolated the major C apolipoproteins it 
was possible to establish the relationship between apolipoprotein 
concentration and dye uptake (as determined by densitometry) for each 
C apolipoprotein on polyacrylamide gels. 
As the Lowry method (Lowry et al., 1951, section 2.1) for 
the estimation of protein mass relies partly on the presence of tyrosine 
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residues, it would be expected that the C-1 apolipoprotein in particular 
(which is almost devoid of tyrosine residues) would be underestimated 
by this procedure. From freeze-dried samples of isolated C apolipo-
p ~oteins, solutions were prepared containing a known mass, determine d 
gravimetrically, of each C apolipoprotein. A comparison of the actual 
protein concentration to that determined by the Lowry technique (using 
albumin as standard) is shown in Table 3.4. From this table it can be 
seen that the mass of 1 mg of eachCapolipoprotein, when estimated 
colourimetrically, gave a range of values indicating that the Lowry 
technique may not be used for C apolipoprotein quantitation if albumin 
is used as a standard. 
Known amounts (determined gravimetrically) of the individual 
C apolipoproteins were electrophoresed on urea-polyacrylamide gels 
using the system of Kane (1973). Following electrophoresis (as described 
in section 2.7) the gels were stained in 0.1% (w/v) amido black in 7% 
(v/v) acetic acid for precisely 60 minutes. After staining, all gels 
were d e stained by diffusion under identical conditions for 72 hours 
by continuous replacement of 7% acetic acid. 
Gels were scann ed at 601 mµ using~ Varian Techtron gel 
scanner fitted with a glass cuvette of the bucket type. Scanning speed 
was 10 mm/min with a chart speed of 30 cm/min. Slit width was set at 
0.2 mm. The protein mass applied to the gel was related to the area of 
its respective peak on the scan record. Area was determined by tri-
angulation or planimetry. 
A linear concentration was established between protein mass 
(over the range 5-60 ug) and peak area for each of the four peptides 
I 
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TABLE 3.4 
ERRORS IN THE COLOURIMETRIC ESTIMATION OF 
C APOLIPOPROTEIN MASS WHEN USING BOVINF. 
ALBUMIN AS STANDARD 
This table co~pares, for each C apolipoprotein, 
the mass estimated colourimetrically to that 
determined gravimetrically. The colourimetric 
estimation procedure 1 [Lowry et al., (1951) 
employed bovine albumin as the protein standard. 
Values (mean± 1 standard deviation from four 
observations) are expressed as the 'estimated' 
mass of 1 mg ( grav.unetric) of each C apolipo-
protein. 
C 
'ESTIMATED' MASS 
APOLIPOPROTEIN mg 
C-1 0.509 + 0.014 
C-11 0.829 + 0.049 
C-111-1 1.101 ± 0.050 
C-111-11 1.116 + 0.021 
1 section 2.1. 
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examined, as shown in Figure 3.7. This relationship applied, though with 
differing slopes when the proteins were loaded in urea or TMU. 
Having established linearity for each C peptide within the 
range dcscrib~d, the mass of individual C apolipoproteins from test 
samples could be determinations by densitometric analysis of gels after 
electrophoresis. A standard mixture of known amounts of Pach of the 
four C apolipoproteins was prepared and applied at 3 different concen-
trations, to separate gels for each gel run. The clear separation of C 
apolipoproteins on urea-polyacrylamide gels resulted in a densitometric 
scan having well resolved peaks as shown in Figure 3.8. 
In using this technique, it has been recognised, as have other 
investigators (Kane et al., 1975; Schonfeld et al., 1976) that the linear 
expression of the area-protein relationship is specific for each C 
apolipoprotein. 
3.3.4 Documented methods for the quantitation of C apolipoproteins 
by densitometry 
By densitometric scanning of polyacrylamide gels, Kane et al . 
(1975) have quantitated the TMU soluble proteins of VLDL, after having 
established the linearity of the area protein relationship for each 
peptide. Using this technique, these authors have described the mean 
apolipoprotein composition of VLDL as well as percentage variations in 
the apolipoprotein content of VLDL particles in various size ranges. 
Schonfeld et al. (1976), also using similar procedures, but applying 
apo-VLDL in 8M urea to 9% gels, have demonstrated variations in VLDL 
C apolipoprotein content induced by high carbohydrate diets. These 
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Figure 3.7 Relationship between area under the peak (from the 
densitometric scan) and protein mass for the major Capo-
lipoproteins. Apolipoprotein mass was determined gravi-
metrically while area was measured by planimetry. Gels 
were scanned as described in section 3.3.3. The C apolipo-
proteins were loaded onto the gels in 6M urea ( ) or 
4.2M TMU (-----). 
60 
Figure 3.8 Typical densitometric scan recordings of gels electro-
phoresed with human apo-VLDL. The upper scan represents that of 
a gel loaded with apo-VLDL in 6M urea while the lower scan 
illustrates that obtained from a gel loaded with TMU soluble 
proteins of VLDL. The scan records are that of main gel only 
(not the stacking gel). 
I 
I 
II 
11 
1,: 
I 
I 
II 
11 
Ii 
I 
methods have also been u~ed to describe changes in the apolipoprotein 
content of rat VLDL (Schonfeld et al., 1974; Bar-On et al., 1974). 
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Although the method for C apolipoprotein quantitation described 
in this chapter was developed independently of similar methods described 
by others (Kane et al., 1975; Schonfeld et al., 1976) it is, in itself, 
not a novel procedurP-. C apolipoproteins, which may be easily and 
reproducibly well reserved by PAGE, are obviously particularly suited 
for quantitation by densitometric techniques. 
Results using this technique are not included in this thesis 
as they are still of a preliminary nature. The technique is at present 
being used to investigate the content and · turnover of the C apolipo-
proteins in various lipoprotein fractions of normal and hyperlipoprotein-
aemic subjects. 
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CHAPTER 4 
THE TN VITRO CONVERSION OF VLDL 
TO · LDL BY LIPOLYTIC ENZYMES 
4.1 INTRODUCTION 
The transport of newly synthesised lipid of endogenous, or 
non dietary origin, is mediated by the VLDL class (Havel, 1961; Barter, 
1974; Clifton-Bligh et al., 1974). Of the protein constituents of 
VLDL of hepatic origin, the R apolipoprotein is secreted together with 
the lipids (Isselbacher et al., Bar-On et al., 1973) whereas the small 
molecular weight C apolipoproteins appear to be derived from circulat-
ing HDL (Havel et al., 1973b). The origin of apolipoprotein E of VLDL 
has not been determined (section 1.2.3). 
The clearance of triglyceride from the plasma into tissues 
is dependent upon the act.ivi ty of the ·enzyme lipoprotein lipase 
(glyceryl-ester hydrolase, E.C. 3.1.1.3) (Robinson, 1970). The removal 
of triglyceride from VLDL is associated with the loss of surface lipids 
and the transfer of C apolipoproteins to HDL. This results in the form-
ation of a population of remnant lipoproteins in which the relative 
proportions of B apolipoprotcin and cholesteryl ester are increased 
(Shore and Shore, 1962; LaRosa et al., 1970; Eisenberg et al., 1973; 
Bierman et al., 1973; Eisenberg and Rachrnilewitz, 1975). The fate of 
these remnant particles may differ in various species. For instance, 
it is probable that in the rat, the bulk of VLDL B apolipoprotein is 
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removed by the liver (Fidge and Poulis, 1975; Faegerman e t al., 1975) 
whereas in man, the VLDL B apolipoprotein may be largely retained in 
the plasma within the LDL class. During infusion of heparin into man, 
virtually all of the prote in that is lost from VLDL is found in the 
smaller lipoproteins (Honuna and Nestel, 1975). 
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The incubation of VLDL with plasma obtained after the injection 
of heparin leads to a redistribution of lipid and protein among the 
plasma lipoproteins resembling that seen in vivo (Shore and Shore, 
1962; Nichols et al., 1968; Eisenberg et al., 1973). This chapter 
describes a series of experiments in which the transfer of the Band C 
apolipoproteins from lipoproteins of very low and intermediate density 
ranges to lipoproteins of higher density has been studied during 
incubation of various radioiodinated lipoprotein fractions with post-
heparin plasma (whole) or post-heparin plasma with lipolytic activity 
of hepatic origin only. By measuring the specific activities of the 
B apolipoprotein, a better understanding of the relationships between 
these lipoproteins was possible. Also, the relevance of hepatic or 
extra-hepatic lipases to these conversions was investigated. 
4.2 METHODS 
4.2.1 Collection of plasma for incubation studies 
Plasma used in the incubations was obtained from fasted healthy 
young subjects before and after the administration of intravenous 
heparin. The plasma obtained prior to heparin was designated HEP-0. 
Ten units of heparin per kg body weight was then rapidly administered 
intravenously and blood was collected in heparinised tubes after 
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10 min (plasma referred to as HEP-10). Three hours later a further 
100 units heparin/kg body weight was injected and blood collected 
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30 minutes later (plasma referred to as HEP-100). This regime provided 
samples possessing negligible, low or hiqh post heparin lipolytic 
activity as described by Boberg (1972). All plasma was maintained at 
4°C and used as soon as possible after collection. 
4.2.2 Incubation procedures 
Four . types of experiments (A, B, C and D) are reported in 
this chapter. Each experiment was carried out at least twice, though 
single experiments only of type A and Bare shown. 
Procedures for lipoprotein isolation, purification and 
iodination have been previously described (sections 2.2 and 2.3). 
Experiments A and B 
The labelled substrate was in VLDL sf 20-400 in experiment A 
and in VLDL sf 100-400 in experiment B. Incubations were performed at 
37°C in 3 flasks containing 50 ml of either HEP-0, HEP-10 or HEP-100 
plasma. The labelled substrate (approximately 1 mg lipoprotein -
protein) was added at zero time and 10 ml aliquots of incubation medium 
were removed at 5, 10, 15 and 30 min for lipoprotein analysis. Further 
lipolytic activity in the removed aliquot was effectively stopped by 
immediate immersion in ice. 0-2.1% of the lipolytic activity observed 
at 37°C was detected at this low temperature (0°C) . The addition of 
inhibitors of lipolytic activity, e.g. NaCl, paroxon (gift from 
Dr G. Schrader, Bayer, Germany) were also tested but the inhibitory 
capacity of these agents was no greater than the chilling procedure. 
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Aliquots were also taken during incubation for FFA determination 
(section 2.1). 
Experiment C 
This study was designed to compare the rate of transfer of 
labelled B apolipoprotein from three lipoprotein fractions, namely, 
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sf 100-400, sf 20-50 and sf 12-20 (LDL1 ) into the LDL2 (1.019-1.063 
g/ml) density range. The protocol was devised to provide equal concen-
trations of all lipoproteins in each incubation system by the addition 
of appropriate amounts of each of the 3 subfractions though each 
flask contained only one labelled subfraction. Incubations were 
carried out as above but aliquots of the incubation medium were removed 
at 2, 15 and 30 min. 
Experiment D 
Lipoprotein lipase of extra-hepatic origin is inhibited in 
the presence of lM NaCl or protarnine sulphate {Korn, 1955; LaRosa et al.~ 
1972). The relative importance of lipases or hepatic or extra-hepatic 
origin in the catabolism of VLDL to higher density lipoproteins was 
studied, in vitro, by incubating VLDL or LDL1 fractions with post-heparin 
plasma in the presence or absence of lM NaCl. The concentration of 
NaCl was adjusted to lM by the addition of solid NaCl 5 min prior to the 
commencement of incubation. The radioiodinated fractions added were 
either large VLDL particles (sf 100-400) or small VLDL remnants (sf 
12-50). These experiments were of similar design to those of experiment 
C so that total lipoprotein concentrations were identical in each 
incubation. Aliquots for lipoprotein analysis and FFA determination were 
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Figure 4.1 Lipolytic activity (as assessed by FFA release) of 
HEP-0, HEP-10 and HEP-100 plasma (see section 4.2.1). The 
activity was an expression of the heparin dose administered. 
Maximal activity was observed in plasma collected following 
the administration of 100 units heparin/kg (HEP-100) while 
there was negligible activity in plasma collected prior to 
heparin administration. (Heparin was obtained from 
Commonwealth Serum Labs., Melbourne, Aust.). 
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taken at 5 and 30 min. For sake of uniformity, prior to ultra-
centrifugation, the concentration of NaCl was adjusted to lM (if 
necess ary) in all aliquot s and the salt density to 1.21 g/ml by the 
addition of solid KBr. In this way, all major apolipoproteins were 
floated in the first ultracentrifugation. The salt density in the 
supernatc nt was then reduced to 1.006 g/ml by dialysis and VLDL, LDL
1
, 
LDL2 and HDL were isolated at their respective densities as described 
in section 2.2. 
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Plasma aliquots (from all experiments) were kept on ice until 
lipoprotein fractionation was commenced. Lipoproteins were isolated 
into VLDL, LDL1 , LDL2 and HDL fractions as previously described (section 
2.2). Aliquots of each lipoprotein fraction were assayed for total 
radioactivity in order to determine the redistribution of radioactivity 
among the plasma lipoproteins. Appropriate quenching corrections were 
incorporated for the salt density of the aliquot being counted. Follow-
ing the purification spin, the lipoprotein fractions (VLDL, LDL
1 
and 
LDL2 only) were dialysed against SmM NH 4Hco3 pH 8.0 and delip idate d 
as described in section 2.5. The apolipoproteins were then separated 
using the NH4Hco3 procedure (section 3.2.5) and the specific activities 
of the insoluble (B apolipop rotein) and soluble fractions were determine d. 
4.3 RESULTS 
4.3.1 
~f 20-400 labelled fraction in pre- and post-heparin plasma 
In experiment A, radioiodinated VLDL (sf 20-400) was incubated 
in HEP-0, HEP-10 and HEP-100 plasma. The rate of lipolytic activity in 
each incubation, as assayed by FFA release, is illustrated in figure 4.1. 
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When radioiodinated VLDL was incubated in HEP-0 plasma, there 
was an immediate and substantial loss of radioactivity from the VLDL 
fraction of which most was recovered in the HDL fraction (Table 4.1). 
This pattern of redistribution continued though at a very slow rate 
over the next 30 minutes. By contrast, in the presence of lipolytic 
activity (HEP-10 and HEP-100 incubations), there was further substantial 
redistribution of radioactivity with time which appeared to be a function 
of the rate of lipolysis, being more pronounced in the HEP-100 than in 
the HEP-10 incubation. Radioactivity was transferred not only into HDL 
but also into LDL1 and to a lesser extent into LDL2 . 
In Table 4.2 are shown the specific radioactivities of the 
separated Band soluble apolipoproteins in experiment A. There was an 
increase in the specific radioactivity of the B apolipoprotein in LDL
1 
in HEP-10 and HEP-100 incubations at 30 min and also in LDL
2 
in the 
HEP-100 incubation but no increases were observed in the absence of 
lipolytic activity. The specific radioactivity of the soluble proteins 
was increased in LDL1 at 30 min in both the HEP-10 and HEP-100 
incubations. The apparent fall in VLDL soluble apolipoprotein specific 
radioactivity probably reflected exchange with unlabelled C apolipo-
proteins of HDL. 
4.3.2 ~f 100-400 labelled fraction in pre- and post-heparin plasma 
The findings in experiment B were similar to those in experiment 
A (Tables 4.3 and 4.4), except that there was a greater initial percent 
transfer of radioactivity to the LDL1 fraction and a proportionately 
smaller transfer to HDL in the absence of lipolytic activity. This 
probably reflected the relative labelling of the Band C apolipoproteins 
TABLE 4.2 
SPECIFIC ACTIVITIES OF THE BAND C APOLIPOPROTEINS OF THE 
VLDL, LDL1 and LDL2 LIPOPROTEIN FRACTIONS DURING 
INCUBATION IN EXPERIMENT A 
Band soluble apolipoproteins were separated by incqbation in 
5mM NH 4Hco3 , pH 8.0 as described in section 3.2.5 
Plasma Time VLDL LDL1 LDL2 
Medium (min) B sol B sol B sol 
counts/min/µg protein 
HEP-0 5 5469 2167 N.D. N.D. 4.3 134 
10 4325 1997 407 482 4.3 144 
15 5077 1710 475 349 4.4 140 
30 4764 1046 472 497 4.8 156 
HEP-10 5 4407 1321 486 284 7.1 180 
10 6018 1131 611 385 7.7 140 
15 6724 1120 589 294 7.7 199 
30 6966 N.D. * 1628 671 9.6 179 
HEP-100 5 7750 1690 440 293 10.6 183 
10 7046 1094 501 293 12.5 174 
15 N.D. * N.D. * 701 374 18.0 176 
30 N.D. * N.D. * 1771 540 27.2 180 
* N.D.: Not determined due to insufficient protein for 
estimation 
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TABLE 4.1 
REDISTRIBUTION OF RADIOACTIVITY AMONG LIPOPROTEIN 
FRACTIONS DURING INCUBATION IN EXPERIMENT A 
125 ( 20 400) . b d . h 1 . VLDL- I sf - was incu ate in uman p asma possessing 
various activities of post-heparin lipolytic activity (see 
section 4.2.1). Incubations were performed at 37°C and 
aliquots taken at various times for lipoprotein separation by 
ultracentrifugation 
1 
Plasma 
Medium 
HEP-0 
HEP-10 
HEP-100 
Time 
(min) 
5 
10 
15 
30 
5 
10 
15 
30 
5 
10 
15 
30 
VLDL 
73.9 
73.l 
70.3 
68.5 
72.3 
66.4 
60.7 
36.2 
67.0 
56.l 
48.2 
16.5 
1 
LIPOPROTEIN FRACTION 
% total radioactivity 
6.1 
4.2 
4.4 
4.5 
3.7 
4.1 
4.8 
15.7 
5.8 
7.0 
9.3 
31.9 
2.5 
2.7 
2.1 
3.0 
2.3 
3.7 
3.4 
4.9 
3.2 
4.0 
5.2 
8.9 
VLDL sf 20-400; LDL1 sf 12-20; LDL2 sf 0-12; 
, HDL d. 1. 063 - 1. 21 g/ml 
HDL 
14.0 
16.2 
18.6 
20.1 
18.3 
21.6 
26.6 
37.5 
20.1 
28.6 
32.0 
36.7 
TABLE 4.3 
REDISTRIBUTION OF RADIOACTIVITY AMONG LIPOPROTEIN 
FRACTIONS DURING INCUBATION IN EXPERIMENT B 
This experiment was similar to experiment A except the labelled 
addition was VLDL- 125 I subfraction sf 100-400 
l 
Plasma 
Medium 
HEP-0 
HEP-10 
HEP-100 
Time 
(min) 
5 
10 
15 
30 
5 
10 
15 
30 
5 
10 
15 
30 
VLDL 
67.9 
69.2 
69.7 
67.3 
68.5 
60.0 
55.3 
38.5 
53.3 
47.3 
40.2 
21.6 
l 
LIPOPROTEIN FRACTION 
LDLl LDL2 
% total radioactivity 
18.6 
14.7 
15.6 
16.4 
15.6 
19.8 
22.7 
30.4 
20.8 
26.8 
26.9 
29.8 
4.0 
4.1 
3.7 
4.2 
5.4 
8.2 
6.4 
12.2 
10.2 
8.2 
14.1 
26.0 
VLDL sf 20-400; LDLl sf 12-20; LDL2 sf 0-12 
HDL d. 1.063 -1.21 g/ml 
HDL 
6.4 
8.7 
8.2 
9.0 
8.0 
11.1 
11.1 
13.0 
12.1 
13.0 
13.7 
16.8 
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TABLE 4.4 
SPECIFIC ACTIVITIES OF THE BAND C APOLIPOPROTEINS OF THE 
VLDL, LDL1 and LDL2 LIPOPROTEIN FRACTIONS DURING 
INCUBATION IN EXPERIMENT B 
B anq soluple apolipoproteins were separated by incubation in 
SmM NH4Hco3 , pH 8.0 as described in section 3.2.5 
* 
Plasma 
Medium 
HEP-0 
HEP-10 
HEP-100 
Time 
(min) 
5 
10 
15 
30 
5 
10 
15 
30 
VLDL 
B 
5489 
5319 
6101 
6230 
4831 
6102 
5902 
5436 
LDL1 LDL2 
sol B sol B 
counts/min/µg protein 
843 
993 
1132 
1435 
1640 
1139 
941 
936 
1456 
1851 
2408 
2490 
2280 
2287 
2487 
3094 
3007 
2952 
1378 2895 
1071 3947 
474 
434 
506 
494 
520 
500 
486 
568 
19 
23 
15 
18 
25 
33 
44 
98 
5 
10 
15 
30 
5873 
4686 
4050 
4489 * N.D. 5156 
554 
584 
652 
491 
51 
65 
103 
230 
N.D.: Not determined. 
sol 
177 
143 
169 
178 
197 
202 
229 
234 
228 
250 
302 
271 
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in the VLDL: the initial specific radioactivity of the C apolipoprotein 
was higher in the preparation used in experiment A and hence the 
transfer of label to HDL was greater. 
In the presence of lipolytic activity the percent reduction in 
VLDL radioactivity at 30 minutes was similar in the 2 experiments. The 
percent increase in the specific radioactivity of LDL2 B apolipoprotein 
was greater in experiment B because the specific radioactivity in LDL1 
B apolipoprotein (the presumed precursor) was initially higher than in 
experiment A. The increase in B apolipoprotein specific radioactivity 
in both LDL1 and LDL2 was greater with the HEP-100 than the HEP-10 
incubations. No change occurred in the specific radioactivity of the 
soluble fraction of LDL1 during lipolysis, although it fell in VLDL 
possibly due to continuing exchange with the much larger mass of 
HDL C apolipoprotein. 
4.3.3 Comparison of the conversion of VLDL and LDL1 subfractions to LDL2 
Experiment C was designed to define more precisely the role 
of LDL1 in the VLDL-LDL2 relationship. Two VLDL subfractions (sf 100-400 
and sf 20-50) and LDL1 (sf 12-20) were incubated with HEP-0 and HEP-100 
plasma. The experiment was carried out twice. 
The data shown in Table 4.5 are results of incubations from 
2 experiments with HEP-100 plasma. The HEP-0 data was essentially the 
same as described in experiments A and B. When the sf 100-400 fraction 
contained the label (study 1), substantial labelling occurred in both 
the LDL1 and LDL2 fractions. In study 2, the labelled fraction was the 
sf 20-50 class which may represent a remnant or intermediate of VLDL 
catabolism (Eisenberg et at., 1973). The labelling of both the LDL1 
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TABLE 4.5 
SPECIFIC ACTIVITIES OF THE B APOLIPOPROTEIN 
DURING INCUBATION IN EXPERIMENT C 
Two independent s tudies are shown. Incubations were in HEP-100 
plasma 
Experiment Stu dy La belled Time LIPOPROTEIN FRACTION
1 
addition (min) 
VLDL LDL1 LDL2 
counts/min/µg protein 
C-A 1 100-400 2 1258 79 7 
15 1249 101 10 
30 1274 172 17 
2 20-5 0 2 1949 259 17 
15 1473 609 24 
30 843 879 35 
3 12-20 2 1376 49 
15 1101 56 
30 803 85 
C-B 1 100-400 2 2139 91 19 
15 1923 165 23 
30 1810 223 40 
2 20-50 2 1430 707 16 
15 1185 1222 26 
30 527 1750 80 
3 12-20 2 1331 64 
15 1287 64 
30 1043 143 
1 
VLDL sf 20-400; LDL1 sf 12-20; LDL2 sf 0-12 
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and LDL 2 fractions was greater and more rapid in study 2 than in study 1. 
One probable explanation for this is that the B apolipoprotein specific 
radioactivity of the sf 20-50 fraction was higher in study 2 than in study 
1, thus inferring that the sf 100-400 fraction is initially degraded 
to lipoproteins in the sf 20-100 range before being transformed into the 
sf 12-20 or LDL1 class. 
The most rapid transfer of radioactivity to LDL2 occurred in 
the presence of labelled sf 12-20 lipoprotein (study 3). This is again 
consistent with a sequential transformation of VLDL (sf 100-400) into 
a series of smaller lipoproteins. An alternative possibility is for 
LDL2 or at least its B apolipoprotein to be derived simultaneously from 
several species of larger lipoproteins of various sizes. The data in 
Table 4.5 make this unlikely for 2 reasons. Firstly, in the incubations 
involving the sf 20-50 and sf 12-20 labelled additions, there was a 
rapid dilution of the labelled fraction from larger non-labelled lipo-
proteins. Secondly, since the mass of B apolipoprotein in VLDL 
sf 100-400 greatly exceeded that in the other 2 fractions, any transfer 
of unlabelled B apolipoprotein directly from the sf 100-400 class to 
LDL2 would have prevented the rapid rise in LDL2 B apolipoprotein 
specific radioactivities that was seen in studies -2 and 3. 
4.3.4 Comparison of the conversion of VLDL and intermediate lipoproteins 
to LDL2 by whole and lM NaCl inhibited post-heparin lipolytic 
activity 
Plasma post-heparin lipolytic activity contains lipases from a 
number of sources. In experiment D, lipases of extra-hepatic origin were 
inhibited by the presence of lM NaCl. The degree of inhibition, of FFA 
Labelled 
Fraction 
100-400 
12-50 
TABLE 4.6 
RELEASE OF FREE FATTY ACIDS DURING INCUBATION 
IN EXPERIMENTS D-A AND D-B 
NaCl 
cone. 
(molar) 
0.15 
1.0 
0.15 
1.0 
Time 
(min) 
5 
30 
5 
30 
5 
30 
5 
30 
µmoles FFA released/ml inc. med. 
D-1 D-2 
1.76 0.41 
7.29 2.10 
0.75 0.18 
3.30 1.31 
1.81 0.37 
7.40 2.47 
1.06 0.14 
3.48 0.91 
0.5 ml aliquots of incubation medium were added to 10 ml 
of Doles extraction medium. The extracted FFA were assayed 
colourimetrically (section 2.1) 
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release was .36-62% of the control (Table 4.6). At the same time, the 
presence of lM NaCl strikingly altered the redistribution of radio-
activity among the lipoprotein fractions when labelled sf 100-400 was 
added to HEP-100 plasma (Table 4.7). In contrast to the rapid transfer 
of radioactivity to LDL1 and LDL2 fractions seen in the absence of 
lM NaCl, its presence inhibited the transfer of radioactivity to LDL1 
and LDL2 fractions. This was also reflected in the B apolipoprotein 
specific radioactivities in VLDL, LDL1 and LDL2 (Table 4.8). However, 
when the sf 12-50 fraction was labelled, some transfer of radioactivity 
from VLDL to LDL1 occurred in the presence of lM NaCl although consider-
ably less than with 0.15 lM NaCl. In contrast, lipolytic transfer 
of sf 12-50 radioactivity did not proceed beyond LDL1 in the absence 
of extra-hepatic lipases. Hepatic lipolytic activity therefore appeared 
to promote some conversion of sf 12-50 to sf 12-20 lipoproteins but 
failed to catabolise the latter to LDL2 . This was also evident from the 
specific radioactivity data. This led to a greater retention of radio-
activity in LDL1 and a greater proportionate increase in the specific 
activity of this fraction than was observed in the uninhibited system. 
4.4 DISCUSSION 
In these studies, we have utilized an in vitro system for 
studying the interaction of VLDL with heparin induced lipolytic activity 
with respect to the fate of the Band C apolipoproteins of VLDL. This 
system has certain advantages in that all metabolic products remain 
available for analysis. There are considerable limitations in extra-
polating in vitro observations to in vivo events. An in vitro system 
excludes many factors which may influence lipoprotein interrelationships 
Experiment 
D-A 
D-B 
1 
TABLE 4.7 
PERCENT REDISTRIBUTION OF RADIOACTIVITY AMONG 
LIPOPROTEIN FRACTIONS DURING INCUBATION 
IN EXPERIMENT D (2 STUDIES) 
l NaCl LIPOPROTEIN FRACTION 
Labelled cone. Time 
addition (molar) (min) VLDL LDL1 LDL2 HDL D > 1. 21 
% total radioactivity 
100-400 0.15 5 34.7 15.6 16.8 25.0 7.9 
30 9.0 24.4 30.0 27.9 8.8 
1.0 5 47.8 7.5 8.9 25.l 10.7 
30 51.9 6.5 9.7 23.9 7.8 
12-50 0.15 5 32.7 30.4 19.4 14.3 3.3 
30 6.6 21.3 50.5 17.4 4.1 
1.0 5 55.0 15.2 12.1 14.2 3.6 
30 45.5 21.5 13.7 15.4 3.9 
100-400 0.15 5 53.4 5.5 5.9 18.8 16.5 
30 47.6 11.3 7.0 17.7 16.1 
1.0 5 52.5 5.6 3.9 16.5 21.5 
30 55.6 5.5 4.2 17.7 17.0 
12-50 0.15 5 55.2 19.1 13.0 8.9 3.8 
30 37.3 19.l 29.0 10.8 3.8 
1.0 5 58.1 16.7 12.2 8.9 3.8 
30 53.4 22.9 13.l 6.9 3.2 
VLDL sf 20-400; LDL1 sf 12-20; LDL2 sf 0-12; HDL d. 1.063 -1.21 g/ml 
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TABLE 4.8 
SPECIFIC ACTIVITIES OF THE B APOLIPOPROTEIN OF 
VLDL, LDL1 and LDL2 DURING INCUBATION 
IN EXPERIMENT D (2 STUDIES) 
NaCl LIPOPRarEIN FRACTION 
Experiment Labelled cone. Time 
addition (molar) (min) VLDL LDLl LDL2 
counts/min/µg B apo-
lipoprotein 
D-A 100-400 0.15 5 10038 1616 42 
30 3800 2225 163 
1.0 5 16105 724 5 
30 17144 802 7 
12-50 0.15 5 4614 7097 404 
30 1153 8004 618 
1.0 5 12508 3672 2 
30 11081 5669 15 
D-B 100-400 0.15 5 4887 282 52 
30 2954 552 91 
1.0 5 5899 236 43 
30 3725 216 54 
12-50 0.15 5 7698 2775 316 
30 N.D. 4323 685 
1.0 5 14795 2434 293 
30 10746 3582 294 
VLDL sf 20-400; LDL1 sf 12-20; LDL2 sf 0-12 
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such as lipoprotein influx and removal and the possible inhibitory effect 
on the LCAT system of post-heparin plasma. 
As a consequence of post-heparin lipolytic activity, radio-
activity associated with VLDL B apolipoprotein was transferred to LDL
1 
and 
LDL2 (as confirmed by the specific activity data). Some VLDL radio-
activity, presumably in C apolipoproteins was transferred to HDL. 
Although there were clear increases in the specific radioactivity of the 
B apolipoprotein in both LDL1 and LDL2 , a proportionately greater increase 
was observed in LDL1 than LDL2 . These relationships appear to be 
dependent upon lipolytic activity. 
The data of experiment C suggest that, in vitro at least, the 
catabolism of VLDL to LDL2 proceeds via an intermediate lipoprotein. The 
catabolism of VLDL triglyceride has previously been described as a 
'cascade-type' degradation with the larger VLDL particles being convert-
ed to lipoproteins of decreasing size and increasing density (Barter 
and Nestel, 1972). In experiment C, conversion of LDL
1 
to LDL
2 
was 
noted only in the presence of lipolytic activity. Eisenberg et al. 
(1973) have suggested from ~n vivo studies of VLDL catabolism following 
heparin administration that the conversion of LDL
1 
to LDL
2 
is independent 
of the lipolytic process. In their studies, little conversion of LDL
1 
to LDL2 occurred despite increased plasma lipolytic activity. On the 
other hand, Homma and Nestel (1975) demonstrated substantial conversion 
of LDL1 to LDL2 during constant infusion of heparin into type 3 hyper-
lipoproteinaemic subjects. 
The frequency distribution of diameters of VLDL remnants (after 
exposure of VLDL to post-heparin lipolytic activity) is quite narrow 
0 
and, in the rat, extends from approximately 160 to 400 A (Eisenberg 
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and Rachmilewitz, 1975). However, when rat VLDL is catabolised 
in vivo by a technique that excludes the liver from the circulation, 
0 
the average diameter is larger (350 to 550 A) (Mj¢s et al., 1975). 
Catabolism of VLDL may thr!rcforc proceed further, perhaps, under 
artificially high concentrations of lipolytic activity (as in post-
heparin plasma) than occuru under in vivo conditions. The present 
studies suggest that post-heparin lipolytic activity, in high 
concentrations, rapidly degrades human VLDL to LDL1 (sf 12-20) and 
beyond to LDL2 . This does not rule out the possibility that, when 
post-heparin lipolytic activity is largely absent from plasma, as 
occurs normally, VLDL catabolism may partly cease at the formation of 
the VLDL remnant which may then be removed from the circulation without 
complete conversion to LDL2 . Evidence for this has been obtained in 
hypertriglycerdernic individuals in whom as much as 2/3 of VLDL B apo-
lipoprotein may bypass conversion to LDL2 (to be described in chapter 5). 
The role, if any, for the hepatic lipase in VLDL catabolism 
is uncertain. It has been suggested that the function of the hepatic 
lipases may be to facilitate uptake of small quantities of triqlycerid0 
from VLDL and chylomicron remnants (Redgrave, 1970; Bergman et al., 
1971) and possibly convert these remnants to LDL
2 
(Felts et al., 1975). 
The relative hydrolytic activities of hepatic and extra-hepatic lipases 
on VLDL indicate that VLDL serves as a much poorer substrate for hepatic 
lipases than extra-hepatic lipases (LaRosa et al., 1972; Krauss et al., 
1973). The present studies suggest that the hepatic lipase is capable 
of some conversion of small VLDL to LDL1 at least in vitro but that it 
does not participate measurably in the conversion of LDL
1 
to LDL
2
. 
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The data on VLDL soluble apolipoproteins is more limited 
because of the heterogeneity of this group of peptides. Nevertheless, 
it was worth noting that very little radioactivity was transferred 
from VLDL to LDL1 during the process of lipolysis despite the presence 
of soluble apolipoproteins in LDL1 . On the other hand, exchange between 
VLDL soluble apolipoproteins and similar proteins, some presumably 
from HDL, appeared to occur throughout the incubation even in the 
absence of lipolysis. It has been previously demonstrated that the 
catabolism of VLDL is associated with a net .transfer of C apolipoproteins 
from VLDL to HDL (LaRosa et al., 1970; Eisenberg et al., 1972). The 
present results suggest that this movement may be partially bidirectional 
and are at variance with the findings of Eisenberg and Rachrnilewitz 
(1975) using rat lipoproteins and rat post-heparin plasma which suggested 
a unidirectional movement of C apolipoproteins from VLDL to HDL during 
catabolism of VLDL. 
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CHAPTER 5 
IN VIVO STUDIES OF VLDL 
AND LDL METABOLISM 
5.1 INTRODUCTION 
Abnormalities of lipid metabolism mny be more meaningfully 
described in terms of lipoprotein metabolism. Investigations of the 
92 
metabolism of plasma lipoproteins has increasingly focussed on the apo-
lipoproteins which appear to be the functional components of these 
macromolecules. 
The plasma concentration of lipoproteins, as for any metabolite, 
1s determined by the relative rates of influx and efflux. A rise in the 
concentration must therefore be due to an increased input into,and/or a 
decreased outflow from the plasma. 
The following two chapters describe a series of in vivo studies, 
carried out in man, of VLDL and LDL metabolism determined from the turn-
over of their common apolipoprotein, the B apolipoprotein. These studies 
utilize the methodology developed for the separation of the B apolipo-
protein from the soluble apolipoproteins described in chapter 3 (section 
3.2.5). Little has previously been reported on this subject because of 
difficulties 1n measuring the specific activity of the B apolipoprotein, 
particularly in VLDL. I t has therefore not been possible to character-
ise, completely, the relationship between VLDL and LDL apolipoprotein 
turnover, although it was known that VLDL B apolipoprotein was at least 
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partly transferred to LDL as a result of VLDL catabolism (Gitlin et al., 
1958; Bilheimer et al., 1972; Eisenberg et al., 1973; Eaton et al., 
1976) . 
The current view, in the rat, 1s that a substantial fraction of 
VLDL B apolipoprotein is removed from the circulation as a 'remnant' 
that is probably larger than LDL. At the same time, the question of the 
origin of LDL remains open, since it is possible that at least some LDL 
may be formed independently of VLDL catabolism (Fidge and Paulis, 1975; 
Faergeman et al., 1975; Fidge, personal communications). Findings in 
man are also at a preliminary stage. It has been suggested that LDL is 
totally derived from VLDL and also, that in normotriglyceridaemic 
individuals, at least, all VLDL is catabolised to LDL (Sigurdsson et al., 
1975). 
The catabolism of VLDL triglyceride is thought to proceed via a 
step-wise conversion of large (and triglyceride-rich) VLDL particles to 
smaller particles of higher density and lower triglyceride content 
(Barter and Nestel, 1972). During the. initial stages of VLDL catabolism, 
lipoproteins of intermediate size and density (termed remnant or inter~ 
mediate lipoproteins) are formed (Shore and Shore, 1962; Bilheimer 
et al., 1972; Eisenberg et al., 1973) some of which, as seen in the rat, 
may be removed without prior conversion to LDL (Fidge and Paulis, 1975; 
Faergeman et al., 1975). As discussed in chapter 4, it has been suggest-
ed that the lipolytic process that converts VLDL to these intermediate 
lipoproteins may not extend to the formation of LDL (Eisenberg et al., 
1973). Excessive accumulation of a subclass of intermediate lipo-
proteins may therefore reflect the failure of VLDL catabolism to proceed 
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beyond a ~pecific point. It has been postulated that type 3 HLP, which 
is characterised by the accumulation of a cholesterol-rich intermediate 
lipoprotein, develops in this way (section 1.7.4). 
This chapter describes the precursor-product relationships 
found between VLDL, LDL1 and LDL2 in ten studies, carried out in normal 
and hyperlipoproteinaemic subjects. Turnover rates of VLDL B apo-
lipor,rot0in w~r0 determined by compartm0ntal analysis. The likelihood 
of LDL1 being the true intermediate lipoprotein between VLDL catabolism 
and LDL formation was examined from the relationships of the relative 
turnover rates of VLDL, LDL1 and LDL2 . The turnover of LDL2 
was 
calculated from the relative rates of change in the specific activities 
of VLDL and LDL2 . 
5.2 METHODS 
5.2.1 Dietary procedures for maintenance of steady-state conditions 
The clinical details of each subject are shown in the result 
section (section 5.4). All subjects were maintained on a fat-free 
diet for the first two days of study. However, dietary carbohydrate 
intake was not increased to replace the fat in order to prevent a 
possible increase in hepatic VLDL production. Thus, during this 
period, the subjects received approximately 65% of their normal 
eucaloric intake. In practice, this regime led to a constant concen-
tration of plasma VLDL B apolipoprotein during the first two days of 
study. For the remaining study period, dietary fat intake was kept 
less than 25% of the normal total calories. Prior to, during and 
following the injection of the radioiodinated lipoproteins, potassium 
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iodide was administered (orally) twice daily to minimise radioactive 
iodine uptake by the thyroid. 
5.2.2 Preparation of radioiodinated lipoproteins for re-injection 
Four days prior to study, 100 ml blood was collected, into 
heparinised tubes, from the fasting subject for preraration of VLDL 
95 
(sf 20 - '100) and LDL2 (sf 0-12) (studies 3 and 5 only) by ultra-
centrifugation as previously described (section 2.2). VLDL was iodinat-
ed with 
125
r and LDL2 with 
131 r as described in section 2.3 and 
prepared for reinjection by Millipore filtration (section 2.4). Sterility 
was checked bacteriologically. 
5. 2. 3 Injection of autologous lipoprotein preparations and the subse·quent 
collection of blood samples 
Approximately 3-5 mg of autologous VLDL protein labelled with 
125 
20-70 µc of I was injected into each subject. In studies 4 and 5, 
the subject was also injected with approximately 15 µc of LDL - 131 r 
containing 3 mgs of LDL protein. The-vials containing the labelled 
lipoprotein were weighed before and after the injection sample was 
removed in order to determine accurately the injected dose {except 
study 1). Following injection, blood samples (approx. 22 ml) were 
drawn at regular intervals over the period of study (3-7 days). 
Studies were usually carried out over a three day period, by which 
most of the radioactivity associated with VLDL and LDL1 had disappeared. 
VLDL turnover was calculated from observations over the first 50 hours 
b h . h t. 1 h 5 f h . . 125 · d h · y w 1c 1me ess tan % o t e 1nJected I dose rema1ne 1n t 1s 
fraction . 
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5.2.4 Determination of B apolipoprotein specific activities in VLDL, 
LDLl and LDL2 
VLDL, LDL1 and LDL2 were isolated and purified from 10 ml 
plasma samples as described in section 2.2. The liporJrotcin prcparat-
ions were delipidated (section 2.5) and the B apolipoprotein isolated, 
using tl1v NI1 4 11co 3 procedure for sp<'cJ f ·ic <1ctivily dl~tc,rmination (section 
3.2.5). 
Plasma concentrations of B apolipoprotein (in VLDL or LDL2 ) 
were corrected for any losses during ultracentrifugation or delipid-
ation. The intravascular mass of VLDL B apolipoprotein was calculated 
assuming the plasma volume to be 4.5% body weight. 
5.3 CALCULATIONS 
This section describes the rationale behind the different 
calculations .and interpretations made from the data of specific activit-
ies of the B apolipoprotein in VLDL, LDL1 and LDL2 . 
5.3.1 Analyses of specific activity-time plots for precursor-product 
relationships 
Zilversmit (1943), in a theoretical consideration of a situation 
where a compound Bis derived from compound A, concluded that "at any 
time, the slope of the specific activity-time curve of Bis proportional 
to the difference between the specific activities of A and B". If this 
criterion is met, the relationship is compatible with a precursor-
product relationship between A and B although it does not necessarily 
prove it. The precursor A could be in rapid equilibrium with a further 
compound X and therefore the relationship between X and B would meet the 
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Figure :5.1 l\ plot of the specific activities of a 
precursor (A) and product (D) against time. 
Position 1 demonstrates the slope of B(+ve) 
before it intersects~ at position (2) when the 
slope of D becomes zero. In Position 3 the slope of 
Bis -ve. The slope of D must be an expression of 
the difference in the specific activities of A and 
B if Bis derived solely from A. (Zilversrnit et al., 
194 3) . 
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above criterion yet X would not be the precursor to B (Zilversmit, 1960). 
The above stated criterion therefore demands that the slope 
of the specific activity-time curve of B will be positive while A 1s 
greater than Bas demonstrated in figure 5.1 (position 1). However, 
as the specific activities of A and B approach each other, the 
difference 1n specific activities approaches zero. This therefore demands 
that, at the point of cross-over of A and B, the slope of B be zero (as 
shown 1n position 2), B having reached peak specific activity. There-
after, the specific activity of B will be greater than that of A and the 
slope of B will become negative (position 3). If Bis not entirely deriv-
ed from A, the fraction of B that is derived from A will equal the ratio 
of the Band A specific activities at the peak of B. In this situation, 
the specific activity of A will cross B after the peak of B. 
Using this criterion, the specific activity-time curves of 
VLDL, LDL1 and LDL2 were examined to indicate the possible precursors 
of LDL1 and more importantly LDL2 ! as well as the relationships between 
the various VLDL and LDL1 fractions investigated in chapter 6. 
5.3.2 Calculation of turnover rates by kinetic analysis 
5.3.2.1 Single pool 
The kinetics of VLDL B apolipoprotein appeared to conform 
more closely to a 2-pool than a 1-pool model as shown 1n figure 5.4 
and subsequently in the experimental data in figures 5.6 to 5.15. 
However, for purposes of comparison with the only previous reports of 
VLDL B apolipoprotein turnover (Sigurdsson et al., 1975, 1976) analyses 
..... 
h 
J 
a 
' 
' 
I 
i . 
I 
I 
'. 
I, 
r, 
were also performed using the s ingle pool model which was used by 
Sigurds s on e l al . 
All analyses f or turnover rates assume the pool or pools 
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being investigated are in a 'steady state' with respect to the particular 
compound being investigated (as devised for these studies in section 
5.2.1). If the concentration of the compound remains constant, its 
rate of entry into the pool will equal the rate at which it is being 
removed. 
If a compound is being metabolised within a single pool 
(in a steady state), the fraction of that pool that is being removed 
(and so replaced) per unit time is referred to as the fractional 
catabolic rate (k). The total amount of metabolite that is leaving the 
pool (which is equivalent to that entering the pool) per unit time is 
referred to as the 'turnover rate', 'synthetic rate' or more recently 
'turnover' . 
The fractional catabolic rate may be determined from analys i s 
of the disappearance of a radioactive tracer, introduced into the pool, 
expressed as a specific activity-time plot. The specific activity of 
the compound is dep~ndent upon two equivalent functions its dilution 
by input of new (unlabelled) metabolite and its removal from the pool. 
It is assumed that, in the removal of the compound, there is no 
discrimination in removal of labelled or unlabelled compound from the 
pool. 
The specific activity (SA) at any time (t) may be defined by 
the expression 
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Figure 5.2 A plot of the expression 
SA (t) = SA -kt (o)e 
where SA( ) is the specific activity at a given time 
(t), e ist the natural base of logarithms and k (the 
slope of the expression) is a constant. The value of 
k may be determined as follows: 
k = 
£n SA 1 - £n SA2 
t2 - tl 
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where e is the base for natural logarithms. Such an expression, if 
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plotted on semi-logarithmic scale (to the base e) will be linear wi th a 
slope equal to k (f i gure 5.2). Therefore, from figure 5.2, if two 
time points (t1 and t 2 ) are selected with their concomitant specific 
activities (SA1 and SA2 ) then k may be expressed as 
k = 
ln SAl - ln SA2 
t2 - tl 
For ease of calculation, it is more convenient to calculate 
this value using 'half times' 
specific activity at any time 
(t1 ) i.e. the time required for the 72 
to decline by half. Therefore, in the 
above equation if 
SA
1 SA2 = - 2- when t - t = t1 then 2 1 72 
ln SAl - ln SA1 
k = 2 
t1 
72 
ln 2 
= 
tk 
2 
= 
(Shipley and Clark, 197 2) . 
Ask is an expression of the fraction of the pool turnin g over 
per unit time, the total turnover may be calculated if the total mass of 
metabolite in the pool is known ( turnover = k x pool mass) . As the plasma 
concentration of B apolipoprotein was known, the plasma pool size could 
be calculated assuming the plasma volume to be 4.5% body weight. The 
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Figure 5.3 The two pool model proposed by Gurpide et al. (1964). 
This model allows for independent rates of entry and exit from 
each pool and independent equilibration rates between each 
pool. 
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value of k (or t 1 ) was determined from the line of best fit for B ~ 
apolipoprotein specific activities over the first 12 to 24 hours. 
5.3.2.2 Two pool 
100 
As previously mentioned, the disappearance curves for VLDL B 
apolipoprotein (Pigures 5.6 to 5.15) were clearly not mono-exponential 
over a SO-hour period. As these curves could be resolved by conventional 
'curve-peeling' techniques into two exponentials, a 2-pool model for 
kinetic analyses was used. 
The 2-pool model proposed by Gurpide et al. (1964) which 
describes the relationship between two pools, A and B, allows for 
independent entry and exit from both pools (Figure 5.3). As will be 
discussed later, the catabolism of VLDL B apolipoprotein may occur 
extravascularly in tissues, as well as 1n the generally accepted manner 
by conversion to LDL within the plasma compartment. It therefore 
seemed appropriate to select a model that incorporated efflux of material 
from the second pool B. This is in contrast to the 2-pool model of 
Matthews (1957) which has been used for kinetic analysis of LDL dis -
appearance curves (Langer et al., 1972; Hurley and Scott, 1970; Simons 
et al., 1975). The Gurpide model has been applied for the kinetic 
analyses of cholesterol turnover (Goodman and Noble, 1968). 
The two pool model, as proposed by Gurpide et al. (1964), is 
illustrated in Figure 5.3. Pools A and Bare in equilibrium with each 
other and both have independent rates of input and removal. With this 
system, the natural logarithm of the specific activity in pool A, when 
expressed as a function of time, will describe a curve which may be 
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Figure 5.4 Plot of the expression 
-at -St 
SA(t) = CAe + CBe 
which may be resolved into two exponentials,CAe-at 
d -St h · h 'f' t· 't an c8 e , were SA( ) is t e speci ic ac ivi y at 
a given time (t). C tand C are the respective 
intercepts. a and SAare th~ rate constants of the 
2 exponentials. Sis the extension of the terminal 
phase of the specific activity curve and a is 
obtained by "curve-peeling". 
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resolved into 2 exponentials as illustrated in Figure 5.4. The 
expression for this curve is the sum of the two exponentials: 
-at -Bt 
SA (t) = CAe + CBe 
The constants CA and CB may be found at t(o) as illustrated where the 
respective exponentials intercept the ordinate axis. a and B 
(equivalent to k) are calculated, from their respective exponential as 
for the 1-pool model from the t 1 (i.e. 0.693/t1 ). 72 72 
The mass of metabolite in pool A (MA) may be calculated 
from the equation 
C +C A B 
where RA is the amount of radioactivity added to pool A . 
The turnover of metabolite in pool A, may also be determined 
from the equation 
where PRA = the turnover in Pool A (other than material recycled through 
pool B) (Gurpide et al., 1964; Goodman and Noble, 1968). It is worth 
noting that this equation does not require knowledge of pool sizes. 
Although the mass in pool A may be calculated, that in pool B 
cannot be unless it is assumed that there is no loss from pool B, an 
assumption that would be unjustified for these studies in view of the 
recent findings of VLDL catabolism by cultured cell preparations (e.g. 
Goldstein and Brown, 1974). 
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5.3.2.3 Non-compartmental analysis 
An alternative procedure for determ{ning turnover is to use the 
Stewart-Hamilton equation (as discussed by Shipley and Clarke, 1972) 
where 
J
oo 
SA . dt 
0 
where PRA = turnover in pool A (as above) and RA is the dose of radio-
activity added to pool A. 
This formula is derived from the obvious premise that the amount 
of tracer ultimately lost from a labelled pool must equal the amount 
originally 
curve ( J
oo 
0 
the 
introduced (R). The integral of the specific activity-time 
SA .dt) was determined graphically by measuring the area under 
curve (by planimetry). This non-compartmental method of 
analysis was used as a verification of values obtained by compartmental 
analysis, as well as providing an index of the turnover of the LDL1 
fraction when labelled from VLDL. 
The turnover as determined in terms of PRA applies only to 
pool A and not to the input-output of the whole system 1.e. to turn-
over in all compartments. However if all the input or all the output 
occurs through pool A into which the label is introduced, then turnover 
in pool A equals that in the whole system. VLDL are secreted directly 
from the liver and the gut into the plasma and it seems likely therefore 
that VLDL influx occurs only through pool A which includes the plasma 
VLDL. The calculated turnover of VLDL is therefore likely to be equal 
to VLDL turnover in the whole system. 
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Figure 5.5 A plot of a precursor-product relationship 
between A and B analysed graphically for the 
determination of the fractional catabolic rate (k) 
of the product (section 5.3.3). 
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5.3.3 Determination of fractional catabolic rate of a product 
In instances where the specific activity time curves of pre-
cursor and product are available, the fractional catabolic rate (k) of 
the product may be determined graphically (Zilversmit, 1960). As 
shown in Figure 5. 5 , 
area shaded 
This mathematical model requires that the product is derived solely from 
the precursor, but does not require that all of the precursor be 
converted to the product. 
This model was used to calculate LDL
2 
turnover. The specific 
activity-time curves of VLDL and LDL2 B apolipoprotein were plotted on 
arithmetic paper. The curves, as shown in Figures 5.6 to 5.15 inter-
sected at various times between 18 and 36 hours after injection of VLDL-
125r generally at or near the peak specific radioactivity of LDL
2
. 
This may be regarded as demonstrating that all LDL
2 
is derived from 
VLDL though it does not require that all VLDL is converted to LDL
2
• 
To verify this model, in two subjects, LDL2 turnover was 
1 1 d b h b d (f 1 . . . · . f 125 ) ca cu ate y tea ave proce ure o lowing 1nJect1on o VLDL- I 
and also simultaneously by the more conventional 2-pool analysis 
determined from the LDL2 B apolipoprotein specific activities obtained 
131 over a 14-day period following injection of LDL2- I. 
To calculate turnover, by the first technique, the pool size 
must be known. However since only the plasma pool size can be directly 
measured and s i nce it is known that approximately 20% of the LDL pool 
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may be found in the liver (Sniderman et al., 1974) this method may 
underestimate the real turnover of LDL2 . 
5.4 RESULTS 
5. 4 .1 _!n~_ividual study results 
104 
In these studies the specific activity of the B apolipo-
protein was determined in VLDL, LDL1 and LDL2 . Throughout the text, 
references to 'specific activity' are always with respect to this 
apolipoprotein. Ten studies are reported in this chapter, each involv-
ing the injection of autologous VLDL-1251 (sf20 - 400). The clinical 
details, kinetic parameters and appropriate specific activity-time 
curves for each study are shown on the following pages. The specific 
activity-time curves for VLDL, LDL1 and LDL2 are shown to illustrate 
the intercepts of the specific activities of these lipoprotein fractions. 
The specific activity-time curves for VLDL B apolipoprotein (over the 
first 50 hours) are also shown, on semi-logarithmic plots to illustrate 
the biexponential nature of the disapp~arance curves. Three values for 
VLDL B apolipoprotein turnover are given for most studies. These were 
obtained using the 1-pool model, 2-pool model or by area under the 
specific activity-time curve (as discussed in section 5.3.2). In 
studies 4 and 5, values for LDL2 B apolipoprotein turnover determined 
from the disappearance of LDL2-
131
r B apolipoprotein (2-pool analysis) 
are also included. 
5.4.2 Precursor-product relationships between VLDL, LDL
1 
and LDL2 
The precursor-product relationships between VLDL, LDL1 and 
LDL2 are illustrated in Figures 5.6 to 5.15. In all studies (except 
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Study # 1 SUBJECT: F . G. 
Age: 74 years 
Plasma lipids 
Weight: 52.2 kg 
Cholesterol: 209 mg/100 ml 
Triglyceride: 90 mg/100 ml 
Lipoprotein phenotype: Normal 
VLDL B APOLIPOPROTEIN 
Plasma concentration = 4.2 mg/100 ml 
1-pool analysis k = 3.9/day 
turnover = 99mg/day 
turnover/kg = 7.0 mg/day 
The first study demonstrated that the 1-pool model described only a 
small portion of the entire VLDL B apolipoprotein specific activity 
curve. A 2-pool analysis was not performed as the dose of B apolipo-
. 125I dm. . t d . 125 d . d protein- a inis ree in VLDL- I was not etermine. 
Figure 5.6 (facing page). The specific activity-time curves for VLDL, 
LDL 1 and LDL 2 B apolipoprotein in study 1 are shown in the upper 
graph. A semi-logarithmic plot of VLDL B apolipoprotein specific 
activity is shown in the lower graph. This curve could be 
resolved into two single exponentials. 
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Study#2 SUBJECT: 
Age: 21 years Weight: 
Plasma lipids Cholesterol: 
Triglyceride: 
Lipoprotein phenotype: 
VLDL B APOLIPOPROTEIN 
1-pool analysis 
Plasma concentration= 1.7 mg/100 ml 
k = 8.4 
turnover= 359 mg/day 
turnover/kg= 6.4 
LDL2 B APOLIFOPROTEIN 
Plasma concentration = 47 mg/100 ml 
k = 0.33/day 
turnover = 405 mg/day 
turnover/kg = 5.5 mg/day 
106 
M.N. 
56.0 kCT 
110 mo/100 ml 
62 mg/100 ml 
Normal 
The plasma concentration of VLDL B apolipoprotein was extremely low in this 
subject. As the VLDL B apolipoprotein specific activity-time curves 
remained monoexponential until approximately 95% of the radioactivity 
was lost from this fraction, a 1-pool analysis only was performed. In 
this study, although LDL1 was isolated, there was insufficient protein 
for further analysis. 
Figure 5.7 (facing page). The specific activity time curves for VLDL 
and LDL 2 B apolipoprotein in study 2 are shown in the upper graph. 
A semilogarithmic plot of VLDL B apolipoprotein specific activity 
is shown in the lower graph. 
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Study #3 SUBJECT: O.K. 
Age: 51 Weight: 55.5 kg 
Plasma lipids Cholesterol: 202 mg/100 
Triglyceride: 110 mg/100 
Lipoprotein phenotype: Normal 
VLDL B APOLIPOPROTEIN 
Plasma concentration = 5.2 mgs/100 ml 
2-pool analysis a. = 22.1/day B = 1.1/day 
turnover = 637 mg/day 
turnover/kg = 11.5 mg/day 
Mass of pool A = 18 mg 
Intravascular mass = 131 mg 
1-pool analysis k = 7.9/day 
turnover = 1041 mg/day 
Area under curve turnover = 976 mg/day 
LDL2 B APOLIPOPROTEIN 
Plasma concentration = 80.l mg/100 ml 
k = 0.29 /day 
turnover = 579 mg/day 
turnover/kg = 10. 3 mg/day 
Figure 5.8 (facing page). The specific activity time curves for 
VLDL, LDL 1 and LDL 2 B apolipoprotein in study 3 are shown in the 
upper graph. A semi-logarithmic plot of VLDL B apolipoprotein 
specific activity is shown in the lower graph. 
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Study #4 SUBJECT: 
Age: 25 years Weight: 
Plasma lipids Cholesterol: 
Triglyceride : 
Lipoprotein phenotype: 
VLDL B APOLIPOPROTEIN 
Plasma concentration= 10.77 mgs/100 ml 
2-pool analysis a = 12.9/day 
turnover = 1092 mg/day 
turnover/kg = 15.8 mg/day 
Mass of pool A= 553.8 mg 
Intra vascular mass = 333.9 mg 
1-pool analysis k = 3.86/day 
turnover = 1291 mg/day 
Area under curve turnover = 2015 mg/day 
LDL2 B APOLIPOPROTEIN 
Plasma concentration= 135.6 mg/100 ml 
k = 0.29/day 
R.T. 
68.9 kg 
295 mg/100 
150 mg/100 
2A 
B = 1.1/day 
turnover= 1177 mg/day (using areas) 
turnover/kg= 17.30 mg/day 
( 1 1 d f d . f 1311 turnover ca cu ate rom isappearance o LDL-
B apolipoprotein) = 976 mgs/day 
Figure 5.9 (facing page). The specific activity-time curves for 
VLDL, LDL 1 and LDL 2 B apolipoprotein in study 4 are shown in the 
upper graph. A semi-logarithmic plot of VLDL B apolipoprotein 
specific activity is shown in the lower graph. 
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Study #5 SUBJECT: 
Age: 58 years Weight: 
Plasma lipids Cholesterol: 
Triglyceride : 
Lipoprotein phenotype: 
VLDL B APOLIPOPROTEIN 
Plasma concentration = 12.7 mgs/100 ml 
2-pool analysis a. = 4.3/day 6 
turnover = 1238 mg/day 
turnover/kg = 17.1 mg/day 
Mass of pool A = 641 mg 
Intravascular mass = 415 mg 
!-pool analysis k = 3.0/day 
turnover = 1255 mg/day 
Area under curve turnover = 1323 mg/day 
LDL2 B APOLIPOPROTEIN 
Plasma concentration= 131.9 mg/100 ml 
k = 0.23/day 
turnover= 990 mg/day 
turnover/kg= 13.7 mg/day 
turnover (calculated from disappearance of LDL-131r 
B apolipoprotein) = 748 mg/day 
R.P. 
72.5 kg 
294 mg/100 
252 mg/100 
2B 
= 0.9/day 
Figure 5.10 (facing page). The specific activity-time curves for 
VLDL, LDL 1 and LDL 2 B apolipoprotein in study 5 are shown in 
the upper graph. A semi-logarithmic plot of VLDL B apolipoprotein 
specific activity is shown in the lower graph. 
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Study# 6 SUBJECT: P.F. 
Age: 40 years Weight: 85.0 kg 
Plasma lipids Cholesterol: 281 mg/100 
Triglyceride: 324 mg/100 
Lipoprotein phenotype: 2B 
VLDL B APOLIPOPROTEIN 
Plasma concentration = 12.7 mgs/100 ml 
2-pool analysis a. = 4.6/day B = 0.4/day 
turnover = 1671 mg/day 
turnover/kg = 19.7 mg/day 
Mass of pool A = 485 mg 
Intravascular mass = 654 mg 
1-pool analysis k = 3.5/day 
turnover = 1680 mg/day 
Area under curve turnover = 1693 mg/day 
LDL2 B APOLIPOPROTEIN 
Plasma concentration = 112.0 mg/100 ml 
k = 0.36/day 
turnover = 1542 mg/day 
turnover/kg = 18.1 mg/day 
Figure 5.11 (facing page). The specific activity time curves for 
VLDL, LDL 1 and LDL 2 B apolipoprotein in study 6 are shown in the 
upper graph. A semi-logarithmic plot of VLDL B apolipoprotein 
specific activity is shown in the lower graph. 
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Study# 7 SUBJECT: E.R. 
Age: 69 years 
Plasma lipids 
Weight: 61 kg 
Cholesterol: 323 mg/100 ml 
Triglyceride: 268 mg/100 ml 
Lipoprotein phenotype: 4 
VLDL B APOLIPOPROTEIN 
Plasma concentration = 13.0 mgs/100 ml 
2-pool analysis a. = 8.5/day s = 0.7/day 
turnover = 3345 mg/day 
turnover/kg = 54.8 mg/day 
Mass of pool A = 732 mg 
Intravascular mass = 355 mg 
1-pool analysis k = 8.3/day 
turnover = 3033 mg/day 
Area under curve turnover = 3983 mg/day 
LDL2 B APOLIPOPROTEIN 
Plasma concentration = 97.0 mg/100 ml 
k = 0.43/day 
turnover = 1144 mg/day 
turnover/kg = 18.8 mg/day 
Figure 5.12 (facing page). The specific activity time curves for 
VLDL, LDL 1 and LDL 2 B apolipoprotein in study 7 are shown in the 
upper graph. A semi-logarithmic plot of VLDL B apolipoprotein 
specific activity is shown in the lower graph . . 
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Study #8 SUBJECT: D.H. 
Age: 62 years Weight: 82.2 kg 
Plasma lipids Cholesterol: 213 mg/100 
Triglyceride: 405 mg/100 
Lipoprotein phenotype: 4 
VLDL B APOLIPOPROTEIN 
Plasma concentration = 25.5 mgs/100 ml 
2-pool analysis a = 4.2/day B = 0.8/day 
turnover = 2323 mg/day 
turnover/kg = 28.3 mg/day 
Mass of pool A = 1061 mg 
Intravascular mass = 942 mg 
1-pool analysis k = 2.8/day 
turnover = 2613 mg/day 
Area under curve turnover = 2380 mg/day 
LDL2 B APOLIPOPROTEIN 
Plasma concentration = 77.1 mg/100 ml 
k = 0.27/day 
turnover = 772 mg/day 
turnover/kg = 9.4 mg/day 
Figure 5.13 (facing page). The specific activity time curves for 
VLDL, LDL 1 and LDL 2 B apolipoprotein in study 8 are shown in the 
upper graph. A semi-logarithmic plot of VLDL B apolipoprotein 
specific activity is shown in the lower graph. 
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Study #9 SUBJECT: J.K. 
Age: 44 years Weight: 80.6 kg 
Plasma lipids Cholesterol: 356 mg/100 
Triglyceride: 765 mg/100 
Lipoprotein phenotype: 4-5* 
VLDL B APOLIPOPROTEIN (sf 20-400 only)* 
Plasma concentration = 35.6 mgs/100 ml 
2-pool analysis a = 2.78/day 6 = 0.5/day 
turnover = 1928 mg/day 
turnover/kg = 23.9 mg/day 
Mass of pool A = 1544 mg 
Intravascular mass = 1326 mg 
1-pool analysis k = 1.9/day 
turnover = 2468 mg/day 
Area under curve turnover = 1917 
LDL2 B APOLIPOPROTEIN 
Plasma concentration = 102.4 mg/100 ml 
k = 0.37/day 
turnover = 1368 mg/day 
turnover/kg = 17.0 mg/day 
* Lipoprotein particles of sf > 400 were removed prior to isolation of 
VLDL (sf 20-400) 
ml 
ml 
Figure 5.14 (facing page). The specific activity time curves for VLDL, 
LDL 1 and LDL 2 B apolipoprotein in study 9 are shown in the upper 
graph. A semi-logarithmic plot of VLDL B apolipoprotein specific 
activity is shown in the lower graph. 
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Study #10 
Age: 36 
SUBJECT: T.B. 
Weight: 90.2 
Cholesterol: 707 mg/100 ml 
Triglyceride: 4,050 mg/100 ml 
Lipoprotein plenotype: s* 
Plasma lipids 
VLDL B APOLIPOPROTEIN (sf 20-400 only}* 
Plasma concentration = 53.0 mg/100 ml 
2-pool analysis a = 3.1/day 
turnover 
turnover/kg 
Mass of pool A 
Intra vascular mass 
1-pool analysis k 
turnover 
Area under curve turnover 
LDL2 B APOLIPOPROTEIN 
Plasma concentration 
k · 
turnover 
turnover/kg 
= 
= 
= 
= 
= 
= 
= 
= 
= 
= 
= 
3,060 mg/day 
33.9 mg/day 
2,611 mg 
2,147 mg 
1.1/day 
2,381 mg/day 
3,163 mg/day 
78.2 mg/100 
0.34/day 
1,074 mg/day 
11.9 mg/day 
B = o.9/day 
ml 
* Lipoproteins of sf> 400 were removed prior of isolation of VLDL 
(sf 20-400). 
Figure 5.15 (facing page). The specific activity time curves for VLDL, 
LDL 1 and LDL2 B apolipoprotein in study 10 are shown in the upper 
graph. A semi-logarithmic plot of VLDL B apolipoprotein specific 
activity is shown in the lower graph. 
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study 2 where LDL1 was not analysed), the LDL1 specific activity curve 
intersected that of VLDL in a manner suggesting a precursor-product 
relationship between these lipoprotein fractions. The specific activity 
of LDL1 rose rapidly to intersect the VLDL specific activity-time 
125 
curve between 30 min and 6 hours after injection of VLDL- I except 
in study 10 (type 5 HLP) where the cross-over was delayed until 18 
hours after injection, presumably because of the greatly expanded VLDL 
pool in this subject. In 6 of the 9 studies, LDL1 specific activity 
reached its peak shortly after intercepting that of the precursor. This 
observation would be consistent with the immediate precursor of the 
sf 12-20 fraction being a smaller particle than newly secreted VLDL 
i.e. a lipoprotein that had undergone partial catabolism. 
The specific activity of LDL2 rose more slowly than that of 
LDL1 and consequently it did not, over the time scale shown, have a 
precise peak. In all studies, both VLDL and LDL1 specific activity 
curves intercepted the curve of LDL2 at its peak suggesting that either 
or both lipoprotein fractions could serve as the precursor to LDL
2
. 
LDL2 specific activities intersected those of VLDL within 12 to 60 
hours of injection and those of LDL1 within 20 to 80 hours. 
These findings strongly imply that, in man, all LDL2 is derived 
ultimately from VLDL although it is not clear from a mere consideration 
of the respective specific activity-time curves whether LDL
1 
is an 
obligatory intermediate in this process. 
5.4.3 VLDL B apolipoprotein kinetics 
In every study, the specific activity-time curve for VLDL was 
TABLE 5.1 
RESULTS FROM KINETIC ANALYSES OF THE TURNOVER OF VLDL B APOLIPOPROTEIN. 
This table summarises the findings of studies #1 - 10. Analyses were performed as described in section 5.3. 
Lipoprot. Study Phenotype 
# 
1 N 
2 N 
3 N 
4 2A 
5 2B 
6 2B 
7 4 
8 4 
9 4 
10 5 
Mean± 1 sot 
B Apolipo. B Apolipoprotein Turnover Rate Constants B Apolipoprotein Mass 
Cone. kt 1-pool 2-pool * s* Pool A Intravascular Area a 
(rng/100 ml) (mg/day) (mg/day) (mg/day) (/day) (/day) (/day) (mg) (mg) 
4.2 99 - - - - 3.9 - 99 
1.7 359 - - - - 8.4 - 44 
5.2 1041 637 751 22.2 1.1 7.9 181 131 
10.8 1291 1092 1052 12.9 1.0 3.9 554 334 
12.7 1255 1238 1323 4.3 0.9 3.0 641 415 
12.7 1680 1671 1693 4.6 0.4 3.5 654 485 
13.0 3033 3345 3983 8.5 0.7 8.3 732 355 
25.5 2613 2323 2380 4.2 0.8 2.8 1061 942 
35.6 2468 1928 1917 2.8 0.5 1.9 1544 1326 
53.0 3401 3060 3163 3.1 0.9 1.1 2611 2147 
2098±897 1912±953 2034±1097 7.8±6.7 0.8±0.?. 4.1±2.7 997±764 767±677 
* Rate constants for each exponential (2-_rx)ol analyses). 
t Fractional catabolic rate (1-pool analyses). 
t Studies #3 - 10 only. 
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multi-exponential over at least 50 hours (as shown by the semi-logarithm-
ic plots in Figures 5.6 to 5.15). The first five points on these curves 
encompassing the first 12 hours almost described a monoexponential 
function in most subjects. However, when the SO-hour curve was resolved 
into 2 exponential functions by the curve peeling technique, the first 
and faster exponential of the 2-pool model conformed closely, if not 
precisely, to a monoexponential function. However, in study 2 where the 
subject has a VLDL B apolipoprotein concentration of only 1.7 mg/100 ml, 
the specific activity-time curve appeared monoexponential until 95% 
of the radioactivity had left the 20-400 fraction (Figure 5.7) and it 
seemed more appropriate to calculate the turnover from a single pool 
analysis only. 
As shown in Table 5.1 (sununarising the data of studies 1-10) 
the calculated values for turnover, using either the 1 or 2-pool model 
were in most cases similar. It should be borne in mind that for 
calculations of the 1-pool model, it is assumed that the pool is confined 
to the plasma compartment only. The 2-pool model requires no knowledge 
of pool sizes to determine the turnover of pool A. The mass of pool A 
(as determined by compartmental analysis described in section 5.3.2.2) 
was in all studies higher (average 30%) than the intravascular mass of 
VLDL B apolipoprotein suggesting that some of the metabolism of sf 20-400 
VLDL might occur in the extravascular space. 
The turnover of VLDL B apolipoprotein in pool A was also 
assessed from the area under the specific activity-time curve (as 
described in section 5.3.2). This alternative calculation gave values 
that were quite similar for all subjects confirming the suitability of 
the 2-pool model. 
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rhe relationship between the intravascular mass of VLDL B apo-
lipoprotein and the turnover (derived by 2-pool analysis) suggested a 
saturable system (Figure 5.16). In the 7 subjects with normal or 
moderately raised levels of triglyceride, turnover and pool size were 
directly related indicating that expansion of the pool was a function of 
increased production. The 3 subjects with the highest triglyceride 
level, 2 of whom also showed chylomicronaemia (though particles of 
sf >400 have been excluded from all assays and calculations) showed an 
increase in pool size that was out of proportion to the increase in 
turnover, suggesting saturation of removal mechanisms. 
5.4.4 LDL1 B apolipoprotein turnover 
i As mentioned in section 5.4.1, in every study, the LDL1 
,J 
I 
ll 
1, 
1: 
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specific activity curve intersected the VLDL curve in a manner suggest-
ive of a precursor-product relationship. An index of the turnover rates 
of LDL1 in relationship to those of VLDL were gained by comparing the 
respective areas under the specific activity-time curves of the two 
lipoprotein fractions (Table 5.2). In all cases, the area under the 
LDL1 curve exceeded that for VLDL (average 80% greater). Since turnover 
is inversely related to the area under the curve, LDL1 turnover was 
clearly less than that of VLDL. If some of the label injected with the 
VLDL lipoproteins was removed by a process other than through the LDL1 
fraction, then the estimated turnover of the latter fraction would be 
even less. It therefore seems highly likely that a substantial fraction 
of VLDL catabolism bypasses the LDL1 fraction, as will be further 
illustrated by results in chapter 6. 
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Figure 5.16 The relationship between VLDL B apolipoprotein 
turnover (2-pool analyses) and intravascular VLDL B apo-
lipoprotein mass (studies #1-10). 
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TABLE 5.2 
THE RATIO OF THE TOTAL AREAS UNDER THE VLDL AND LDL1 
B APOLIPOPROTEIN SPECIFIC ACTIVITY-TIME CURVES. 
Areas ( for studies # 3 - 10) were determined by planimetry. 
Study Area Ratio 
# VLDL: LDL1 
3 1.0: 2.6 
4 1.0: 1.4 
5 1.0: 1.4 
6 1.0: 1.1 
7 1.0:1.7 
8 1.0: 3.1 
9 1.0: 1.9 
10 1.1 : 1.2 
Mean + 1 SD 1.0: 1.8 ± 0.7 
I!] 
I 
j 
I 
11 
ii 
i 
i 
~I 
"1 
il 
' 
I 
118 
5.4.5 Conversion of VLDL to LDL2 
The specific radioactivity of the B apolipoprotein in LDL2 
was also measured primarily to define the nature of the VLDL to LDL 
relationship. In addition, the fractional rate of labelling of LDL2 
protein was calculated from the rate of rise in LDL specific activity 
and the rate of fall in VLDL specific activity during the first 18 hours. 
As described 1n section 5.3.J, this model requires that LDL2 B apo-
lipoprotein be derived solely from the corresponding apolipoprotein in 
VLDL. This was indicated by the cross-over of VLDL and LDL2 specific 
activities occurring at or very near to the peak specific activity of 
LDL2 as previously mentioned (section 5.4.1). 
The calculation of LDL2 turnover by this method was compared 
in two subjects with the conventional technique of a 2-pool analysis of 
LDL2 B apolipoprotein specific activities over a period of 14 days 
after the intravenous administration of LDL2-
131r. In both subjects, the 
present method (i.e. as described in section 5.3.4) gave values that 
were 20% less than by 2-pool analysis. However, the 2-pool method may 
overestimate turnover when compared with the possibly more appropriate 
3-pool model (Goodman et al., 1973). On the other hand, the present 
method may underestimate LDL2 turnover since the calculation utilises 
only the mass of intravascular LDL2 B apolipoprotein whereas it is 
known that some LDL2 B apolipoprotein metabolism occurs extravascularly 
(sect ion 1 . 5 . 3) . 
This much more rapid estimate of LDL2 turnover was therefore 
compared in all subjects (except study 1) with the turnover of VLDL 
sf 20-400 lipoproteins (Table 5.3). The LDL2 turnover ranged from 5.5 
to 18.7 mg/kg/day which is in line with findings reported by others with 
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2
•  
L i p o -
L D L  B  A p o l i p o p r o t e i n  D a t a  V L D L  
A p o l i p o -
L D L / V L D L  
S t u d y  
p r o t e i n  
C o n c e n -
T u r n o v e r  p r o t e i n  B  T u r n o v e r  
P h e n o t y p e  
t r a t i o n  
R a t e  
T u r n o v e r  
T u r n o v e r  
#  
m g / 1 0 0  m l  k / d a y  m g / d a y  m g / d a y / k g  
m g / d a y  
%  
2  N  
4 7  
0 . 3 3  
4 0 5  5 . 5  3 5 9  1 1 3  
3  
N  
8 0  
0 . 2 9  
5 7 9  1 0 . 3  
6 3 7  9 1  
4  
I I A  
1 3 5  
0 . 2 9  
1 1 7 7  
1 7 . 3  
1 0 9 2  1 0 7  
5  
I I B  1 3 1  
0 . 2 3  
9 9 0  
1 3 . 7  
1 2 3 8  
8 0  
6  
I I B  1 1 2  0 . 3 6  
1 5 4 2  1 8 . 1  
1 6 7 1  
9 2  
7  
I V  9 7  
0 . 4 3  1 1 4 4  1 8 . 7  
3 3 4 5  
3 4  
8  
I V  7 7  0 . 2 7  
7 7 2  9 . 4  
2 3 2 3  
3 3  
9  
I V  1 0 2  
0 . 3 7  
1 3 6 8  1 7 . 0  
1 9 2 8  
7 0  
1 0  
V  
7 8  
0 . 3 4  1 0 7 4  1 1 . 9  
3 0 6 0  
3 5  
M e a n ±  1  S D  9 4  ±  3 0  0 .  3 2  ±  •  0 6  9 9 6  ±  3 8 4  1 3 . 5  ±  4 . 6  
1 7 3 9  ±  1 0 3 0  
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the 2-pool model (Bilheimer et al., 1975). There was little difference in 
LDL2 turnover between the 4 subjects with hypertriglyceridaemia alone 
and the others. However, whereas LDL2 turnover was substantially less 
than VLDL turnover in the 4 hypertriglyceridaemic subjects, the 2 
measurements were similar in the other 5 subjects. This suggests that, 
at higher concentrations of VLDL, a considerable fraction of VLDL B apo-
lipoprotein turnover is catabolised by a route other than .through LDL 2 . 
5.5 DISCUSSION 
5.5.1 LDL formation from VLDL 
ii 
'i 
l 
,: The existence, in man, of precursor-product relationships 
·~ 
·, 
between VLDL and LDL has been well documented with respect to both the 
triglyceride and protein moieties (Gitlin et al., 1958; Havel, 1961; 
Farquhar et al., 1965; Quarfordt et al., 1970; Bilheimer et al., 1972; 
Eisenberg et al., 1973; Sigurdsson et al., 1975; Eaton et al., 1976). 
Some of these studies, involving VLDL labelled in its protein moiety 
125 131 35 
with I, I or Se have demonstrated the transfer of the B apo-
lipoprotein of VLDL to LDL. However, as B apolipoprotein specific 
activity data was not obtained in the quoted studies (with the exception 
of Sigurdsson et al., 1975) it was not possible to determine the extent 
to which LDL was derived from VLDL and conversely the amount of VLDL 
that was catabolised to LDL. Eisenberg et al. (1973) and Eaton et al. 
(1976) have unequivocally demonstrated, by use of heparin administration, 
that the VLDL catabolic process leads to the transfer of the B apo-
lipoprotein from VLDL to LDL. 
Sigurdsson et al. (1975), recently described precursor-product 
relationships between VLDL and LDL (sf 0-20) utilising the specific 
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activities of the B apolipoprotein in these two lipoprotein fractions 
(f 1 . . . . f 125! . t ) o lowing the inJection o VLDL- in o man. The method used by these 
authors for the determination of B apolipoprotein specific activities 
has previously been discussed (section 3.2.3). From the nature of the 
cross-over of the specific activity-time curves of the B apolipoprotein 
of VLDL and LDL (Figure 5.17a) these authors have proposed that LDL B 
apolipoprotein is solely derived from VLDL. 
In the studies presented in this chapter, the LDL1 fraction 
(sf 12-20) was also isolated as a distinct lipoprotein species. Bilheimer 
et al. (1972) have suggested that LDL1 may serve as the intermediate 
between VLDL and LDL2 (sf 0-12}. As shown in Figures 5.6 - 5.15, 
precursor-product relationships were found suggesting firstly, that 
LDL1 is derived solely from VLDL and secondly, that LDL2 is derived 
from either VLDL or LDL1 , so that eventually it is derived from VLDL. 
Thus these studies agree with those of Sigurdsson et al. (1975), in 
showing that in man LDL2 is solely derived from VLDL. However, both 
in the monkey (Illingworth, 1975) and in the rat (Fidge, personal 
communications) some LDL may be formed independently of VLDL catabolism 
and this may yet be demonstrated in man under certain circumstances. 
Sigurdsson et al. (1975) have the LDL1 fraction (sf 12-20) 
in the analysis of LDL specific activity. These authors did not isolate 
LDL1 separately as the protein content of this pool was too small to 
measure by their technique. To compare the results of this chapter with 
those of Sigurdsson et al., the specific activity of the LDL fraction 
(sf 0-20) has been recomputed to include both the LDL1 and LDL2 
fractions, taking into account the differences in pool size of these two 
fractions. The values so obtained together with those for VLDL, from 
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a representative study (#8), are shown in Figure 5.17b. Although the 
VLDL disappearance curves are dissimilar, the specific activities of 
LDL cross the VLDL curves in an identical manner. However, the influence 
of the LDL1 fraction on the rate of labelling of LDL is evident when 
the LDL 2 specific activity curve of study 8 is compared (Figure 5.17c). 
Although the LDL1 fraction is small, it markedly alters the rate of 
labelling of the LDL fraction. As LDL1 appears to be a metabolically 
distinct lipoprotein class, it should not be included in the LDL class 
of lipoproteins. 
5.5.2 VLDL B apolipoprotein turnover 
In every study, the specific activity-time curve during the 
first 50 hours, conformed to a 2-pool model. Sigurdsson et al. (1975) 
had also noted the curvilinear nature of the log-linear plot of the 
specific activity-time curve but concluded that the initial 24-hour 
segment was consistent with a monoexponential rate of removal. The 
present studies showed that was possibly true in only some subjects and 
then only over the first 12 hours. 
The 2-pool characteristics of VLDL B apolipoprotein turnover 
could have arisen artefactually if the specific radioactivity values 
were distorted by contaminating labelled proteins with turnover 
kinetics that differed from those of the B apolipoprotein. This possibil-
ity has been dealt with in section 3.2.5. In summary however, the 
presence of only trace amounts of apolipoprotein E in SOS gels of 
NH 4Hco3 insoluble proteins, the similarity in the amino acid composition 
of the insoluble proteins derived from VLDL and LDL and the similarity 
in the turnover rates derived from analysis of NH
4
Hco
3 
and TMU 
insoluble protein strongly suggest that contamination of the VLDL B 
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Figure 5.17 A comparison of the precursor-product 
relationships between VLDL and LDL (s 0-20) 
B apolipoprotein as observed by Sigur!sson et al. 
(1976) (A) or in these studies (B) - study #8. 
Differences in the rate of labelling of sf 0-20 
and sf 12-20 B apolipoprotein from VLDL may 
be seen by comparing figures Band C (results of 
study #8). 
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apolipoprotein was minimal. 
A 2-pool model is consistent with some of the known metabolic 
characteristics of VLDL. Firstly, more than one population of particles 
may be secreted into the plasma. It is known that carbohydrate-
induced hypertriglyceridaemia leads to the secretion of VLDL that are 
larger than found in subjects eating normally (Ruderman et al., 1971), 
and measurements of VLDL particle size show that hyperlipidaemic subjects 
may have a much higher proportion of large VLDL than fasting normo-
lipidaemic individuals (Sata et al., 1972; Kane et al., 1975). 
Secondly, the 2-pool model might also reflect heterogeneity 
of catabolic processes. It is clear from experiments in which the 
protein or the lipid moieties of VLDL have been labelled that smaller 
species of lipoproteins are progressively formed as triglyceride and 
surface components of VLDL are removed. Barter and Nestel (1970, 1972) 
considered the possibility of independently metabolized pools of VLDL 
triglyceride that would lead to differing turnover rates for different 
subclasses of VLDL. Instead, the findings suggested a step-wise 
transformation of larger to smaller lipoproteins with LDL representing 
the final step. However, the catabolism of the B apolipoprotein moiety 
of VLDL is likely to differ from that of triglyceride since the small 
remnants of VLDL metabolism appear to contain all the B apolipoprotein 
of the parent VLDL but very much less triglyceride (Eisenberg et al., 
1973; Eisenberg and Rachmilewitz, 1975). Experiments in the rat show 
that catabolism of VLDL B apolipoprotein may indeed proceed by more 
than one route; less than 10% of labelled B apolipoprotein in injected 
VLDL was reported to have been recovered in LDL whereas the uptake of 
label in the liver was substantial (Fidge and Poulis, 1974; Faergeman 
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et al., 1975). The rate and extent of .uptake of the B apolipoprotein 
in rat liver resembles that of the cholesteryl esters (Mj¢s et al., 
1975) which remain as the major core component of the partially 
catabolized VLDL. This provides strong evidence that at least in the 
rat, some remnant particles are removed by the liver while others 
are destined for conversion to LDL. 
A third contributing factor to multiexponential kinetics 
might occur from the distribution of VLDL B apolipoprotein in more than 
one pool with each pool having different turnover characteristics. 
While it is highly probable that the catabolism of VLDL takes place 
largely within the plasma, lipoproteins resembling VLDL have been 
identified in human lymph (Ockner et al., 1968, 1969; Windmueller and 
Levy, 1968). Catabolism of VLDL remnants has been described in several 
tissues (Stein et al., 1974) and VLDL B apolipoprotein can be degraded 
in a variety of cultured cells (Bierman et al., 1973; Goldstein and 
Brown, 1974). The presence of VLDL-like particles in the intestine 
(Tytgat et al., 1971; Jones and Ockner, 1971) represents another possible 
pool of VLDL that might exchange with the intravascular pool. In this 
regard, it is also important to note the recent demonstration by 
Rachmilewitz el al., (1967) of the capacity of the human intestine to 
s ynthesise the B apolipoprotein. 
One can only speculate about the physiological or anatomical 
dimensions of the 2 pools. Pool A may include in addition to plasma, 
the lymph and possibly tissues such as liver and gut which give rise to 
VLDL. Pool B may include cells like fibroblasts, arterial walls and 
lymphocytes. Human lymphocytes have recently been shown to bind and 
degrade VLDL B apolipoprotein (Vijayogopal and Nestel, personal communicat-
ions) . 
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The multiexponcntial nature of the specific activity curves 
might therefore reflect several factors including heterogeneity of 
turnover rates among several populations of VLDL particles, alternative 
catabolic processes and catabolism within several tissue or lipoprotein 
pools. 
5.5.3 LDL turnover in relation to VLDL turnover 
The values obtained for LDL turnover by the present technique 
were in reasonable agreement in 2 subjects with the turnover calculated 
from reinjected labelled LDL and were in the range reported for LDL 
turnover by others (Bilheimer et al., 1975). Of special interest was the 
similarity between VLDL B apolipoprotein and LDL B apolipoprotein turnover 
in the 5 subjects without hypertriglyceridaemia, suggesting the total 
conversion of VLDL particles to LDL (Table 5.3). However, alternate 
pathways may be available for VLDL catabolism in hypertriglyceridaemic 
subjects. In 3 of the 4 hypertriglyceridaemic subjects, as little as 
one third of VLDL B apolipoprotein turnover appeared in LDL2 . Since the 
turnover of LDL was similar in those with and without hypertriglycerid-
aemia, whereas the turnover of VLDL B apolipoprotein was much higher 
in the hypertriglyceridaemic subjects, it is possible that LDL turn-
over cannot be readily increased to accommodate the higher flux of VLDL 
B apolipoprotein. A proportion of the latter is then catabolized else-
where possibly in the liver, as occurs in the rat. Sigurdsson et al. 
(1976) have also reported normal values for LDL turnover in hypertri-
glyceridaemic subjects many of whom presumably showed increased VLDL 
turnover. Thus, in normotriglyceridaemic subjects it appears that 
almost all VLDL is catabolised to LDL2 , as proposed by Sigurdsson 
et al. (1975). However, in hypertriglyceridaemic subjects only a portion 
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of VLDL is totally catabolised to LDL. This latter observation has also 
been proposed from a computer-based analysis of VLDL catabolism by Hall 
et al. (1974, abstract only). 
5.5.4 VLDL B apolipoprotein turnover and hypertriglyceridaemia 
The curvilinear relationship between the mass and turnover of 
VLDL B apolipoprotein with its suggestion of a saturable system is 
similar to the kinetics obtained by labelling the triglyceride moiety 
of VLDL. The studies of Reaven et al. (1965) and of Nestel (1966) 
have shown a direct correlation between the turnover and mass of VLDL 
triglyceride up to a VLDL triglyceride concentration of about 200 
mg/100 ml. At higher levels, the expansion in pool size could not be 
explained solely by increased production and was therefore attributed 
to diminishing removal capacity. The relative importance of over-
production and reduced removal in the pathogenesis of hypertriglycerid-
aemia has not been resolved with measurements of triglyceride turnover 
(Nestel, 1973). Similar conclusions have been reported by Sigurdsson 
et al. (1976). 
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CHAPTER 6 
DEFINITION OF THE INTERMEDIATE 
LIPOPROTEIN CLASS 
n.l INTRODUCTION 
- --------
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Th e immediate products of VLDL catabolism are referred to as 
'remnant' or 'intermediate' lipoproteins. The nature of these remnants 
has been investigated extensively in vitPo (Shore and Shore, 1962; 
Bierman et al., 1973; Mj¢s et al., 1975; Eisenberg and Rachmilewitz, 
1975); however, few studies have attempted to characterise, in vivo, 
the metabolism of this lipoprotein species. 
VLDL is defined as that lipoprotein class in which trigly-
ceride of endogenous origin is released into the circulation (section 
1.4.2). Th e se lipoproteins are said to be in the sf 20-400 range. The 
immediate product of VLDL catabolism was initially considered to be the 
LDL1 c lass {Bilheime r et al ., 1972; section 1.5.2) though recent 
analytical ultracentrifugation studies have suggested that the inter-
mediate c la ss may also inc lude lipoproteins in the sf 20-60 range 
(Eisenberg et al ., 19 73). 
Thi s c hapt0. r d0sr. ribes a limite d number of i n vivo studie s, 
extending from those of chapter 5, devised to determine the flotation 
charac teristics of the i ntermediate lipoprotein class. As described in 
the previous c hapt e r (sec tio n 5.4.4) the turnover of LDL1 B apolipo-
prote in was markedly l es s than that of VLDL B apolipoprotein in most 
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of the subjects investigated (Table S.).) ~;uqci<•stjnq that J.DL 1 was not 
the sole or major intermediate lipoprotein in the conversion of VLDL 
to LDL2 . 
Four studies are described in this chapter. In the first study 
(#8), the turnover of VLDL and LDL1 B apolipoprotein were both directly 
d . d f 11 . h . . . f 12s d 131 etermine o owing t e 1nJection o VLDL- I an LDL1- I. This 
study was carried out to confirm, from direct observation, that LDL1 
turnover was not equal to VLDL turnover. The final three studies (# 11, 
# 12 and # 13) investigated the turnover of various fractions in the 
sf 12-400 range in an attempt to define, from the nature of the pre-
cursor product relationships and turnover values, the probable inter-
mediate lipoprotein class. 
6.2 METHODS AND RESULTS 
The new studies reported in this chapter employed the same 
experimental protocol as described in chapter 5. 
6.2.1 Comparison of the turnover of the B apolipoprotein of VLDL 
LDL1 
If LDL1 were the major intermediate lipoprotein between VLDL 
and LDL 2 , then the turnover of both VLDL and LDL1 should be similar. 
How,,vc~r, sinc0 the po0l size of LDL1 is very much less than that of 
VLDL, its fractional catabolic rate (k) would need to be very much 
grPat e r. This is illustrat<.~d for studies# 3-10 in Table 6.1. It is 
evident that the fractional catabolic rate would need to be exception-
ally high. 
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TABLE 6.1 
THE THEORETICAL FRACTIONAL CATABOLIC RATES REQUIRED FOR LDL 1 
IF ALL VLDL HAD BEEN CATABOLISED TO LDL 1 (E.G. STUDIES #3 - 10). 
Study 
# 
3 
4 
5 
6 
7 
8 
9 
10 
VLDL Turnover 
mg B/day 
637 
1092 
1238 
1671 
3345 
2323 
1928 
3060 
LDL 1 Pool Size 
mg B 
118 
132 
26 
54 
103 
133 
219 
313 
F.C.R. 
k/day 
5.4 
8.3 
47.6 
30.9 
32.5 
17.5 
8.8 
9.8 
100 
IO 
\o 
\ 
SOL 0 \ 
0 0 LDL 1 0 .. I \ 
~ 
" \ * * LDL2 E I 0. 
-a 
C 20 
·- 0 • I .. 
0 
.. 
t 
A. 
a 
• 
10 
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·-> 
·-.. 
_,,,,,,-* ............. q " ,l a 
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\I 
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Figure 6.1 The specific activity-time curves (on a log 
scale) for LDL1 and LDL2 B apolipoprotein following 
d . . . f 131 . d #8 ( the a ministration o LDL1 - I in stu y see Chapter 5) . 
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In studies# 3-10, the turnover of LDL1 B apolipoprotein was 
shown to be less than that of VLDL (as determined by comparing areas 
under the respective specific activity-time curves). The proportion 
of VLDL that might be catabolised to LDL1 was measured directly in study 
#8 by injecting simultaneously VLDL- 125I and LDL1 -
131I. In figure 
6.1, the LDL1 and LDL2 B apolipoprotein specific activity (
131I) 
time curves are shown. The disappearance of LDL1 B apolipoprotein was 
predominantly monoe xponent ial up to 20 hours (by which time only 5% of 
· · d 131 d. . . . d . ) h 5 the inJecte Ira 1oact1v1ty remaine in LDL1 ; owever, over a 0-
hour period, the plot could easily be resolved into two exponentials. 
The turnover, determined using both 1 and 2-pool models gave similar 
rates (462 and 444 mg/day respectively). However VLDL B apolipoprotein 
turnover was approximately five times greater (2323 mg/day), suggest-
ing that a substantial proportion of VLDL particles must by-pass the 
LDL1 fraction. The precursor-product relationship between LDL1 and 
LDL2 (as in figure 6.1) likewise suggested that not all LDL2 was 
derived from LDL1 , as the peak of the LDL2 specific activity curve 
occurrPd before the crossover with LDL1 . Thus, since LDL1 alone was 
not the sole product of VLDL catabolism and unique precursor to LDL2 , 
other lipoprotein fractions were investigated . 
6.2.2 Precursor-product relationships between sf 100-400 and sf 12~00 
lipoproteins 
In study # 11, the VLDL subfraction sf 100-400 was injected 
into a type 4 hyperlipoproteinaemic subject. The B apolipoprotein 
specific activity-time curves (on a log scale) of the sf 100-400 and 
sf 12-100 fractions are shown in figure 6.2. The disappearance of the 
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Figure 6.2 The specific activity-time curve (on a log 
scale) for the B apolipoprotein of sf 100-400 and 
sf 12-100 fractions following the administration of 
sf 100-40o-
125
r in study #11. This study was per-
formed on a female subject exhibiting, at the time 
of study, the type 4 HLP phenotype (triglyceride: 
410 mg/100 ml plasma; cholesterol: 290 mg/100 ml 
plasma). 
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B apolipoprotein in the sf 100-400 fraction conformed to a single ex-
ponential function in contrast to the previous findings with the 
sf 20-400 fraction. However, the specific radioactivity curve of the 
sf 12-100 fraction did not intercept the sf 100-400 curve in the manner 
of a precursor-product relationship. At its peak, the specific radio-
activity of the sf 12-100 class was only 55% of the sf 100-400 specific 
radioactivity, sugqestinq that nearly half of the sf 12-100 lipoproteins 
entered the plasma independently. This also seemed likely in view of 
the relatively small turnover of 371 mq/day in this subject's sf 100-400 
lipoproteins and the finding that the B apolipoprotein pool size of 
the sf 12-100 lipoproteins was 5 times as great as that of the 
sf 100-400 fraction. 
It therefore seemed likely that the major VLDL remnant was 
smaller than sf 100 but larger than sf 20. As previously mentioned 
it has been suggested on the basis of studies employing the analytical 
ultracentrifuge that the appropriate flotation range of the remnant 
might be sf 12-60 (Eisenberg et al., 1973). 
6.2.3 Precursor-product relationships between sf 60-400 and sf 12-60 
lipoproteins 
· 
125 I and In study # 12, sf 60-400 lipoproteins labelled w1 th 
131 
sf 12-nO lipoproteins labelled with I were simultaneously injected 
into a type 4 hyperlipoproteinaemic subject. The B apolipoprotein 
specific activity-time curves c125I) for the sf 60-400 and sf 12-60 
fractions are shown, on a log scale, in figure 6.3. These curves 
describe a precursor-product relationship between these two lipoprotein 
fractions, the peak specific activity of the product (sf 12-60) occurring 
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Figure 6.3 The specific activity-time curve (on a log 
scale) for the B apolipoprotein of sf 60-400 and 
sf 12-60 fractions following the administration of 
sf 60-40o- 125 r in study #12. The study was per-
formed on a male subject exhibiting, at the time of 
study, the type 4 HLP phenotype (triglyceride: 
320 mg/100 ml plasma; cholesterol: 265 mg/100 ml 
plasma). 
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at the cross-over of the two curves. The sf 60-400 specific activity 
curve could be resolved into two exponentials whereas, although not 
131 
shown, the disappearance of the I labelled B apolipoprotein in the 
sf 12-60 fraction was monocxponential . 
The turnover of the two lipoprotein fractions, measured directly 
(using both isotopes) were of a similar order (605 and 544 mg/day respect-
ively) which, when taken together with the precise precursor-product 
characteristics of their respective specific radioactivity curves 
(det0rmined from the sf 60-400 labelling), suggested that the true VLDL 
remnant lies in the sf 12-60 flotation range. 
The sf 60-400 study was repeated in another subject with type 
2B hyperlipoproteinaemic phenotype (study# 13) . The kinetics of the 
specific radioactivity-time curve conformed to a 2-pool model as in 
subject# 12 and showed a distinct precursor-product relationship with 
the sf 12-60 fraction (figure 6.4). The turnover of the sf 60-400 
and sf 12-60 fractions was also compared by the area under the specific 
activity-time curve method. In subject# 12 the respective values, 
obtained from the injection of sf 60-400 lipoproteins, were 583 and 514 
mg/day, which were similar to those derived from a 2-pool analysis of 
125 
the injected I labelled sf 60-400 lipoproteins and the 1-pool analysis 
f . . d 131 l o the inJecte I abelled sf 12-60 lipoproteins. In subject # 13 the 
values for the turnover of the sf 60-400 and sf 12-60 B apolipoprotein 
were also similar, being 521 and 462 mg/day respectively. 
6.3 DISCUSSION 
Bilheirner et al. (1972) suggested that the conversion of VLDL 
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Figure 6.4 The specific activity-time curves (on a log 
scale) for the B apolipoprotein of sf 60-400 and 
sf 12-60 fractions following the administration of 
sf 60-40o-125 r in study #13. The study was per-
formed on a male subject exhibiting, at the time of 
study, the type 2B HLP phenotype (triglycerides: 
426 mg/100 ml plasma; cholesterol: 341 mg/100 ml 
plasma) . 
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to LDL
2 
occurs via an intermediate lipoprotein in the sf 12-20 range. 
This lipoprotein class was designated LDL1 . These authors however did 
note that without specific activity data, they could not accurately 
d(·finc this VLDL-LDL1 -LoL 2 conversion sequence. The studies of 
chapter 5 indirectly suggPstPd the unlikely nature of LDL1 as the inter-
mediat<.• 1 iroprot<,in spnci<~s c,ven though precursor-product relationships 
indicated that it was a product of VLDL catabolism. In these studies, 
it wa:..:; appan•nt that th(• turnovr•r of LDL1 B apolipoproteiri was not 
sufficient to accommodate VLDL B apolipoprotein catabolism. These 
observations were directly confirmed in study # 8 where the turnover of 
VLDL and LDL
1 
B apolipoprotein were simultaneously but independently 
determined. Also, upon examination of the pool sizes of LDL1 , it was 
realisPd that the fractional catabolic rate of this lipoprotein species 
would have to be exceptionally rapid were it to be the major inter-
mediate lipoprotein. 
Analysis of precursor-product relationships between sf 100-400 
and sf 12-100 lipoproteins fractions (study 11) demonstrated that the 
sf 12-100, pPr se, was not the intermediate fraction as it was not solely 
derived from catabolism of sf 100-400. Thus, more than one population 
of triglyceride-rich lipoproteins may enter the circulation (presumably 
from the liver or the gut). In contrast, the studies with sf 60-400 
and sf 12-60 lipoproteins (studies #12 and 13) suggested that the inter-
mediatP lipoprotein class was in the sf 12-~0 range. Data obtained 
from Schlieren patterns of lipoproteins in the analytical ultracentrifuge 
have indicated a discrete lipoprotein species in the sf 12-60 range 
(Jensen et al., 1970; Quarfordt et al., 1971; Eisenberg et al., 1973). 
' 
I 
I 
II 
Ii 
Ii 
II 
1·1 
I! 
I! 
11 
I I 
I 
I 
I ' 
II 
132 
As these results are limited in number, it is not possible to 
comment on variations that may occur 1n the 'cut-off point' of the 
intermediate lipoprotein. It is likely that in some hyperlipoprotein-
aemic subjects e.g. type 5 phenotypes larger intermediate lipoproteins 
are present derived from chylomicrons. It is of interest to note also 
that the disappearance of the sf 100-400 fraction (study# 11) was mono-
exponential in contrast to the biexponential disappearance observed in 
the sf 60-400 fractions. Since this study also shows that more than 
one population of newly synthesised VLDL may enter the circulation, 
the biPxponential nature of the disappearance of sf 20-400 represents 
at least the influx of more than one population of particles. 
Remnant or intermediate lipoproteins have been implicated in 
the pathogenesis of atherosclerosis primarily because of the high 
incidence of this disease associated with type 3 hyperlipoproteinaemia. 
In animal studies where atherosclerosis has been induced by cholesterol 
feeding, remnant particles (8-VLDL) rich in apolipoprotein E are seen 
to accumulate. Thus it is important to define the characteristics 
of the intermediate lipoprotein species. The studies in this chapter 
suggest that it 1s found in the flotation range sf 12-60 though 
further studies are required for confirmation. 
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CHAPTER 7 
SYNOPSIS 
An association between elevated plasma concentrations of 
cholesterol and triglyceride and the incidence of coronary heart 
disease has been well documented (Keys, 1970; Carlson and Bottiger, 1972; 
Goldstein et al., 1973). These lipids are present in plasma as 
components of lipoproteins and recent evidence suggests that it is 
lipoprotein, rather than lipid, concentration that is a risk factor in 
the pathogenesis of atherosclerosis. For instance, hypertrigly-
ceridaemia is associated with 6 of the 7 HLP phenotypes (types 1, 2B, 
combined, 3, 4 and 5). Of these, however, only types 2B, combined, 
3 and 4 have been associated with an increased risk of atherogenesis. 
Furthermore, with respect to type 4 HLP, which is characterised by 
excess VLDL, the relevance of hypertriglyceridaemia alone as a risk 
factor is presently being questioned (Brunzell et al., 1976; Rhoads 
et al., 1976). In these studies, the risk of coronary heart disease 
did not appear to be increased by hypertriglyceridaemia alone. 
Interestingly, examination of the findings of Carlson and Ericsson(1975), 
who have examined serum lipoprotein concentrations in survivors of 
myocardial infraction, shows that among patients with hypertrigly-
ceridaemia only 20% had an elevation of VLDL alone. In the others 
hypertriglyceridaemia was associated with hypercholesterolaemia as in 
types 2B, combined or type 3 HLP or in a hitherto neglected entity in 
which there was an accumulation of triglyceride enriched LDL (42% of 
I 
I 
I~ 
' 
I 
' 
I, 
I! 
1, 
1, 
1, 
I~ '1 
II 
Ii 
I.I 
134 
all subjects). The increased LDL tr·iglyceride concentration implied an 
accumulation of a type of intermediate density lipoprotein. The 
importance of the intermediate lipoprotein in atherogenesis is indicated 
by the high incidence of the disease in association with type 3 HLP. 
Atherosclerosis may therefore develop much more readily in the presence 
of excess small lipoproteins extending from LDL through to cholesterol 
rich VLDL remnants than with larger lipoproteins such as VLDL. This 
has been demonstrated more clearly in experimental pathology where 
cholesterol induced atherosclerosis in several species including the dog, 
rat, rabbit and pig (see section 1.8) is associated with the accumulation 
of two unusual lipoproteins: HDL and B-VLDL. Both appear to be 
C 
remnants of VLDL and chylomicron catabolism and are rich in apolipo-
protein E. 
In this regard, the findings presented in this thesis are 
relevant in that a number of aspects of the metabolism of these lipo-
proteins have been investigated. These include (a) the nature of the 
intermediate lipoprotein species; (b) the metabolic interrelationships 
bP.tween low and very low density lipoproteins including the intermediate 
species; (c) alternate pathways that may operate for the removal of the 
intermediate lipoprotein from the circulation. 
A number of the analyses and interpretations included in this 
thesis have been facilitated by having B apolipoprotein specific activity 
data. ThP B apolipoprotein remains common to these lipoproteins fron 
their entry into the circulation until their eventual removal (normally 
as LDL). It was therefore appropriate to investigate the metabolism of 
this apolipoprotein for the purposes of the present studies. The B apo-
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lipoprotein was isolated, for specific activity determination, by a 
procedure based on the relative insolubility of this apolipoprotein 
(when delipidated with organic solvents) in low ionic strength buffers. 
The method, using 5mM NH 4Hco3 , pH 8.0, isolated the B apolipoprotein (as 
the NH 4Hco 3 insoluble fraction) from the remaining soluble apolipo-
proteins of VLDL and LDL (chapter 3). The adequacy of this technique 
in isolating the B apolipoprotein was confirmed hy a number of procedures 
including amino acid analysis, SOS-PAGE and comparison with the TMU 
pror.~oure of Kane (chapter 3). The NH 4 Hco3 procedure was employed in 
all of the metabolic studies included in this thesis. The main 
findings to emerge from these studies are presented below. 
1. Role of lipases in the transformation of VLDL to LDL 
An ~n vitro system employing normal human plasma and containing 
varying concentrations of post-heparin lipolytic activity was used to 
investigate the catabolism of 125 r labelled VLDL (chapter 4). These 
studies demonstrated that, in vitro at least, the sequential trans-
formation of VLDL to LDL2 was dependent upon lipolytic activity. No 
conversion of VLDL or intermediate lipoproteins to LDL2 was observed 
in the absence of lipolytic activity. These findings are partly at 
variance with those of Eisenberg et al. (1973), discussed previously 
(chapter 4), which appeared to show that the conversion of the inter-
mediate lipoproteins to LDL2 was less dependent upon lipolytic activity 
than the initial transformation of VLDL to the intermediate lipoprotein. 
However, this conclusion was based on the findings in a hypertrigly-
ceridaemic subject, and as shown by studies on these patients in 
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chapter 5, as much as 70% of the intermediate lipoprotein may be 
catabolised by a process, other than conversion to LDL2 . The roles of 
the hepatic and extrahepatic lipases (which make up the total lipolytic 
activity of post-heparin plasma) in the conversion of VLDL to LDL was 
also examined under in vitro conditions (chapter 4). Hepatic lipase alone 
was not capable of converting VLDL to LDL. On the other hand some 
conversion of sf 20-50 lipoproteins to sf 12-20 did take place in vitro 
even when lipoprotein lipase activity was inhibited. This suggests 
that the hepatic lipase system may have a role in the removal of 
circulating lipoproteins, possibly of the intermediate class. 
2. Kinetics of VLDL B apolipoprotein catabolism 
The turnover and catabolic fate of the B apolipoprotein of 
VLDL (sf 20-400) was studied in ten normal or hyperlipoproteinaemic 
subjects (chapter 5). The disappearance of VLDL B apolipoprotein, when 
plotted on a semi-logarithmic scale, was multiexponential but conformed 
to a 2-pool model over the first 50 hours of catabolism. The 2-pool 
model was interpreted as reflecting heterogeneity of VLDL catabolism as 
a consequence of (a) input of more than one population of VLDL into the 
circulation (some evidence for this was obtained from the studies of 
chapter 6); (b) heterogeneity of catabolic processes; (c) the possible 
presence pf separate and discrete plasma and tissue VLDL pools. The mass 
of the primary pool (A) exceeded the intravascular content of VLDL 
B apolipoprotein by 30% (on average) indicating extravascular metabolism 
of VLDL. It was speculated that pool A may include plasma, liver, gut 
and lymph while pool B may include cells in connective tissue such as 
fibroblasts and in arterial walls. 
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3. VLDL B apolipoprotein production and removal 
From a kinetic analysis of VLDL B apolipoprotein disappearance 
by a number of methods (section 5.3) the turnover (i.e. production rate) 
of VLDL B apolipoprotein was ascertained. The turnover of VLDL B apo-
lipoprotein was highest in hypertriqlyceridaemic subjects suggesttng 
VLDL over-production as a major factor in this disorder. However, a 
comparison of the intravascular VLDL B apolipoprotein content and VLDL 
8 apolipoprotein turnover demonstrated a 'saturable system' indicating 
that in marked hypertriglyceridaemia, defective removal of VLDL also 
contributes to the disorder. These findings are similar to those 
reported by Sigurdsson et al. (1976) and are in agreement with previous 
studies investigating VLDL triglyceride turnover in relation to the 
development of hypertriglyceridaemia (Reaven et al., 1965, 1967; Nestel, 
1966) . 
4. sf 12-60 lipoproteins as the intermediate lipoprotein class 
. The &n V&VO studies of chapter 6, although limited in number, 
suggest that the intermediate lipoprotein lies in the flotation range 
sf 12-60. This conclusion was reached following analysis of precursor-
product relationships and turnover data of various lipoprotein fractions 
(chapter~). Calculations of the turnover of LDL1 (sf 12-20) which has 
hitherto been regarded as the major intermediate lipoprotein class 
showed that only a proportion of VLDL is converted to LDL (chapters 5 
and 6). These studies demonstrated that newly synthesised VLDL may 
be secreted as several populations of particles within the flotation 
range of sf 60-400. 
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5. Origin of LDL 
Precursor-product relationships between VLDL, LDL1 and LDL2 
(10 studies, chapter 5) confirmed previous suggestions that LDL was 
derived from VLDL and did not have an independent origin. The studies 
of Sigurdsson et al. (1975) have also shown that, in man, LDL was solely 
derived from VLDL. LDL turnover was determined in most studies (chapter 
5) using a technique based on the relative rate of labelling of LDL2 
from its precursor, VLDL (section 5.3.3). The values obtained with 
this technique were in reasonable agreement with those obtained from 
analysis of the disappearance of LDL-1311 (studies #4 and 5). In 
comparison with the wide range of values observed for VLDL tur~over, 
LDL turnover appears to vary less among individuals. LDL over-production 
has been clearly demonstrated only in the very rare type 2A homozygote 
(section 1.7.2). The type 2A HLP phenotype as seen commonly in the 
general population is mostly the result of defective LDL removal from 
the circulation. LDL overproduction may result from increased VLDL 
catabolism thus requiring an increase in VLDL (and so triglyceride) 
production and secondly, through independent secretion of LDL into the 
circulation. There is so far no evidence for the former in 2A HLP 
homozygotes but the latter process has been suggested for the rat and 
monkey (Fidge, personal communications; Illingworth, 1975) and possibly 
may be found in man under certain circumstances. 
6. Direct removal~ in hypertriglyceridaemic subjects, of the inter-
mediatP, lipoprotein from the circulation 
In the studies of chapter 5, the turnover of B apolipoprotein 
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in VLDL and LDL
2 
was similar in subjects without hypertriglyceridaemia. 
These findings are in agreement with the proposal of Sigurdsson P, t al. 
(1975) that, in normotriglyceridaemia at least, all VLDL is catabolised 
to LDL. Howe ver, in thre e of the four hypertriglyce ridaemia subjects, 
the turnover of LDL B apolipoprotein was as little as one third that 
of VLDL suggesting that in these subjects, not all VLDL was converted 
to LDL (similar values for LDL turnover, in hypertriglyccridaemic 
subjects, have also been reported by Sigurdsson et al., 1976). From 
these observations it was suggested that, in hypertriglyceridaemia a 
proportion of VLDL B apolipoprotein may be catabolised elsewhere 
without being converted to LDL2 . The studies of chapter 6 (studies #12 
and 13) suggest that this occurs after VLDL have been converted to the 
sf 12-60 class. 
In figure 7.1 _is shown a possible model for the metabolism 
of the B apolipoprotein-rich lipoproteins in man. This model 
incorporates the findings of this thesis into previously described 
concep ts of lipoprotein metabolism. The newly secreted VLDL particle 
(i.e. prior to any catabolism) lies in the sf 60-400 flotation range 
(as suggested by the studies of chapter 6). The form 'VLDL' may be 
more appropriate to this fraction (sf 60-400) than to the sf 20-400 
fraction which contains some products of VLDL catabolism. The trans-
formation of VLDL to the intermediate lipoprotein is a lipase mediated 
process. Th e lipase s involved in this conversion are probably located 
in extra-hepatic tissues. The intermediate lipoprotein species, in 
accordance with the suggestions of Eisenberg et al. (1973) and the 
findings in chapter 6 occupies the sf 12-60 range. The fate of this 
Intestine 
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Figure 7.1 A model for the metabolism of B apolipoprotein-
rich lipoproteins in man. 
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lipoprotein species is heterogeneous: in normotriglyceridaemic 
individuals in whom the flux of VLDL and transformation into the inter-
mediate lipoprotein is not elevated, probably all of the intermediate 
lipoprotein is converted into LDL. However, in hypertriglyceridaemic 
subjects in whom there is an increased turnover of VLDL, the inter-
mediate liporrotein is largely removed from the circulation by an 
alternative and as yet undefined process. In this model LDL is limited 
to th0 sf (l-12 range i.e. the major cholesterol-rich lipoprotein class. 
It cto(~s not include LDL1 (sf 12-20) which belongs to, but does not 
solPly constitute the intermediate lipoprotein class. 
Current and future research proposals 
A number of studies reported in this thesis are of a pre-
liminary nature and many of the observations require further studies 
for confirmation. This particularly applies to the studies of chapter 6 
involving the intermediate lipoprotein. Although the 2 studies shown 
indicate that this lipoprotein species lies in the sf 12-60 range, 
it is not known if these findings may be generally applied to most HLP 
statPs. FurthermorP, all of the in vivo studies were carri0d out on 
subj0c ts rf~ceiving fat-free diets (to maintain steady state conditions) 
whP.re the contribution of dietary fat to lipoprotein metabolism was 
minimal. This situation does not reflect usual circumstances where many 
of the lipoprotein catabolic processes involve dietary particles. The 
catabolism of chylomicrons has been well characterised with respect to 
the triglyceride and cholesterol moieties but little is known of the 
fate of their apolipoprotein components and so also remains to be 
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investigated. The turnover studies of the type described in this thesis 
could also be usefully employed to investigate other aspects of lipo-
protein metabolism, e.g. the mechanism of action of hypolipidaemic drugs 
and th0 (~ffects of dietary changes (particularly the mechanism of 
action of polyunsaturated fat intake in reducing plasma cholesterol 
concentrations). Studies on the turnover of individual C apolipoproteins 
and their presence 1n various lipoprotein classes (employing the 
technique for quantitation of C apolipoproteins - chapter 3) in normal 
and diseased states may qive some insight into possible defects leading 
to the development of some of the hyperlipoproteinaemias. Individual 
C apolipoproteins appear to activate or inhibit lipoprotein lipase and 
lecithin: cholesteryl acyl transferase, enzymes which are crucial to 
normal catabolism of lipoproteins. Simultaneous measurements of B 
apolipoprotein and C apolipoprotein turnover would define the 
anabolic and catabolic phases of lipoprotein interconversion. 
In conclusion, perhaps the most significant finding to 
eventuate from these studies was the realisation of the complexity and 
heterogeneity of VLDL catabolism. The catabolism of triglyceride-rich 
lipoproteins may no longer be regarded solely as an intravascular 
phenomenom but rather, as in the case of LDL catabolism, to involve 
a number of tissues includinq probably the liver. The possible 
significance, of the extravascular component of VLDL catabolism and the 
removal of intermcdiat~ spocios directly from the circulation in the 
pathogenesis of atherosclerosis remains to be ascertained. 
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APPENDIX 
The studies reported in this thesis were performed according to 
the Declaration of Helsinki (part of which is shown below) 
Basic Principles 
1. Clinical research must conform to the moral and scientific principles 
that justify medical research, and should be based on laboratory and 
animal experiments or other scientifically established facts. 
2. Clinical research should be conducted only by scientifically 
qualified persons and under the supervision of a qualified medical man. 
3. Clinical research cannot legitimately be carried out unless the 
importance of the objective is in proportion to the inherent risk to 
the subject. 
4. Every clinical research project should be preceded by careful assess-
ment of inherent risks in comparison to foreseeable benefits to the 
subject or to others. 
5. Special caution should be exercised by the doctor in performing 
clinical research in which the personality of the subject is liable to be 
altered by drugs or experimental procedure. 
Non-the~apeutic Clinical Research 
1. In the purely scientific application of clinical research carried out 
on a human being it is the duty of the ·doctor to remain the protector of 
the life and health of that person on whom clinical research is being 
carried out. 
2. The nature, the purpose, and the risk of clinical research must be 
explained to the subject by the doctor. 
3a. Clinical research on a human being cannot be undertaken without his 
free consent, after he has been fully informed; if he is legally incompetent 
the consent of the legal guardian should be procured. 
3b. The subject of clinical research should be in such a mental, 
physical, and legal state as to be able to exercise fully his power of 
choice. 
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3c. Consent should as a rule be obtained in writing. However, the 
responsibility for clinical research always remains with the research 
worker; it never falls on the subject, even after consent is obtained. 
4a. The investigator must respect the right of each individual 
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to safeguard his personal integrity, especially if the subject is in a 
dependent relationship to the investigator. 
4b. At any time during the course of clinical research the subject 
or his guardian should be free to withdraw permission for research to 
be continued. The investigator or the investigating team should dis-
continue the research if in his or their judgment it may, if continued, 
be harmful to the individual. 
